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Abstract 
Graft-versus-host disease (GvHD) remains the main complication 
associated with haematopoietic stem cell transplantation (HSCT). GvHD is 
caused by allo-reactive donor T cells mounting an attack against specific target 
tissues. CD4+CD25HiFoxp3+ regulatory T cells have been shown to modulate 
GvHD in vitro and also in vivo animal models. More recently early stage clinical 
trials have described the successful use of Treg to reduce the incidence of 
GvHD following HSCT. The aim of this study was to investigate further the 
suppressive mechanisms by which Treg are able to modulate GvHD and 
assess the influence of Treg on the beneficial graft-versus-leukaemia (GvL) 
effect therefore providing further insight into the use of Treg in the therapeutic 
management of GVHD. 
Data presented in this thesis demonstrates the successful isolation and 
expansion of a highly pure Treg population which maintained suppressive 
capacity throughout culture. We also confirmed that Treg retain suppressive 
capacity following cryopreservation resulting in reduced workload and increased 
consistency when used for in vitro functional studies. We also provide the first 
human in vitro evidence that Treg are able to prevent cutaneous GvH reaction 
by blocking the migration of effector T cells into the target tissues. The presence 
of Treg during allo-stimulation caused reduced effector cell activation, 
proliferation, IFNγ secretion and decreased skin homing receptor expression. 
Further investigation into the Treg modulation of dendritic cells demonstrated, 
for the first time in experimental in vitro human GvHD, that this was due to 
ineffective effector T cell priming in the presence of Treg caused by impairment 
of dendritic cell functions. Comprehensive phenotypic and functional analysis of 
Treg treated moDC showed their decreased antigen processing ability and allo-
stimulatory capacity, resulting in a less severe GvH reaction in the skin explant 
model. Furthermore, this work has revealed that despite Treg impairing in vitro 
GvL mechanisms at a cellular level there was no association observed between 
increased Treg levels and the incidence of relapse in a small clinical cohort of 
HSCT patients. In conclusion this study has provided further insight into the 
mechanisms by which Treg are able to modulate GvHD. This would inform 
future clinical trials using Treg as a therapeutic alternative to current GvHD 
treatment and prophylaxis. 
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1 Chapter 1- General Introduction 
This chapter will introduce the pathophysiology of graft-versus-host disease 
– a common complication associated with allogeneic haematopoietic stem cell 
transplantation – and discuss how and why regulatory T cells may act as a 
potential treatment or prophylaxis option in the clinic. Introductions for specific 
research objectives are included in individual results chapters. 
  Allogeneic haematopoietic stem cell transplantation 1.1
Allogeneic haematopoietic stem cell transplantation (HSCT) is a well-
established and effective treatment for haematological malignancies and other 
inherited or acquired disorders of the haematopoietic system which would 
otherwise prove fatal (Shlomchik, 2007). Patients are first subjected to a 
conditioning regimen of chemo/radiotherapy and immuno-suppression which 
facilitates engraftment, reduces the risk of graft rejection and lowers the number 
of malignant cells. The patient is then infused with donor haematopoietic stem 
cells and over time recipient immuno-deficiency improves as their immune 
system is gradually replaced by donor lymphoid cells (Deeg and Storb, 1985).  
Since the first human HSCT pioneered by Thomas et al. in 1959 the number 
of patients receiving HSCTs has continued to rise, with current estimates at 
around 55,000-60,000 transplants each year (Thomas et al., 1959, Ferrara et 
al., 2009, Li and Sykes, 2012). However, acute graft-versus-host disease 
(aGvHD) remains the main complication associated with HSCT; approximately 
50% of patients are treated at some stage for aGvHD and it is responsible for 
up to 26% of transplant related mortality (Appelbaum, 2001, Jagasia et al., 
2012, Gooley et al., 2010). aGvHD is an allo-immune disease which occurs 
when donor T cells recognise a genetic disparity within the host and mount an 
immune response against various host tissues in particular the skin, GI tract, 
liver and lungs, typically developing within 100 days of transplantation (Ferrara 
et al., 2009). The severity of aGvHD and incidence of graft failure can be 
directly correlated with the level of mismatch between the human leukocyte 
antigen (HLA) proteins of the donor and the recipient (Atkinson et al., 1990, 
Loiseau et al., 2007, Petersdorf, 2007). Even in cases where donor and 
recipient are HLA identical about 50% of recipients require treatment for aGvHD 
due to differences in the minor histocompatibility (miHA) antigens (Ferrara et al., 
2009).  
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Following HSCT, recipients can also develop chronic GvHD (cGvHD); this 
typically occurs more than 100 days post-transplant and can occur with or 
without the patient having aGvHD previously. cGvHD mainly depends on the 
polarisation of CD4+ T cells towards a Th2 response and it presents as an auto-
immune-like syndrome. While cGvHD is a significant issue following 
transplantation, this introduction will focus on the pathophysiology of aGvHD. 
Despite the fact GvHD is a potentially lethal complication associated with 
HSCT, a certain level of the graft-versus-host reaction is beneficial to maintain 
the graft-versus-leukaemia (GvL) effect. It has been noted in several studies 
over the last 30 years that patients who suffered from GvHD had a lower 
incidence of relapse (Weiden et al., 1981, Weiden et al., 1979). The allo-
reactive T cells respond to both the host tissue (causing GvHD) and the 
leukemic cells (leading to the desirable GvL reaction) (Weiden et al., 1979). 
Prevention of aGvHD by T cell depletion of the graft is possible however it 
causes increased relapse and graft failure due to the loss of the beneficial GvL 
effect of the donor T cells (Shlomchik, 2007, Martin et al., 1985). Also the use of 
donor lymphocyte infusions to treat recurring or residual malignancy post-
transplantation illustrates the GvL effect (Kolb, 2008). Therefore treatment of 
patients in the clinic is a balancing act between the beneficial and detrimental 
graft-versus-host reactions. The GvL effect will be discussed in detail in Chapter 
6. 
Over the last 20 years the procedures used to treat patients with HSCT have 
advanced tremendously.  The source of donor stem cells has expanded from 
bone marrow harvested under general anaesthesia to also now include 
peripheral blood stem cells (PBSS) and umbilical cord blood (UCB). The source 
of the stem cells used for transplantation has historically been implicated in 
transplant outcome and GvHD status. The use of peripheral blood stem cells 
(PBSC) requires administration of growth factors such as G-CSF to the donor, 
stimulating haematopoietic stem cell mobilisation into the peripheral blood of the 
donor, which can then be harvested by apheresis. Despite the highest relative 
increase in the use of cord blood as a stem cell source between 2006-2008 
(Figure 1.1), PBSC remains the most common source of donor cells  (Gratwohl 
et al., 2013). The use of UCB as a stem cell source is associated with a 
decrease in the incidence of GvHD which is thought to be due to the immaturity 
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of the donor T cells and the higher regulatory T cell content within UCB (Li and 
Sykes, 2012). The disadvantage of UCB is the low number of stem cells 
available from each unit – however transplantation of UCB from two donors can 
actually lead to improved engraftment. The ‘sacrifice’ of 1 cord unit enables 
successful engraftment of the other (Barker et al., 2009). The use of PBSC had 
previously been associated with increased incidence of aGvHD. However a 
recent study reported the stem cell source is associated with incidence of 
chronic GvHD rather than aGvHD (Flowers et al., 2011).  
 
Figure 1.1 Stem cell sources for transplants performed in 2006-2008 (Gratwohl et al., 
2013). 
Additionally there have been considerable advances in the conditioning 
regimens used to prepare patients for transplantation; the objectives of 
conditioning being immunosuppression and the eradication of underlying 
disease (Figure 1.2). Originally, myeloablative conditioning regimens were used 
to eradicate leukemic cells, and then HSCT was used as a rescue therapy. 
Myeloablative regimens involve high doses of chemotherapy which is often 
combined with total body irradiation (TBI). However the intensive cytotoxic 
therapy itself can cause morbidity and mortality and is considered to be too 
toxic for elderly patients.  
The development of non-myeloablative conditioning regimens has allowed 
for more patients, particularly older patients, to be considered for HSCT due to 
reduced toxicity. The reduced intensity conditioning regimens provide sufficient 
immune-suppression to allow for engraftment of the donor cells and rely on the 
GvL activity of the graft followed by donor lymphocyte infusion post-transplant to 
eradicate the tumour cells (Martino et al., 2002). 
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Figure 1.2 Myeloablative and non-myeloablative conditioning regimens (Bleakley and 
Riddell, 2004). Ovals represent chemotherapy and lightning bolts represent TBI. 
When deciding upon the transplant protocol there are many factors that 
influence the transplant and the conditioning regimen including age, disease, 
overall health, gender mismatch between donor and recipient and stem cell 
source. Donors who are considered first for transplantation are HLA matched 
siblings; if this is not possible then matched unrelated donors (MUD) or haplo-
identical related donors are used. Of the allogeneic transplants that occurred 
worldwide between 2006-2008, 51% were performed from family members and 
the remaining 49% from MUD donors (Gratwohl et al., 2013). 
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 The Human Leukocyte Antigen complex 1.2
The level of HLA matching between the donor and the recipient is crucial to 
the outcome of HSCT. The HLA system (also known as the human major 
histocompatibility (MHC) region) is located on the short arm of chromosome 6. 
The HLA region contains over 220 genes, 40 of which are believed to function 
in the immune response (Horton et al., 2004, Klein and Sato, 2000). Three 
distinct regions have been identified (shown in Figure 1.3) that encode proteins 
responsible for allo-antigen recognition and greatly influence the outcome of 
allogeneic transplantation as well as being responsible for normal immune 
defence against pathogens.  
 
 
Figure 1.3 Gene map of the HLA region (Mehra and Kaur, 2003). 
 
Class I molecules (HLA-A, HLA-B and HLA-C) are expressed on the surface 
of all nucleated cells and are responsible for the presentation of peptides 
derived from intracellular proteins to CD8+ T cells. Class I molecules consist of 
two polypeptide chains, the β chain is encoded by a gene on chromosome 15 
and the α chain encoded by genes from the class I HLA region (Figure 1.4). 
Class II molecules are structurally different to the class I molecules, however 
they both function to present peptides to T cells as part of the adaptive immune 
response. Both the Class II α and β chains are coded for by genes from within 
the class II region (Klein and Sato, 2000). Class II molecules are expressed on 
cells involved in the immune response, in particular antigen presenting cells 
(APC) – presenting peptides from extra-cellular proteins to CD4+ T cells. The 
class III region, located between Class I and Class II regions, contains non-HLA 
genes which are involved in the immune system such as TNFα (Robinson et al., 
2013). 
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Figure 1.4 The structure of HLA class I and II molecules (Klein and Sato, 2000). 
The main function of HLA molecules is to present pathogen derived peptides 
to T cells, initiating the adaptive immune response. In HSCT settings recipient 
HLA Class I and Class II molecules function as allo-antigens which can be 
recognised by engrafted donor T cells initiating a powerful GvH immune 
response, which contributes to both beneficial GvL and detrimental GvHD. 
Following HSCT antigen presentation can occur through the direct pathway 
where donor T cells recognise allogeneic host HLA molecules either with or 
without peptide present (Chakraverty and Sykes, 2007). Antigen presentation 
can also occur through the indirect pathway where host allo-antigens are 
presented by donor APC following the uptake and processing of host material. 
There are many cell types which are able to act as APC including dendritic cells 
(DC), monocytes, macrophages and occasionally B cells. These APC are able 
to take up antigens through a variety of methods including phagocytosis, 
endocytosis and scavenger receptors (Merad et al., 2007). Once DCs have 
been exposed to antigen in the periphery they mature and migrate to the lymph 
nodes. When in the lymph nodes the mature APC are able to present these 
HLA-peptide complexes to T cells and initiate T cell activation (Merad et al., 
2007). Typically donor CD4+ T cells are activated via class II HLA-peptide 
presentation and CD8+ T cells via class I HLA-peptide presentation (Goker et 
al., 2001). However, in the HSCT setting donor dendritic cells are also able to 
cross-present allo-antigens on Class I MHC to CD8+ T cells (Shlomchik, 2007).  
Additional signals provided by co-stimulatory molecules engaging complete 
T cell activation as TCR-HLA/peptide binding in the absence of co-stimulatory 
signals drives T cells to an anergic state. Co-stimulatory signals also govern the 
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outcome of T cell activation as either stimulatory or regulatory depending on the 
molecules and ligands involved. This will be discussed in the following sections. 
HLA matching between donor and recipient is crucial in the outcome of 
HSCT. The overall survival of patients is significantly improved when patient 
and donor are HLA identical (Figure 1.5) and as the degree of mismatch 
increases patient survival decreases (Loiseau et al., 2007). Therefore the 
number of mismatches between donor and patient is a major risk factor post 
HSCT.  
 
Figure 1.5 Effect of the number of HLA mismatches on overall survival post HSCT 
(Loiseau et al., 2007). 
Recent advances have resulted in an increase in both the number of known 
HLA alleles and an understanding of their importance in HSCT. The HLA 
system is one of the most complex regions of the human genome with, to date, 
over 9000 known polymorphisms (Figure 1.6) (Robinson et al., 2013). Although 
registries of unrelated donors now include 20 million HLA-typed volunteers 
worldwide, the complexity of the HLA system remains a barrier to the success 
of HSCT with many patients unable to find a suitable match. Only 30% of 
patients have a suitable HLA matched or single mismatch related donor (Li and 
Sykes, 2012, Lee et al., 2007, Gratwohl et al., 2013). An ideal donor has 
matches at 5 HLA loci; HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1. 
Some mismatches are worse than others in terms of transplant outcome and 
GVHD (Petersdorf and Hansen, 2008). 
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Figure 1.6 The number of named HLA alleles (Robinson et al., 2013). 
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 Graft-versus-host disease 1.3
Graft-versus-host disease (GvHD) is generally classified into acute and 
chronic forms, commonly distinguished by the time of onset after HSCT. Early 
work suggested that aGvHD occurred within 100 days of transplantation and 
cGvHD was >100 days, however late onset acute GvHD and overlap syndrome 
(with features of both chronic and acute) show that this classification is not 
strictly accurate (Ferrara et al., 2009). Although considered to be different 
conditions, there is evidence to suggest a close relationship between risk 
factors for chronic and acute GvHD (Atkinson et al., 1990).  
The mechanisms behind chronic GvHD are complex and are not entirely 
understood with a more diverse range of symptoms; it often resembles 
autoimmune disorders (Shlomchik, 2007).  It can be progressive (acute to 
chronic), quiescent (acute then chronic) or de novo (chronic only) (Ferrara et al., 
2009). This review will focus on the mechanisms of aGvHD rather than cGvHD. 
 The pathophysiology of acute graft-versus-host-disease 1.3.1
In the 1960s Billingham proposed a set of three criteria for the development 
of aGvHD (Billingham, 1966).  By the mid-1990s a revised set of 4 criteria had 
been proposed: they state that (1) the host immune system must be incapable 
of mounting an immune response, (2) the graft must contain immune-competent 
cells, (3) host cells must express tissue antigens not present in the donor and 
therefore appear foreign to the donor cells, and (4) the effector cells must be 
able to migrate to the target tissues (Sackstein, 2006). When all these criteria 
are fulfilled the patient is then at risk of developing aGvHD following HSCT.  
The pathophysiology of aGvHD is commonly described as a three phase 
process: the effects of conditioning, donor T cell activation and finally cellular 
and inflammatory effector phase (Figure 1.7). Each phase will be discussed in 
more detail. 
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Figure 1.7 The three phase model of aGvHD (Jaksch and Mattsson, 2005). 
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Phase I: Conditioning regimen induces up-regulation of HLA molecule 
expression on host APC and inflammatory cytokine production by host 
target tissues.  
A side effect of conditioning regimens is injury to GvHD target tissues, in 
particular the intestinal mucosa and liver. These damaged tissues produce 
several pro-inflammatory cytokines, chemokines and adhesion molecules 
(Ferrara et al., 2009). The cytokines most commonly secreted during phase I by 
activated host cells are TNFα, IL-1 and IL-6 (Cooke et al., 1998, Matzinger, 
2002). These pro-inflammatory cytokines in turn increase expression of further 
adhesion molecules, HLA and co-stimulatory molecules  activating residual host 
dendritic cells (DC) cells (Matzinger, 2002).  
Conditioning also causes increased serum levels of lipopolysaccharides 
(LPS) which have been able to leak through the damaged intestinal mucosa; 
there is a direct correlation between the serum levels of LPS and the degree of 
intestinal damage after HSCT (Cooke et al., 1998). Following conditioning 
additional damage to the intestinal mucosa can occur when LPS leaks through 
triggering further production of TNFα and IL-1 by macrophages (Nestel et al., 
1992). Increased levels of TNFα receptor 1 have been detected early post 
HSCT which were associated with the development of GvHD (Choi et al., 2008).  
Several studies have been carried out in murine models to demonstrate the 
importance of LPS in the pathophysiology of GvHD.  Toll-like-receptor-4 (TLR-
4) detects LPS and experiments in TLR-4 mutant mice, compared to wild type, 
have shown a reduction in GvHD risk (Imado et al., 2010). In addition LPS 
antagonists have been shown to reduce GvHD while maintaining GvL in murine 
models (Cooke et al., 2001). In murine modes recombinant human keratinocyte 
growth factor has been shown to reduce GvHD mortality, GvH pathology in the 
GI tract and lower levels of serum LPS while still maintaining the beneficial GvL 
and could therefore provide a potential therapeutic option (Krijanovski et al., 
1999).  
Gut decontamination using antimicrobial chemotherapy prior to 
transplantation has been reported to reduce the severity of GvHD, supporting 
the principle that gut micro flora are important in the pathogenesis of GvHD 
(Beelen et al., 1999). Damage to the GI tract is particularly important as it allows 
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the translocation of inflammatory stimuli such as LPS which then lead to further 
stimulation of APCs in phase 2 of aGvHD (Ferrara et al., 2009) 
The conditioning regimen prior to HSCT in essence primes the host for 
induction of GvHD. Production of danger signals and maturation of host DC 
mean that upon infusion of the donor cells all the signals are already there to 
activate the donor T cells and allow for the induction of phase II of aGvHD. 
Phase II: Allo-antigen recognition induces donor T cell activation, 
proliferation and differentiation. 
Phase II of GvHD occurs once the transplant has taken place. The 
maturation of immature host DCs under the influence of inflammatory cytokines 
and LPS continues during and immediately after HSCT (Janeway and 
Medzhitov, 2002). Following HCST both host and donor APC are able to 
process and present allo-peptides to donor T cells, resulting in T cell activation. 
The donor T cells then proliferate and secrete cytokines including IL-2 and 
IFNγ, causing a cytokine storm further promoting antigen presentation and T 
cell recruitment; this sequence of events is crucial to the pathophysiology of 
GvHD (Jaksch and Mattsson, 2005).  
Many different APC are involved in phase II of aGvHD; both those from the 
host and the donor, including non-haematopoietic APC. DCs which are situated 
in various barrier tissues, such as the skin and GI tract are particularly 
important. Interestingly the location of DCs correlates with the specific group of 
target tissues associated with aGvHD. Using animal models it has been shown 
that the removal of DCs from an organ may prevent aGvHD in that particular 
organ but have no effect on aGvHD in other target organs (Zhang et al., 2002).  
The presence of donor DCs in peripheral blood can be detected as soon as 1 
day post-transplant implicating both host and donor DC in the pathophysiology 
of aGvHD (Merad, Collin et al. 2007). It has been suggested that depletion of 
DCs from the graft may reduce GvHD as donor APC are not required for GvL 
effect (Matte et al., 2004) and donor derived APC may increase severity of 
GvHD following transplant (Shlomchik, 2007).  
The key process in phase II is activation of T cells by APC (Figure 1.8), and 
as previously mentioned this requires both the presentation of antigen to the T 
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cell and a co-stimulatory signal, the absence of a co-stimulatory signal results in 
T cell anergy rather than T cell activation (Banchereau et al., 2000).  
  
Figure 1.8 T cell activation (Alegre et al., 2001). 
The consequence of T cell receptor signalling by cognate antigenic peptides 
is determined by the co-signalling receptor - which can be co-stimulatory or co-
inhibitory. The CD80/86-CD28 co-stimulatory receptor-ligand interaction (Figure 
1.8) was the first to demonstrate the two-signal process of T cell activation 
(Bretscher and Cohn, 1970, Lafferty and Cunningham, 1975). The discovery of 
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) as a co-inhibitory 
CD80/86 ligand highlighted the complexity of the T cell activation system 
(Linsley et al., 1991). CD28 is constitutively expressed on T cells and provides a 
co-stimulatory signal following ligation with CD80/86, conversely interactions 
between CTLA-4 and CD80/86 result in cell cycle arrest. CTLA-4-CD80/86 
interactions can also induce the expression of indoleamine-pyrrole 2,3 
dioxygenase (IDO) in the APC which can act in trans to supress T cell 
responses and induce Regulatory T cells (Treg). Furthermore when CLTA-4 
expression is increased CD28 is down regulated by endocytosis providing 
another level of regulation of the T cell responses (Rudd et al., 2009). In 
addition to the CD80/86-CD28/CTLA-4 receptor ligand interactions there are 
dozens of other interactions between co-signalling receptors, forming a highly 
complex regulatory system (Chen and Flies, 2013). 
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T cell activation is a highly regulated process with multiple levels of control. 
It requires the correct spatial and temporal expression of receptors and their 
ligands on the different cell types, and co-signalling receptors/ligands are able 
to interact with more than 1 ligand/receptor resulting in multiple functions and bi-
directional co-signalling provides additional control. T cell activation is a balance 
between various stimulatory and inhibitory factors; these pathways and 
interactions between T cells and APC provide a potential method for treatment 
and prevention of GHVD and therefore has been the subject of various 
investigations.  
The importance of the co-stimulatory B7 antigens expressed on APC, B7-1 
(CD80) and B7-2 (CD86) was shown by blockage of B7-CD28 interaction 
inhibiting aGvHD in murine models (Ogawa et al., 2001). Additionally  when  
cells were transplanted from CD28(-/-) mice there was a reduction in T cell 
activation, proliferation and ultimately better survival following transplantation 
(Yu et al., 1998). Furthermore blockage of interactions between CD40 and 
CD154 co-stimulatory pathway has been shown to prevent CD28 independent 
aGvHD (Saito et al., 1998). Over the course of APC-T cell interaction various 
cytokines and chemokines are released. The secretion of IL-1 by APC 
stimulates TNFα production and also the production of IL-2 by T cells. IL-2 is 
commonly considered the most important cytokine in the pathophysiology of 
aGvHD because of its central role as a T-cell growth factor; IL-2 causes allo-
reactive T cells to expand and differentiate into CD8+ cytotoxic T lymphocytes 
(Jaksch and Mattsson, 2005).  
In addition IFN-γ is produced during the cytokine storm and it has many 
roles in aGvHD. Mice with aGvHD have higher levels of IFN-γ than those 
without aGvHD (Hill et al., 1997). Along with IL-2, IFN-γ is able to promote T-cell 
expansion and induce cytotoxic T lymphocyte and NK cell responses (Jaksch 
and Mattsson, 2005). IFN-γ also induces increased expression of chemokines, 
adhesion molecules and HLA molecules and it appears to mediate nitric oxide 
production and FAS expression (Jaksch and Mattsson, 2005). Although it is 
commonly seen as detrimental, IFN-γ can have opposing functions in the 
pathophysiology of aGvHD. IFN-γ is also able to suppress the immune system 
by inducing FAS expression on donor cells and causing activation-induced cell 
death (Goker et al., 2001). This provides an example of why targeting cytokines 
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as a method of GvHD prophylaxis or treatment would prove challenging. It is a 
highly complex system requiring a fine balancing act, reducing levels and 
increasing levels may both have beneficial and detrimental outcomes. 
Chemokines have an important role in the pathophysiology of aGvHD. The 
process of recruitment of effector T cells to target tissues involves all three 
families of migration molecules including chemokines, integrins and lectins. 
Many of the inflammatory cytokines (for example IL-1, TNFα and IFNγ) 
produced during phase I and II induce expression of chemokines and 
chemokine receptors in GvHD target tissue and on effector T cells respectively 
(Jaksch and Mattsson, 2005). Increased gene expression of CCR5, CXCR3, 
CCR1 and CCR2 has been shown to correlate with aGvHD following HSCT 
(Jaksch et al., 2005). Chapter 4 contains a more detailed review of the role of 
chemokines in the pathophysiology of GvHD. 
Phase 2 of aGvHD is one of T cell activation and proliferation and also 
production of pro-inflammatory cytokines and chemokines which recruit effector 
T cells to aGvHD target tissues. 
Phase III: Effector cells and inflammatory cytokines induce target tissue 
damage.  
The third and final phase of aGvHD is a complex cascade of effector 
processes. Effector cells which were activated during phase II induce target cell 
damage during phase III. Through the action of chemokines and adhesion 
molecules allo-reactive T cells (CD4+ and CD8+) are able to migrate into the 
target tissue and cause damage characteristic of aGvHD. The ability of allo-
reactive cytotoxic T cells to migrate to target tissues will be discussed in more 
detail in Chapter 4.  
There are three main pathways responsible for tissue damage in aGvHD 
target tissues; The FAS/FASL pathway, the perforin/granzyme pathway and 
direct injury mediated by cytokines. The importance of each of these processes 
has been shown in knockout mouse models (Jaksch and Mattsson, 2005). 
Figure 1.9 from Shlomchik, 2007, summarises various methods of tissue injury 
caused by infiltrating T cells. Perforin and FAS mechanisms account for most 
CD8+ T cell effector function in aGvHD (Via et al., 1996). CD8+ T cells tend to 
favour FAS/FASL pathway (shown in figure 1.11 as CD95/CD95L), but also 
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cause target cell death via the perforin/granzyme cytolytic granules pathway 
(Lowin et al., 1994). The perforin/granzyme pathway requires binding of perforin 
– following direct cell contact – then penetration of the cell granule (granzyme A 
and B) which then leads to activation of the caspase cascade and cell cytolysis 
takes place (Goker et al., 2001).  The FAS receptor (CD95) is expressed on 
many tissues and expression levels increase during inflammation and FAS 
receptor ligand (FASL/CD95L) is predominantly expressed on activated T cells, 
macrophages and neutrophils. Interaction between FAS and FASL results in 
FAS mediated apoptosis (Nagata and Golstein, 1995). During aGvHD FASL 
expression is increased on CD8+ T cells and CD4+ T cells and serum levels of 
both FAS and FASL correlate with GvHD severity grade (Jaksch and Mattsson, 
2005). The FAS/FASL mechanism appears to be particularly important in 
hepatic GvHD as FAS deficient recipients are protected from hepatic GvHD 
(van Den Brink et al., 2000). 
  
Figure 1.9 Mechanisms of tissue injury by T cells in GVHD (Shlomchik, 2007). 
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Further TNFα and IL-1 are produced by APC once they have been 
stimulated. TNFα activates further DCs thereby increasing allo-antigen 
presentation, production of cytokines and recruitment of more effector cells 
exacerbating the situation (Jaksch and Mattsson, 2005). It is also able to induce 
tissue destruction through apoptosis (Wall and Sheehan, 1994).  
The pathophysiology of GvHD is highly complex with several important 
mechanisms acting together resulting in damage to the specific set of target 
organs. GvHD still presents a very real challenge in the clinic and therefore 
remains the focus of much research both into the cellular mechanisms of the 
disease and new therapeutic options. 
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 Current clinical strategies for management of GVHD 1.3.2
The aim of clinical management of GvHD is to limit the risk of patients 
developing GvHD without reducing engraftment or the beneficial GvL effect. 
Unfortunately despite all the advances made over the past decades the overall 
outcome of GvHD treatment has not improved significantly therefore prevention 
of severe GvHD is imperative. A combination of prophylactic tactics can be 
used in the clinic such as high resolution HLA typing, manipulation of donor T 
cells, immuno-suppressants including methotrexate, cyclosporine and 
corticosteroids (Goker et al., 2001). Another approach is to T cell deplete the 
graft either before infusion or post-transplant using mono-clonal antibodies; this 
however often results in a higher incidence of graft failure and relapse 
(Shlomchik, 2007, Martin et al., 1985). The administration of monoclonal 
antibodies against leukocytes (for example alemtuzumab-anti CD52) has also 
been used as a method of GvHD prophylaxis (Ferrara et al., 2009).  
Current first line treatment for GvHD is still steroids, however being a pan 
immunosuppressive there is an association with prolonged infection, graft 
failure and relapse (Ferrara et al., 2009). Furthermore in some cases patients 
do not respond to steroids therefore alternative treatments must be explored. 
An alternative treatment option for GvHD sometimes used in the clinic is 
extracorporeal photopheresis (ECP). In ECP white blood cells are removed by 
apheresis, incubated with DNA-intercalating agent and exposed to UV light 
before being returned to the patient. The first report of ECP treatment of 
patients with GvHD came in 1996 (Rossetti et al., 1996)  Murine models 
suggest that ECP works by increasing the number of donor regulatory T cells 
(Treg) (Gatza et al., 2008). 
More recently the use of cellular therapy for clinical management has 
become an interesting prospect. Clinical trials have been carried out using 
different populations of suppressive or regulatory cells to prevent GvHD. Treg 
have been identified as a particular population that are able to suppress allo-
immune responses in a HSCT setting and therefore interest for use in the 
prevention of GvHD. Various studies both in murine models and human studies 
progressing as far as clinical trials have shown that potentially Treg are able to 
reduce incidence of aGVHD possibly by prevention of T cell activation in phase 
2 of aGVHD.  
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 Immune tolerance and regulatory T cells 1.4
Immune tolerance is a state of un-responsiveness to particular antigens. 
Immune tolerance can be established during T cell development in the thymus 
(central tolerance through depletion of T cells with a high affinity TCR to self-
antigens) or in the periphery through anergy induction, Treg suppression and 
inhibitory molecules. Central tolerance is an important gatekeeper stopping 
large numbers of auto-reactive T cells being released into the periphery, while 
the small numbers of auto-reactive T cells which escaped thymic negative 
selection are eliminated or kept under control by peripheral tolerance 
mechanisms.  
Progenitor double negative T cells enter the thymus at the cortico-medullary 
junction (Lind et al., 2001) and migrate through the cortex. As cells migrate 
through the thymus they pause as their TCR interacts with peptide-HLA 
complexes; low avidity interactions induce survival signals and enrich for useful 
T cells able to recognise HLA molecules (Takahama, 2006). High avidity 
interactions between the TCR and peptide-HLA complexes lead to the deletion 
of the thymocytes, through the induction of apoptosis. This negative selection 
results in the deletion of self-reactive T cells. The positively selected double 
positive thymocytes then differentiate into single positive thymocytes, either 
CD4+ or CD8+ (Egerton et al., 1990). Following negative selection in the thymus 
naïve T cells are released back into circulation, and only around 3-5% of cells 
survive this process (Takahama, 2006). 
The thymus also functions in the generation of naturally occurring Foxp3+ 
Treg. Most Foxp3+ cells are found in the medulla region of the thymus, 
suggesting this is where Treg development occurs (Takahama, 2006). The 
current model states that when the TCR avidity lies between the levels which 
drive positive and negative selection Treg development occurs (Maloy and 
Powrie, 2001). This model is supported by more recent data showing self-
antigens for Treg are relatively uncommon (Hsieh et al., 2012). The APC 
present in the thymus are also believed to be influential in the development of 
Treg as co-stimulation promotes maturation of Treg precursors, preventing their 
deletion (Hinterberger et al., 2011). The control of central tolerance is a highly 
regulated process, controlling the number of auto-reactive T cells and 
generating Treg. Any auto-reactive T cells which do escape central tolerance 
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are then controlled by Treg mediated tolerance induction in the periphery. The 
mechanisms by which Treg do this are discussed in section 1.6. 
In the context of normal physiology, both central and peripheral tolerance 
function to abolish auto-reactive T cells, preventing autoimmune responses and 
therefore protecting individuals from developing autoimmune diseases. In 
allogeneic transplant settings, peripheral tolerance plays a key role to maintain 
certain levels of immune tolerance against allo-antigens. Therefore most 
transplant tolerance induction utilises peripheral tolerance mechanisms, and of 
particular interest are Treg. 
 Regulatory T cells and their role in immune regulation 1.4.1
Treg are a heterogeneous sub population of T cells; the best defined 
population of Treg is the naturally occurring Treg, commonly characterised as 
being CD4+CD25HiFoxp3+. They have a vital role in maintaining self-tolerance 
and preventing proliferation of auto-reactive T cells (Sakaguchi et al., 1995). 
Tregs have been shown to be able to influence most immune responses: 
autoimmunity, transplantation tolerance, anti-tumour immunity and anti-
infectious responses (Tang and Bluestone, 2008). Undoubtedly Treg are an 
exciting component of the immune system and are worthy of significant further 
study. In order to study their mechanisms of action in more detail further in vitro 
studies are required.  
After controversy in the late 1980s and early 1990s as to the existence of 
Treg, Sakaguchi and colleagues identified a population of murine T cells which 
were CD4+ and expressed high levels of the IL-2Rα subunit CD25. This 
subpopulation, between 5-10% of CD4+ cells, was shown to have suppressive 
properties (Sakaguchi et al., 1995).  Further characterisation and isolation of 
this population of murine Treg and confirming their existence in humans 
attracted a huge amount of attention in the following 5 years. By 2001 several 
groups had confirmed the existence of a CD4+CD25Hi sub-population of Treg in 
human peripheral blood (Baecher-Allan et al., 2001, Dieckmann et al., 2001, 
Jonuleit et al., 2001, Ng et al., 2001, Taams et al., 2001, Levings et al., 2001). 
Although Treg had been successfully characterised as CD4+CD25Hi the 
identification of more markers was required in order to distinguish regulatory T 
cells from activated T cells. CD62L adhesion molecule L selectin was first 
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identified in NOD mice as a Treg marker, although it is not exclusively 
expressed on Treg and is therefore of little use as an isolation aid (Lepault and 
Gagnerault, 2000). The co-signalling molecule CTLA-4 was also shown to be 
expressed on Treg, however again this marker is also present on other T cell 
subsets (Takahashi et al., 2000). 
The discovery of Foxp3 as a marker for Treg came about in 2001 through 
studies into severe auto-immune disorders both in humans and mice. Immune-
dysregulation-polyendocrinopathy-enteropathy X linked syndrome (IPEX) is a 
rare autoimmune disease in humans with the murine equivalent being scurfy 
(Powell et al., 1982, Godfrey et al., 1991). These diseases were found to be 
caused by mutations in the gene for the transcription factor Foxp3 which in turn 
resulted in a lack of functional Treg (Wildin et al., 2002). In 2003 two groups 
reported the importance of Foxp3 in the development and regulation of Treg 
illustrating its functional importance and confirming its reliability as an 
identification marker for Treg (Fontenot et al., 2003, Hori et al., 2003). Fontenot 
et al showed adaptive transfer of wild type Treg could rescue disease 
development when transferred to neo-natal Foxp3 deficient mice. Additionally 
Hori et al used retro-viral transfer to convert naïve T cells into Treg which were 
phenotypically similar to naturally occurring Treg. Recent work has shown that 
Foxp3 gene transfer into CD4+ T cells from IPEX patients allows for the 
conversion into functionally stable Treg emulating the function of Treg from 
healthy donor cells thereby confirming Foxp3 as the master transcription factor 
for functional Treg (Passerini et al., 2013). Therefore Foxp3 is now considered 
to be the gold standard identifier of Treg. 
CD4+CD25HiFoxp3+ Treg can be further classified into naturally occurring 
Treg (nTreg) which develop in the thymus and induced Treg (iTreg) which are 
induced in the periphery. Naïve CD4+CD25- cells can become regulatory T cells 
in the periphery or in vitro through a variety of signals including IL-10 and TGFβ 
(Sojka et al., 2008). Expression of the transcription factor Helios was thought to 
differentiate between nTreg and iTreg; Thornton et al. showed that 100% of 
CD4+Foxp3+ thymocytes expressed Helios but only 70% CD4+Foxp3+ 
peripheral cells expressed Helios (Thornton et al., 2010). This notion has 
recently been challenged by an observation showing Helios expression in Treg 
induced in the periphery (Gottschalk et al., 2012) However the current 
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consensus is that Helios expression is a reasonable, although not definitive, 
marker for distinguishing nTreg from iTreg. 
 Other regulatory cell populations 1.4.2
In addition to CD4+CD25HiFoxp3+ Treg there are other populations of T cells 
able to promote tolerance and regulate immune functions. One such population 
of regulatory T cells which have been suggested to have a beneficial role in 
aGvHD are CD8+Foxp3+ Treg. These cells were shown, in murine models, to be 
induced during early GvHD and have the ability to potently suppress allo-
reactive T cell responses in vitro (Beres et al., 2012). CD8+ Treg cells, also 
identified in humans express many of the same surface markers as their CD4+ 
equivalents; such as glucocorticoid-induced TNFR family related gene (GITR), 
CD103 and CTLA-4. Although Foxp3 is often seen as the master regulator of 
Treg other populations of regulatory CD4+ T cells which lack Foxp3 expression 
have also been described, including CD4+ Tr1 cells which secrete IL1-0 and 
TGFβ in response to antigen stimulation (Liu et al., 2014, Banchereau et al., 
2012). 
Other subpopulations include “adaptive” or “induced” regulatory CD4+ T cells 
which are created ex vivo. Haque et al have used a mouse model to 
demonstrate a potential method of generating large numbers of Treg – they 
were able to programme Treg from induced pluripotent stem (iPS) cells which 
functioned to reduce arthritis development (Haque et al., 2012). This provides 
an interesting and exciting alternative to the isolation and expansion of naturally 
occurring Treg. Zhang et al reported the conversion of human conventional CD4 
and CD8 donor T cells into large numbers of iTreg in just 1 week (Zhang et al., 
2013). However unlike nTreg these cells lost expression of Foxp3. 
Administration of rapamycin and IL-2 to the patients did significantly improve 
Foxp3 stability. This study demonstrated the feasibility of generating large 
numbers of iTreg which function to induce tolerance post transplantation in the 
presence of systemic rapamycin (Zhang et al., 2013). 
Various populations of regulatory T cells exist, some naturally occurring in 
vivo and others generated ex vivo, although all important and of potential use in 
the prevention and/or treatment of aGvHD only the function and role of nTreg 
will be discussed and investigated further within this thesis.   
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 Treg in autoimmunity 1.4.3
Autoimmune disorders are caused by a breakdown in the mechanisms 
which balance tolerance and protection against invading pathogens. Treg are 
able to subdue peripheral activation of auto-reactive T cells which escaped 
negative selection in the thymus thereby preventing auto-immune diseases. The 
importance of Treg in the control of autoimmunity is seen in conditions such as 
IPEX where a lack of Treg results in severe autoimmune disorders (Wildin et al., 
2002). Peripheral Treg are polyclonal and undergo a similar selection process in 
the thymus with the exception of positive selection for recognition of auto 
peptides (Andre et al., 2009). Once Treg are exposed to antigen in the lymph 
nodes they become activated and exert their suppressive properties. Treg are 
activated at a much lower concentration of antigen than conventional T cells 
preventing autoimmunity (Sakaguchi et al., 2008). The important role of Treg 
has been shown in several auto-immune disorders, and in some cases 
administration of Treg is being investigated as a possible treatment option. 
Multiple Sclerosis (MS) is a progressive auto-immune disorder characterised 
by demyelination of axonal tracks (Sospedra and Martin, 2005). In MS the 
suppressive function and number of Treg was seen to be reduced, along with 
lower Treg proliferative capacity (Viglietta et al., 2004, Carbone et al., 2014). 
Murine models of MS showed that depletion of Treg accelerated disease 
progression while adaptive transfer of Treg was able to attenuate disease 
progression (McGeachy et al., 2005, Kohm et al., 2002).  
Type 1 Diabetes is caused by a breakdown in regulation leading to the 
activation of β-cell specific auto-reactive CD4/CD8 cells. Several studies 
observed that supplementation of Treg prevented disease whereas 
administration of anti-CD25 exacerbates progression (Anderson and Bluestone, 
2005, Tarbell et al., 2007). Various clinical trials are ongoing to evaluate the 
infusion of Treg for the prevention/treatment of autoimmune disorders and Treg 
have been successfully used to delay the onset of type 1 diabetes in children 
(Marek-Trzonkowska et al., 2012). 
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 Treg in tumour immunity 1.4.4
Treg are abundant in solid tumours which raises the question do Treg 
prevent immune surveillance against tumours? Treg depletion in rodents has 
been shown to enhance tumour immunity and therefore provides a potential 
therapeutic option for the treatment of solid tumours (Shimizu et al., 1999, 
Sakaguchi et al., 2008). The ability of Treg to prevent tumour immunity 
becomes a concern in the use of Treg as a method of managing GvHD 
following HSCT as Treg may be detrimental to the GvL effect of the graft. This 
will be discussed further in Chapter 6. 
 Treg in solid organ transplant 1.4.5
Over 4,200 solid organ transplants were carried out in the UK last year 
(www.uktransplant.org.uk) and these transplants are able to take place due to 
the development of immunosuppressive drugs which are able to prevent organ 
rejection. However, the long term use of immuno-suppressants is not ideal due 
to an increased risk of infection and side effects which can reduce the both the 
life of the graft and of the patient. In rare cases some patients have a 
functioning graft in the absence of any immunosuppression and Treg are one 
reason implicated in the tolerance of these grafts (Tokita et al., 2008, Wood et 
al., 2012, Mazariegos, 2011). 
In animal models of transplantation, including humanized mouse models, the 
infusion of Treg has been shown to prevent both acute and chronic graft 
rejection. Treg are able to protect against the adverse effects of transplantation 
including transplant arteriosclerosis, the thickening of arteries in transplanted 
grafts, and allo-immune damage to skin grafts can be controlled by Treg, with a 
more potent suppression by antigen specific Treg (Nadig et al., 2010, Sagoo et 
al., 2011). In addition depletion of Treg from hosts in experimental models of 
transplantation appears to accelerate rejection of the donor organ (Tang et al., 
2012). These studies in animal models provide evidence for the ‘proof of 
concept’ supporting the translation of Treg therapy into a clinical transplantation 
setting. A large multi-centre safety and feasibility clinical trial has been initiated 
assessing the use of Treg in kidney transplant patients (Geissler, 2012). 
Additionally a recent report has described the safe use of induced Treg in living 
donor liver transplant patients, permitting weaning of immunosuppression (Juvet 
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et al., 2014) however these results are only preliminary and further follow up of 
these patients is required. 
 Treg in allo HSCT  1.4.6
The role of Treg in HSCT has been of great interest for many years. Co-
transfer of Treg in murine models was shown to prevent lethal GvHD both in 
vitro and in vivo (Hoffmann et al., 2002, Taylor et al., 2002, Cohen et al., 2002). 
More importantly, in addition to prevention of GvHD, infusion of Treg maintained 
the GvL effect mediated by the conventional T cells (Edinger et al., 2003). Not 
only is the effect of Treg important on the incidence of GvHD following 
transplantation but also on the levels of immune reconstitution and engraftment. 
In murine models the immune reconstitution following transplantation is 
unaffected by the co-administration of Treg (Gaidot et al., 2011). Several murine 
studies had therefore indicated that infusion of Treg following transplantation 
had the potential to be an effective treatment for GvHD. 
In addition to experimental aGvHD there were several observations from 
clinical cohorts of patients suggesting the beneficial role of Treg following 
transplantation. Wolf et al reported that in a cohort of 58 patients, split into 
either high or low Treg content within the graft, the patients with a lower content 
had a much higher incidence of aGvHD that those with a higher Treg content 
without any difference in incidence of relapse (Wolf et al., 2007). Further 
observations have supported that high levels of Treg result in a reduced risk of 
aGvHD (Rezvani et al., 2006, Li et al., 2010, Ukena et al., 2011). The role of 
Treg in cGvHD remains controversial. Clark et al suggested that increased 
peripheral blood levels of Treg are associated with cGvHD (Clark et al., 2004) 
whereas Zorn et al report an association between low levels of Treg and chronic 
GvHD (Zorn et al., 2005). 
In vitro studies have shown that Tregs are able to suppress GvHD, and still 
allow for beneficial GvL, this opened the door for a small number of clinical trials 
aimed at safety testing and prevention of GvHD. A small number of clinical trials 
have shown Treg administration to have no safety issues (Di Ianni et al., 2011, 
Brunstein et al., 2011, Trzonkowski et al., 2009).   
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 Clinical application of Treg in HSCT 1.4.7
Just 8 years after the first reports in murine models clinical trials began 
investigating ex vivo isolated and expanded Treg for the treatment/prevention of 
GvHD. The first-in-man case report from Trzonkowski et al included just two 
patients, one successfully treated for de novo chronic GvHD by expanded donor 
Treg cells. The other patient unfortunately was not successfully treated for their 
severe acute GvHD, however the administration of Treg was considered to be 
rather late at 75 days post transplantation and the authors did note a slight 
improvement in the patient following infusion of Treg (Trzonkowski et al., 2009). 
The ex vivo expanded Treg used in this trial were isolated by FACS cell sorting, 
although not under GMP conditions. 
The results of two early stage clinical trials were recently published. One trial 
enrolled 28 patients with high risk malignancies where freshly isolated Treg 
using cliniMACS were infused after conditioning and then again 4 days prior to 
transplantation (Di Ianni et al., 2011). This trial provided evidence to suggest 
that Treg did not prevent engraftment, 26 patients achieved full engraftment and 
in a high risk cohort of patients there were only 2 cases of aGvHD (Di Ianni et 
al., 2011). Patients treated for high risk malignancies are still associated with 
high transplant-related mortality; in this report after 12 months, 12 of the 26 
evaluable patients were alive and disease free and only 1 report of relapse 
which was improved when compared to a cohort of historical controls. The other 
trial included 23 patients - also with high risk malignancies - for a dose-
escalation trial. These patients received non-myeloablative conditioning 
regimens and were treated with a double UCB transplant (Brunstein et al., 
2011). Treg were isolated from partially HLA-matched third party UCB by 
cliniMACS and ex vivo expanded prior to infusion on day 1 and day 15 post 
transplantation. There were no dose-limiting toxicities or changes in the 
frequency of adverse events when compared to a historical cohort or patients. 
Importantly a significant decrease in the incidence of severe acute GvHD was 
seen in patients who received Treg therapy.  
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 Future directions of the clinical use of Treg for transplantation 1.4.8
Over recent years significant advances in the understanding of Treg in 
transplantation have resulted in the completion of early stage clinical trials in 
HSCT and the initiation of clinical trials in sold organ transplantation. Although 
these early results look promising it is important to continue the research and to 
follow up the patients involved in these early stage trials. The two HSCT clinical 
trials have demonstrated the safety and feasibility of early Treg infusion with the 
added benefit of a reduction in the incidence of GvHD. The Treg infusion did not 
lead to impaired immunity against infections or lead to global 
immunosuppression. Questions still remain as to the effect of Treg infusion on 
the GvL effect, this issue will be explored in Chapter 6.  
The use of Treg to promote tolerance in solid organ transplantation is an 
appealing prospect and unlike HSCT there are no potential problems with Treg 
impairment of the beneficial GvL effect. Currently global immunosuppression is 
used to prevent solid organ graft rejection however this impairs immune 
responses to infections and tumour surveillance as well as leading to diabetes, 
nephrotoxicity and cardiovascular disease (Tang and Bluestone, 2013). Ideally 
post-transplant immunosuppression would be able to prevent immune 
responses against the graft whilst maintaining normal protective immune 
functions, and Treg may provide the answer to this problem. In mouse models, 
Treg therapy after transplantation prevents rejection and encourages further 
induction of Treg which promotes long term survival of the graft (Waldmann, 
2008). It has been reported that allo-antigen specific Treg have a more potent 
effect than polyclonal Treg (Tang et al., 2012). However this could be 
problematic, especially in the case of deceased donor transplants, if the Treg 
were to be administered early for maximum potency. 
An additional consideration is the cost of Treg therapy in comparison to 
currently used therapies. Estimates for the cost of Treg administration to 
patients on the ONE study are around £30 000, which when compared to the 
cost of typical kidney transplant immunosuppression of £6000 for a year 
appears rather high (Juvet et al., 2014). Although the initial cost is off-putting if 
Treg treatment enables immunosuppression weaning and reduces adverse side 
effects of transplantation it may become economically viable.  
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 Mechanism of action of Foxp3+ Treg 1.5
Over the last 20 years there has been significant research into the action of 
Treg which has revealed a broad range of mechanisms. It is this wide range of 
mechanisms available to Treg and their versatility which makes them so 
effective at coping with auto-reactive cells that escape central tolerance control 
(Tang and Bluestone, 2008). Similar mechanisms may also apply to Treg 
mediated tolerance induction to allo-reactive T cell responses in transplantation. 
Treg have been shown to act through both contact independent and dependant 
mechanisms some of which are summarised in Figure 1.10.  
Treg are able to act through several mechanisms simultaneously, some 
mechanisms may still remain un-discovered. The mechanisms by which Treg 
exert their suppressive function depends upon the particular micro-environment 
of the Treg. Once Treg have become activated they are able to supress in a 
non-specific manner, termed “bystander suppression”. This bystander 
suppression has been shown to remain even after the original Treg population 
has been either lost or removed (Qin et al., 1993, Tarbell et al., 2007). 
Understanding the mechanisms behind the suppressive action of Treg is 
important as it provides opportunities for the development of the use of Treg in 
a clinical setting, in particular a understanding of the role of Treg in the 
prevention of GvHD following HSCT. 
Figure 1.10 Suppressive mechanisms of Treg (Vignali et al., 2008). 
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 Treg suppression by inhibitory cytokines 1.5.1
The suppressive cytokines IL-10, TGFβ and IL-35 are all produced by Treg 
and therefore have received significant attention in investigations into Treg 
function. The secretion of suppressive cytokines provides a mechanism for a 
non-cell contact dependent Treg mediated suppression (Vignali et al., 2008). 
The specific role of IL-10 has proved controversial with opposing reports as to 
the importance of IL-10 in Treg suppressive function. Mouse models have 
shown the function of IL-10 to be important in transplantation tolerance (Hara et 
al., 2001) but not in diabetes (Balasa et al., 2000). Treg cell-specific deletion of 
IL-10 does not result in systemic auto-immunity, however it did result in 
enhanced pathology of the lungs following induced hypersensitivity (Rubtsov et 
al., 2008).  Therefore it appears that the importance of IL-10 in Treg function 
depends on the disease or experimental system being investigated (Vignali et 
al., 2008). 
TGFβ produced by Treg can either be membrane bound - and therefore act 
in a cell-cell contact dependent manner - or the TGFβ can be secreted acting in 
a contact independent mechanism. Similar to IL-10 there were opposing views 
as to the importance of TFGβ in Treg suppressive action. Early work suggested 
that TGFβ was not essential for Treg function as TGFβ knock-out mice and 
TGFβ blocking antibodies did not result in Treg dysfunction (Nakamura et al., 
2001, Vignali et al., 2008, Piccirillo et al., 2002). Alternative studies 
demonstrated a crucial role for membrane bound TGFβ; membrane bound 
TGFβ on Treg has been shown to control the infiltration of CD8+ cells into islets 
resulting in a delay in the progression of diabetes (Green et al., 2003). More 
recent reports have reported the ability of TGFβ to skew T cells away from 
effector functions towards a regulatory phenotype (Clayton et al., 2007), and 
TGFβ is commonly used for the generation of induced regulatory T cells both in 
vivo and in vitro (Vignali et al., 2008). 
The inhibitory cytokine IL-35 contributes to Treg suppressive function; it is a 
hetero-dimeric cytokine member of the IL-12 family. IL-35 is up regulated in 
Treg cells which are actively supressing (Collison et al., 2007). Recombinant IL-
35 is able to supress T cell proliferation in vitro and ectopic expression of IL-35 
has been shown to be sufficient for suppressive capacity in naïve T cells 
(Collison et al., 2007). 
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 Suppression by cytolysis  1.5.2
In addition to the production of suppressive cytokines Treg are able to 
supress through cytolysis of target cells through mechanisms more commonly 
associated with cytotoxic T lymphocytes (CTL) and NK cells (Lieberman, 2003). 
Treg are able to kill target cells through granzyme A and perforin (Grossman et 
al., 2004). Treg have been shown to prevent tumour clearance by CTL and NK 
cells by killing them in a granzyme/perforin dependent mechanism (Cao et al., 
2007). In addition to target cell cytolysis by granzyme/perforin Treg are able to 
induce effector cell apoptosis through the TNF-related apoptosis-inducing ligand 
(TRAIL) DR5 pathway (Ren et al., 2007). The D5 ligand of TRAIL is the only 
ligand capable of transducing the apoptotic signal in humans and is thought to 
induce apoptosis on transformed cells, but spare normal healthy cells (Smyth et 
al., 2003). 
 Treg secretion/deprivation of cytokines-metabolic disruption 1.5.3
Imaging studies have shown that suppression can occur with no direct cell-
cell contact (Tang and Krummel, 2006). Deprivation of cytokines provides a cell-
cell contact independent mechanism for their action. A significant point of 
debate in the Treg field is the ability of Treg to starve their surroundings of IL-2 
due to their high expression of the IL-2 receptor (CD25). Some studies have 
suggested that IL-2 deprivation is not a bona fide mechanism of action (Vignali 
et al., 2008) however other evidence suggests that it is possible for Treg to 
induce apoptosis in effector T cells due to cytokine deprival, in particular IL-2 
(Pandiyan et al., 2007). Additional disruption of effector cell metabolism by Treg 
can occur through CD39/CD73 ectoenzyme interactions and the transmission of 
cAMP directly into effector cells through gap junctions (Vignali et al., 2008). 
 Treg suppression by modulation of dendritic cells 1.5.4
It is well established that Treg’s have a central role in tolerance by acting 
directly upon effector T cells by a combination of the previously discussed 
mechanisms (Thornton and Shevach, 1998, Takahashi et al., 2000). However 
Treg have a close relationship with dendritic cells, and are also able to 
modulate immune responses through interactions with APC (Vignali et al., 
2008). Treg are able to influence dendritic cell maturation and function through 
a variety of mechanisms including preventing the maturation of dendritic cells by 
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LAG-3-MHC class II interactions (Liang et al., 2008) and inducing the secretion 
of indoleamine 2,3-dioxygenase (IDO) which depletes local tryptophan, limiting 
T cell proliferation and survival (Grohmann et al., 2003). More detail of 
interactions between Treg and dendritic cells will be discussed in Chapter 5. 
 Treg stability and heterogeneity 1.6
Treg are able to influence the immune system through a variety of 
mechanisms and are crucial in the prevention of auto-immune disorders. Proof-
of-concept studies and early stage clinical trials are showing promising results 
however concerns still remain as to the stability of Treg during cellular therapy. 
It has been suggested that under some inflammatory circumstances Treg 
become unstable and adopt an effector cell function and phenotype (Duarte et 
al., 2009). However, there are reports demonstrating notable stability even in 
highly inflammatory conditions (Rubtsov et al., 2010). General consensus is that 
under normal circumstances naturally occurring thymus derived Treg are stable 
and long lived due to many mechanisms ensuring maintenance of Foxp3 
expression (Sakaguchi et al., 2013).  
Within the CD4+CD25+Foxp3+ population of Treg there is both functional and 
phenotypic heterogeneity (Shevach, 2006, Campbell and Koch, 2011). The 
Treg population can be separated into suppressive subsets which mirror the T-
helper subsets based on chemokine receptor expression suggesting they are 
able to co-locate, which is important for the maintenance of tolerance (Duhen et 
al., 2012). Treg expressing the master transcription factor for Th1 cells T-bet 
and the chemokine receptor CXCR3 accumulate at the sites of Th1 
inflammation (Koch et al., 2009). The Th2 specific differentiation factor IRF4 
facilitates Treg control of Th2 mediated autoimmune responses (Zheng et al., 
2009). Likewise expression of the Th17 transcription factor STAT3 is required 
for the control of Th17 responses (Chaudhry et al., 2009). In addition a subset 
of Treg expressing the lectin-like receptor CD161+ has been shown to produce 
the pro-inflammatory cytokines IL-17 and IFNγ whilst remaining suppressive 
(Pesenacker et al., 2013). This heterogeneity of Treg occurs at a single-cell 
level, determined by single cell profiling, rather than lineage reprogramming 
(Dong et al., 2013). This adaptability and variation in Treg subsets has raised 
questions as to the stability of the Treg when faced with changing 
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microenvironments, particularly with the use of Treg in a clinical setting (Sawant 
and Vignali, 2014). 
The stability of Treg requires the maintenance of Foxp3 expression. Foxp3 
gene is seen to be the master regulator of self-tolerance, not only is it of 
importance in the development of Treg, but also in the function of Treg (Hori et 
al., 2003, Fontenot et al., 2003). Foxp3 is able to bind to the promoter of 
hundreds of genes and influence their expression, including promotion of its 
own expression through interactions with other transcription factors (Zheng et 
al., 2007). Foxp3 works with other transcription factors to establish the Treg 
phenotype and it is becoming clear that epigenetic changes are important in 
Treg lineage (Ohkura et al., 2012). Treg lineage commitment relies on de-
methylation of a CpG island (CNS2 element) in the promoter region of the 
Foxp3 locus. Foxp3+ Treg which are generated in vitro in the presence of TGFβ 
initially express high levels of Foxp3, however due to failure to de-methylate the 
CNS2 element these cells loose Foxp3 expression (Miyao et al., 2012). 
Therefore differences in the methylation status of this region between nTreg 
and iTreg are of importance, suggesting that it is the iTreg population which is 
unstable rather than the nTreg (Rudensky, 2011, Sakaguchi et al., 2013). 
Consequently the isolation of nTreg for use in a clinical setting is important to 
ensure they maintain their phenotype and function. Issues regarding 
identification and isolation of nTreg will be discussed in Chapter 3. 
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 General aims and hypothesis 1.7
It was hypothesised that Treg are able to prevent GvHD without adversely 
affecting GvL. Hence the general aim of this study was to investigate the 
suppressive mechanisms by which Treg are able to modulate GvHD whilst 
assessing the influence of Treg on the GvL effect. This was to be done by:- 
1. Optimising and validating methods for isolation, expansion and storage of 
suppressive Treg. 
2. Assessment of whether Treg prevention of GvH tissue damage is associated 
with blocking of effector T cell migration. 
3. Investigating whether Treg induced impairment of DC functions had an 
impact on cutaneous GvH reactions. 
4. Investigation if Treg are able to impair GvL reactions and therefore impact on 
relapse using in vitro cellular assays and phenotypic analysis of patient 
samples post transplantation.  
34 
2 Chapter 2 - General Materials and Methods 
2.1 Sample source 
All human peripheral blood and skin samples were collected under approval 
of the local ethics committee with informed consent.  
2.2 General cell culture 
All cultured cells were incubated at 37ºC with 5% CO2 in a humidified 
incubator (Flow Laboratories IR 1500 incubator). All cell culture was carried out 
in class II containment cabinets to minimise the risk of infection. 
2.2.1 Isolation of PBMC  
PBMC were isolated by density centrifugation from heparinised peripheral 
blood or leukocyte reduction system (LRS) cones using Lymphoprep™ (Axis-
Sheilds). Whole blood was diluted 1:1 with phosphate buffered saline (PBS) and 
carefully layered over the Lymphoprep™ solution. Samples were then 
centrifuged at 800g for 20 minutes. Most of the top phase was discarded and 
PBMC removed from the interface with a sterile Pasteur pipette. PBMC were 
then washed in sterile PBS. 
2.2.2 Cell counting 
Cell viability was assessed by trypan blue (Gibco) dead cell exclusion dye. 
Cells were washed in appropriate media/PBS and re-suspended in a known 
volume; 20µl of cell suspension was then mixed 1:1 with trypan blue dye. 
Counting was performed using Improved Neubauer cell counting chamber 
(Weber Scientific International). Cells within five squares were counted and 
multiplied by 105 to determine the cell concentration per ml. 
2.2.3 Cell culture media and buffers 
General culture medium (RF10) contained Roswell Park Memorial Institute 
(RPMI) medium 1640 supplemented with 100IU/ml penicillin, 100µg/ml 
streptomycin, 2mM L-glutamate and 10% Heat Inactivated Foetal Calf Serum 
(HI FCS) (Invitrogen). Fluorescence activated cell sorting (FACS) buffer 
consisted of PBS, 2% heat inactivated FCS and 1mM endotoxin free 
Ethylenediaminetetraacetic acid (EDTA) (Invitrogen).  Magnetic activated cell 
sorting (MACS) buffer contained PBS supplemented with 1mM EDTA and 0.5% 
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HI FCS. Skin explant media consisted of RPMI 1640 supplemented with 100IU-
ml penicillin, 100µg/ml streptomycin, 2mM L-glutamate and 20% human AB 
serum (Sera Lab). 
2.2.4 Cryopreservation and thawing of isolated cell populations and 
PBMC  
Isolated cell populations were cryo-preserved in freezing solution which 
contained 90% HI FCS (Sera Lab) and 10% dimethly sulphoxide (DMSO, Kock-
light Ltd). Whole PBMC fractions were cryo-preserved in 70% RPMI, 20% HI 
FCS and 10% DMSO. All cells were dispensed into cryovials (Nunclon), 
wrapped in bubble plastic and stored at -80°C for 24 hours. Cells were then 
transferred to -140ºC for long term storage. Thawing of the cells was carried out 
by gently thawing them in a 37ºC water bath and washing twice with pre-
warmed RF10. Cells were then counted as previously described and re-
suspended in appropriate media at the correct concentration, depending on the 
requirements of the experiment. 
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2.3 Cell isolation/depletion 
RosetteSep® (StemCell Technologies) and immuno-magnetic separation 
were used to isolate cell populations from PBMC. Methods used to isolate each 
cell population are summarised in Table 2.1 
Table 2.1 Summary of methods used to isolate cell populations. PBMC was isolated by 
density centrifugation either from peripheral blood or leukocyte reduction system (LRS) 
cones. 
Cell population Samples source Isolation method 
CD8 LRS cone RosetteSep® 
CD4 LRS cone RosetteSep® 
Treg LRS cone RosetteSep® then RoboSep® 
CD14 PBMC Miltenyi MACS 
CD4 naive PBMC RoboSep® 
NK PBMC Miltenyi MACS 
 
Tregs were isolated from LRSC in a two-step process; CD4+  negative 
enrichment (StemCell Technologies RosetteSep® CD4+ Human T cell 
enrichment cocktail) then RoboSep® automated selection of CD25Hi (CD25 
positive selection kits StemCell Technologies).  
2.3.1 RosetteSep enrichment 
RosetteSep® negative enrichment cocktail contains tetrameric antibody 
complexes which cross-link unwanted cells to red blood cells forming immuno-
rosettes. The unwanted cells then pellet with the red blood cells when layered 
over Ficol and centrifuged at 1200g for 20 minutes at room temperature. This 
allows desired cells to be removed from the interface. This method is 
advantageous as the desired cells themselves are not labelled and it results in a 
high purity. A diagrammatic representation of the Rosettes formed by the 
tetramaric antibody complex between unwanted cells and red blood cells is 
shown in Figure 2.1. 
2.3.2 RoboSep positive selection 
RoboSep® cell isolation is an automated immuno-magnetic separation 
method where cells are labelled with a tetrameric antibody complex. RoboSep® 
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can be used for either positive selection or negative enrichment. The 
magnetically labelled cells are then separated from unlabelled ones using 
RoboSep® automated separation. A diagram of the tetrameric antibody 
complex used for the magnetic labelling of required cells is shown in Figure 
2.1B. 
 
Figure 2.1 StemCell Technologies cell isolation.   
A) RosetteSep® Negative enrichment cocktail B) CD25 positive selection cocktail. 
Images from www.stemcell.com. 
 
2.3.3 Miltenyi MACS separation 
Miltenyi MACS separation is a column based immuno-magnetic separation 
technique. Cells are labelled with MACS MicroBeads then applied to a MACS 
column. Un-labelled cells pass through the column (negative fraction) while 
labelled cells remain in the column (positive fraction). After washing the 
columns can be removed from the magnet and the positive fraction eluted. This 
technique can be used for positive cell isolation as well as depletion of 
unwanted cells. 
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2.4 In vitro cell culture  
2.4.1 Expansion of Treg 
Isolated Treg were expanded for up to 3 weeks, unless otherwise stated, in 
RF10 supplemented with additional 500IU/ml IL-2 (Roche), 100nM Rapamycin 
(Sigma-Aldrich) and CD3/CD28 Dynabeads® T cell expander (Invitrogen). 
Initially the ratio of Beads:Cells was 3:1, this ratio was reduced to 1:1 after Treg 
numbers had begun to increase, usually days three-seven after isolation. Prior 
to use, Treg were detached from the Dynabeads using EasySep® magnet 
(Stemcell Technologies). 
 
Figure 2.2 T cell activation by Dynabeads®. Picture from Invitrogen.com. 
 
2.4.2 Generation of moDC 
Monocyte-derived dendritic cells were generated using CD14+ MACS 
isolated cells. CD14+ cells were cultured in 24 well plates at 5x105 cells/ml for 7 
days in RF10 supplemented with IL-4 (50ng/ml, ImmunoTools) and GM-CSF 
(50ng/ml, ImmunoTools). After three days half the media was replaced with 
fresh media. Mature moDCs were generated by the addition of 0.1μg/ml LPS for 
the final 24 hours of culture.  
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2.5 Flow Cytometry 
Flow cytometry is a technique which is used for multi-parametric analysis of 
cells, including information about cell size, cell type, complexity and viability. 
Flow cytometers are made up of a fluidics system to present the cells and 
remove the waste; lasers to generate fluorescence; optics and detectors to 
gather and detect the light, and a computer system to collect and store the data. 
Cells are passed through the flow cytometer by means of hydrodynamic 
focusing ensuring that only one cell is analysed at once. Laser beams are 
aimed at this stream of cells which then scatter. Side scatter and forward scatter 
are used to assess the granularity and size of cells respectively. Larger, more 
complex cells generate a higher side scatter and forward scatter than smaller 
less granular cells.  
The addition of antibodies labelled with flourophores can identify specific 
markers either on the cell surface or within the cell. Each flourophore has a 
characteristic excitation and emission spectra allowing several to be used at 
once for multi-parameter analysis. When several flourophores are being used 
together compensation is required, as the flourophores may have slightly 
overlapping excitation and emission spectra resulting in a false elevation of the 
signal. Compensation is easily achieved through the use of single colour 
stained cells or compensation beads. 
Unless otherwise stated for staining of cell surface markers 1x105-1x106 
cells were re-suspended in FACS buffer and incubated with appropriate 
concentrations of antibodies at 4°C for 20 minutes. Table 2.2 contains a 
complete list of antibodies used. Cells were then washed with FACS buffer and 
300µl FACS buffer was added prior to flow cytometry analysis. All flow 
cytometry data was collected on a BD Canto II flow cytometer and data 
analysed with FlowJo software, version 7.4 (TreeStar). 
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Table 2.2 Antibodies used with fluorochrome, isotype, clone and supplier. Summary table 
of antibodies used showing the marker, fluorochrome, isotype, clone and supplier. 
Marker Flourochrome Species Isotype Manufacturer Clone 
7AAD 
   
BD 
 
CCR10 PE Rat IgG2a R&D 314305 
CCR7 (CD197) PEcy7 Rat IgG2a BD 3D12 
CD107a PE Mouse IgG1 BD H4A3 
CD127 Brilliant Violet Mouse IgG1 Biolegend AD19D5 
CD14 FITC Mouse IgG2b BD MφP9 
CD16 FITC Mouse IgG1 BD NKP15 
CD1a APC Mouse IgG1 BD HI149 
CD25 APC Mouse IgG1 BD M-A251 
CD40 APC Mouse IgG1 BD 5C3 
CD25 FITC Mouse IgG1 BD 2A3 
CD25 PE Mouse IgG1 BD 2A3 
CD25 PEcy7 Mouse IgG1 BD 2A3 
CD3 PerCPcy5.5 Mouse IgG1 BD SK7 
CD4 FITC Mouse IgG1 BD SK4 
CD4 V500 Mouse IgG1 BD RPA-T4 
CD4 Pacific Blue Mouse IgG1 BD RPA-T4 
CD45RA V450 Mouse IgG2b BD HI100 
CD56 APC Mouse IgG1 BD B159 
CD69 PEcy7 Mouse IgG1 BD FN50 
CD8 APC Mouse IgG1 BD SK1 
CD8 APCcy7 Mouse IgG1 BD SK1 
CD8 PerCPcy5.5 Mouse IgG1 BD SK1 
CD80 PE Mouse IgG1 BD L307.4 
CD83 FITC Mouse IgG1 BD HB15e 
CD86 PEcy7 Mouse IgG1 BD FUN-1 
CLA FITC Rat IgM BD HECA-452 
CTLA-4 PE Mouse IgG2a eBioscience 14D3 
CXCR3 APC Mouse IgG1 BD 1C6/CXCR3 
Foxp3 APC Rat IgG2a eBioscience PCH101 
GranzymeB FITC Mouse IgG1 BD GB11 
Helios PE Hamster IgG BioLegend 22F6 
HLA-ABC FITC Mouse IgG1 BD G46-2.6 
HLA-DR PerCP Mouse IgG2a BD L243 
IFNγ PE Mouse IgG2b BD 25723.11 
IL-10 PE Rat IgG2a BD JES5-16E 
IL-17a PE Mouse IgG1 BD N49-653 
IL-2 APC Mouse IgG1 BD 5344.111 
IL-4 APC Mouse IgG1 BD 8D4-8 
LAP(TGFβ) PE Mouse IgG1 R&D 27232 
NKG2D PerCPcy5.5 Mouse IgG1 BD 1D11 
Perforin PE Mouse IgG2b BD δG9 
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2.5.1 Phenotypic assessment of Treg 
Unless otherwise stated Treg purity was assessed by flow cytometry using 
antibodies CD3 PerCPcy5.5, CD4 FITC, CD25 PE, CD127 Brilliant Violet and 
Foxp3 APC (Antibody supplier and clone shown in Table 2.2). Treg were 
defined as CD4+CD25HiCD127LowFoxp3+. Surface staining was carried out as 
previously described. Cells were then washed with FACS buffer and then 
intracellular Foxp3 staining was carried out according to manufacturer’s 
instructions (eBiosciences Fix/Perm staining kit).  
2.5.2 Assessment of intra-cellular cytokine production 
Intra-cellular (IC) staining for cytokine production was carried out by 
stimulating cells with phorhol 12-myristate 13 acetate (PMA) (20ng/ml) and 
Ionomycin (500ng/ml) (Sigma) in RF10 and incubating at 37°C for one hour. 
Brefeldin A (10μg/ml) (BD Biosciences) was added and incubated for a further 
three hours. Cells were then washed in FACS buffer, and then fixed and 
permebalised using eBioscience Fix/Perm staining kit. Cells were blocked with 
normal mouse serum (Dako) and stained with appropriate antibodies then 
washed in perm buffer for flow analysis.  
2.5.3 Flow cytometry to measure activation markers 
Markers CD69 and CD25 were used to assess the level of activation of 
CD8+ T cells by flow cytometry. Early activation marker CD69 was assessed 24 
hours after stimulation by allogeneic moDC. The late activation marker CD25 
was measured five days following allo stimulation. 
2.5.4 CBA analysis of culture supernatants 
As well as detailed phenotypic analysis of cells, flow cytometry is a 
technique able to assess soluble factors present in serum or culture 
supernatants. Cytometric bead assay (CBA) is a particle based immunoassay 
which is able to measure levels of multiple soluble proteins in supernatants or 
serums. The assay involves the ‘capture’ of the soluble protein of interest by a 
capture bead (Figure 2.3A). A PE-conjugated antibody forms a complex with the 
protein and capture bead; it is this complex which is detected. Each detection 
bead population has a discrete fluorescence intensity which is assigned an 
alpha-numeric position (Figure 2.3B). Comparison to a standard curve allows 
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the ability to use several of these kits in a multiplex situation and allow for 
accurate measurement of the concentration of several soluble factors 
simultaneously. Culture supernatants were collected and analysed using CBA 
Flex sets, included in Figure 2.3C, according to manufacturer’s instructions (BD 
Biosciences). Data was analysed using BD FCAP array software to calculate 
the protein concentration in culture supernatants. 
 
Figure 2.3 Diagram of the process of a CBA assay. 
A) The protein of interest is captured on a bead. Detection beads are then added which 
bind to the protein forming a complex. This complex has a distinct fluorescence intensity 
which is assigned an alpha-numeric position.  
B) Alpha-numeric positions of all the beads as they appear after flow cytometry. Mean 
fluorescence intensity is calculated and compared with the standard curve in order to 
calculate protein concentration. Image from www.bdbiosciences.com. 
C) Summary table of CBA kits used, including bead position. 
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2.6 Assessment of Treg suppressive properties 
Mixed lymphocyte reactions (MLRs) were used to assess the suppressive 
properties of Treg. CD8+ T cells were stimulated with allogeneic moDC, either in 
the presence or absence of autologous Treg. A minimum of three conditions 
were set up for each MLR: CD8+ T cells alone (1x106 cells per ml), CD8+ T cells 
plus moDC (1x106 CD8 cells per ml and 1x105 moDC cells per ml) and thirdly 
CD8+ T cells with moDC and Treg (1x106 CD8 cells per ml, 1x105 moDC cells 
per ml and between 6.25x104-5x105 Treg per ml). The ability of the Treg to 
suppress the activation and proliferation of CD8+ T cells was measured using 
flow cytometry for activation markers CD69 and CD25 as well as 3H-thymidine 
incorporation and carboxyfluorescein diacetate succinimidyl ester (CFSE) 
dilution. 
Table 2.3 Cell concentrations used for MLR. MLR reactions were cultured in RF10 with 
25IU/ml IL2 added. 
 CD8+  moDC Treg 
CD8 1x106cells/ml - - 
+moDC 1x106cells/ml 1x105cells/ml - 
+2:1 Treg 1x106cells/ml 1x105cells/ml 5x105 cells/ml 
+4:1 Treg 1x106cells/ml 1x105cells/ml 2.5x105 cells/ml 
+8:1 Treg 1x106cells/ml 1x105cells/ml 1.25x105 cells/ml 
+16:1 Treg 1x106cells/ml 1x105cells/ml 6.25x104 cells/ml 
 
2.6.1 3H-thymidine incorporation 
Radioactive 3H-thymidine incorporation is a method used to measure the 
proliferation of cells. Each time a cell replicates it incorporates radioactive 
thymidine and this can then be analysed to give a measure of proliferation. MLR 
reactions were set up in 96 well U-bottomed plates with a range of Treg 
concentrations (Table 2.3). After five days the cells were harvested using 
micromate 196 cell harvester (Packard) onto a filter. Cells were pulsed with 3H-
thymidine 16 hours prior to harvesting. The filter was left to dry at room 
temperature for 24 hours and assessed for their level of proliferation by sealing 
in a plastic pocket with scintillation fluid (PerkinElmer) and counting radioactivity 
using a Betaplate TriLux counter (PerkinElmer). The whole process was carried 
out following all local rules on the safe use of radioactive material.  
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2.6.2 CFSE dilution 
CFSE dilution was used to measure the proliferation of allo-stimulated cells. 
Briefly CD8+ T cells were labelled with CFSE on day 0. Cells were labelled by 
incubating with 1μM CFSE in PBS for 5 minutes in the dark and then washed 3 
times in RF10. Labelled cells were then used to set up MLR reactions as 
previously described. After 5 days proliferation was assessed using flow 
cytometry. 
2.7 Skin explant assay 
The skin explant assay was originally developed to aid the prediction of 
developing GvHD following allo HSCT. It was first described by Vogelsang et al 
in 1985 and has been widely used since as an effective tool to study the 
immuno-biology of GvHD and predict the outcome of allo-HSCT (Vogelsang et 
al., 1985, Wang et al., 2009, Dickinson et al., 1998, Wang et al., 2006, Kim et 
al., 2011). Briefly, “donor” PBMC are sensitised to host cells by means of a 
MLR. The cells are then co-cultured with small sections of recipient skin and 
then analysed for histologic changes associated with GVHD. 
 This method has been modified to detect the capacity of Treg to prevent 
allo-reactive CD8+ T cell induced tissue damage in the skin and is summarised 
in Figure 2.4. MLR were set up with CD8+ T cells, allo-stimulated (CD8+moDC) 
and allo-stimulated in the presence of Treg (CD8+moDC+4:1 Treg). After seven 
days the cells were harvested and were subjected to MACS CD4 depletion 
(Miltenyi Biotech) to remove any remaining moDC (which are CD4low) and any 
Treg, leaving only the allo stimulated CD8+ T cells, allo stimulated CD8+ T cells 
in the presence of Treg and the control CD8+ un-stimulated T cells. These cells 
were then re-suspended in skin explant media (RPMI 1640 supplemented with 
100IU/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamate and 20% human 
AB serum). One million CD8+ T cells from each condition were placed into a 96 
well U-bottomed plate with a small piece of skin. The assay was then incubated 
at 37°C for three days when the skin was either stored in RNA later (Ambion) or 
fixed in formalin then embedded in paraffin wax. Sections were stained with 
haematoxylin and eosin (H&E) by the department of Cellualr Pathology Royal 
Victoria Infirmary, Newcastle UK. Remaining MLR cells and supernatants were 
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stored for future use. The damage to the skin was graded according to the 
criteria described by Lerner et al 1974. 
 
Figure 2.4 Skin Explant assay methods.  
A) Diagram to summarise the methods used in the modified skin explant assay. B) 
Images of skin sections following skin explant; Grade 0 is normal healthy skin; Grade I 
shows very mild vacuolization of basal cells; Grade II has diffuse vacuolization of basal 
cells with dyskeratotic bodies; Grade III has cleft formation between dermis and 
epidermis; Grade IV demonstrates complete separation of the dermis & and the 
epidermis (Lerner et al., 1974). 
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2.8 Gene expression 
Total RNA was extracted from cryo-preserved cell pellets using Qiagen 
RNeasy mini kit, following manufacturer’s instructions. RNA purity and quantity 
was assessed using NanoDrop (NanoDrop®, ND-1000). Complementary DNA 
(cDNA) was generated by reverse transcription of the RNA using an equal 
volume of cDNA master mix containing random hexamers (Thermo Scientific), 
dichloro-diphenyl-trichloroethane  (DTT) (Invitrogen), first strand buffer 
(Invitrogen), dNTP (Roche Diagnostics) RNAsin (Promega) and reverse 
transcriptase, MMLV-RT (Invitrogen). The reaction mix was incubated at 37ºC 
for 80 minutes then 65ºC for a further 10 minutes. The final cDNA concentration 
was estimated to be half the concentration of the RNA, assuming 100% 
efficiency of cDNA generation. Once generated the cDNA was stored at -20°C 
until used for quantitative real-time PCR using Taqman® gene expression 
assays. 
Taqman® gene expression assays use a fluorogenic probe to detect PCR 
products as they are generated. The probe sets, which have a fluorescent dye 
on the 5’ end and a quencher dye on the 3’ end, anneal downstream from one 
of the primer sites. Prior to DNA polymerase acting the quencher dye reduces 
the fluorescence from the reporter dye by the use of fluorescence resonance 
energy transfer (FRET). As Taq DNA polymerase extends the primer it 
displaces and cleaves the 5’ reporter dye, increasing the fluorescence signal. 
Taq polymerase then continues to the end of the template strand completely 
displacing the probe. During each cycle additional reporter molecules are 
cleaved from the quencher molecules meaning the fluorescence intensity is 
proportional to the amount of amplification. Taqman® gene expression assays 
were used to measure expression of several genes of interest, summarised in 
Table 2.4. Reactions were carried out in triplicate where possible using 7900HT 
Fast Real Time PCR System and standard thermal cycling conditions (Applied 
Biosystems). Ct values were normalised to the reference gene GAPDH using 
the comparative CT threshold method. 
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Table 2.4 Primer/probe sets used for qPCR. 
Gene of interest Primer/Probe set 
GAPDH Hs99999905_m1 
CXCR3 Hs00171041_m1 
IFNγ Hs00989291_m1 
SELPG/CLA Hs00380945_m1 
CD80 Hs00175478_m1 
CD86 Hs01567026_m1 
MARCH1 Hs00215631_m1 
TBX21 Hs00203436_m1 
GATA3 Hs00231122_m1 
Foxp3 Hs01085834_m1 
RORC Hs01076122_m1 
 
2.8.1 Calculation of RQ values 
Relative quantification (RQ) is used to describe the change in gene 
expression in relation to a reference group. When analysing MLR gene 
expression the CD8 cultured alone were used as the reference group. Ct is the 
cycle number where the number of amplified targets crosses the threshold. The 
Ct was normalised (ΔCt) by subtracting the Ct of the reference gene from the 
test gene Ct.  
     (                                         ) 
Where test group is either CD8+DC or CD8+DC+Treg and reference group is 
CD8 only (Livak and Schmittgen, 2001). 
2.9 Statistical analysis 
All statistical analysis was performed using Graphpad Prism™ software. 
Either Mann-Whitney U tests or paired t tests were used with a p value of less 
than 0.05 being considered significant. 
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2.10 Phenotypic analysis of patient  PBMC  
Serial samples of patient peripheral blood were taken 7 days prior to HSCT 
then at regular intervals post transplantation under approval of the local ethics 
committee. PBMC were isolated by density centrifugation and stored as 
previously described. Samples were stored where possible 7 days prior to 
transplant, then 28 days, 3 months, 6 months, 9 months and 12 months post 
transplantation. Samples were then thawed and stained with either panel A and 
B or panel C alone (Table 2.5). Sample data was collected with Canto II and 
analysed using FlowJo (TreeStar). Patient characteristics are shown in Table 
2.6 
Table 2.5 Patient PBMC staining panels. 
 Panel A Panel B Panel C 
FITC CLA CD4 CLA 
PE CD4 CCR10 CCR10 
PerCPcy5.5 CD3 CD3 CD3 
PEcy7 CD25 CD25 CD25 
APC CXCR3 Foxp3 CXCR3 
APCcy7 CD8 CD8 CD8 
Brilliant violet 450/V450 CD45RA CD45RA CD127 
V500 - - CD4 
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Table 2.6 Patient characteristics. 
Number 30 
Median age 48 (range 20-67) 
Sex  
   Male 12 
   Female 18 
Diagnosis  
   Acute lymphoblastic leukaemia 2 
   Acute myeloid leukaemia 14 
   Non-Hodgkins lymphoma 6 
   Hodgkins lymphoma 4 
   Myelodysplastic syndrome 2 
   Chronic myelogenous leukaemia 1 
   Chronic Granulomatous disease 1 
Reduced Intensity Conditioning  
   Yes 23 
   No 7 
Stem Cell Source  
   PBSC 24 
   BM 6 
aGvHD Grade  
   0 13 
   I 2 
   II 12 
   III 3 
cGvHD  
   Yes 15 
   No 15 
Relapse  
   Yes 8 
   No 22 
Donor Type  
   MUD 25 
   SIB 5 
50 
3  Chapter 3 - Isolation, Expansion and Cryo-preservation of 
suppressive Regulatory T cells 
 Introduction 3.1
One significant barrier to the use of Tregs in a clinical setting is their low 
number in peripheral blood. The ex vivo expansion of regulatory T cells has 
therefore been important for both development of their use in a clinical setting 
and functional in vitro studies. This chapter aims to show the successful 
isolation and expansion of suppressive Treg for their use in in vitro studies and 
discuss issues relevant to the clinical translation of Treg therapy. This chapter 
provides the basis for the entire thesis, validating the methods used to isolate 
and expand Treg ex vivo and characterising the Treg both phenotypically and 
functionally. 
 In vitro identification and isolation of Treg 3.1.1
The gold standard identifier for Treg is the transcription factor Foxp3 
although its intracellular location disqualifies it’s use as an isolation marker in 
human studies. In murine studies it is possible to sort Treg based on Foxp3 
expression using GFP-Foxp3 mice (Simonetta et al., 2012). Tregs do all 
express CD4 and CD25 so consequently this combination of markers has 
formed the basis of many commercially available isolation kits for Treg 
(Sakaguchi et al., 1995). However Treg isolation based on these two markers 
does not exclude the selection of other highly activated T cells along with Treg 
especially in an inflammatory situation. Liu et al (Figure 3.1) reported that the 
brightest 2% of CD25 cells were more than 90% Foxp3+ but looking at the 
brightest 5%, 10% and 15% there was variation between individuals (Liu et al., 
2006). It is therefore not possible to rely fully on CD4+CD25+ selection to 
achieve high Foxp3+ purity. However, selecting only the cells which expressed 
the highest levels of CD25 could result in a population of cells with a high 
percentage of Foxp3 expression. There are other surface markers which are 
constitutivelty expressed on Treg such as, HLA-DR, GITR, CTLA-4 and 
CD45RA however, they are also present on other cell lineages and may not be 
expressed by 100% of Treg, so unless used with a combination of other 
markers they are of little use in the identification and isolation of Treg.  
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Figure 3.1 Foxp3 expression correlates with CD4 cells expressing high levels of CD25 
(Liu et al., 2006). 
Also of relevance in the isolation of Treg is the absence, or low expression, 
of cell surface markers. The IL-7 receptor α chain, CD127 can be used as a 
negative marker of Treg and its expression inversely correlates with Foxp3 
expression and Treg suppressor activity (Liu et al., 2006). Therefore CD127low 
could be used as an additional marker to aid in the identification and separation 
of Treg cells (Seddiki et al., 2006). More recently CD26low has been suggested 
as a marker for Treg. CD26 is a serine protease which is expressed at high 
levels of activated T cells and low levels on Treg which may aid in the isolation 
of Treg in inflammatory situations (Salgado et al., 2012). As an alternative to 
CD4 positive selection, CD8 and CD19 depletion, followed by CD25 positive 
selection  has been reported, resulting in a GMP population of Treg suitable for 
use in clinical trials (Di Ianni et al., 2012). 
Undoubtedly there are several potential combinations of markers which are 
capable of isolating Treg from whole blood, leukapheresis products or other 
cell/tissue sources and the required use, yield and purity of isolated Treg must 
be taken into consideration when deciding which markers and methods to use 
for Treg isolation. 
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 In vitro activation and expansion of Treg 3.1.2
Due to the low number of Treg in peripheral blood it is often necessary to ex 
vivo expand them prior to use. Several methods for the expansion of Treg have 
been reported over the years. In 2001 Levings et al showed that it was possible 
to expand human Tregs in vitro using exogenous IL-2 (40U/ml) and feeder cells 
(Levings et al., 2001). This study stimulated Treg with anti-CD3 and used a 
cocktail of irradiated allogeneic cell types as feeder cells similar to one 
described in the 1980s by van de Griend to expand allo-specific cytotoxic T 
lymphocytes (van de Griend and Bolhuis, 1984). In a move away from feeder 
cells and towards a more clinical grade Treg product in 2004 Hoffman et al 
described the successful use of CD3/CD28 T cell activator beads to activate 
and expand Treg. Initially cells were cultured at 4 beads per cell, but then 
reduced to 1 bead per cell, in the presence of high dose (300IU/ml) IL-2 up to 
40 000 fold expansion could be achieved without the need for feeder cells. 
(Hoffmann et al., 2004).  
Earle et al also demonstrated that in vitro expansion using anti CD3/CD28 
beads was possible without the loss of suppressor function (Earle et al., 2005). 
This study cultured Treg in media supplemented with much higher 
concentration of recombinant human IL-2 (2000 IU/ml) and anti CD3/CD28 
beads at a 1:1 ratio. They reported a lag in expansion for the first week, 
sometimes even seeing cell death, but after this initial lag phase cells expanded 
well. Reporting cell death in the early stages of expansion is not seen in any 
other studies which use an increased bead number and then reduce the 
number of beads per cell after the cells have begun to expand. 
A 2006 study by Hoffmann et al suggested that only naive CD4+CD25Hi Treg 
(CD45RA+) were able to maintain high purity during expansion, they used 
300U/ml recombinant IL-2 with either CD3 and CD28 antibodies or T cell 
expander beads coated with antibody, and suggested RA- Treg were more 
likely to lose Foxp3 expression and have less suppressive properties (Hoffmann 
et al., 2006). It was shown by the same group that upon repetitive in vitro 
stimulation CD4+CD25+ Tregs lose Foxp3 expression, in particular memory-type 
Treg (Hoffmann et al., 2009). Prevention of this loss of Foxp3 expression was to 
be the next advance in methods to expand Treg ex vivo. 
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In 2007 Strauss et al described the use of rapamycin (sirolimus) in Treg 
expansion culture to preferentially select for Tregs and prevent the loss of 
Foxp3 expression (Strauss et al., 2007). Rapamycin is a powerful 
immunosuppressive reagent, blocking signalling in response to the T cell growth 
factor IL-2 (Abraham and Wiederrecht, 1996). The exact mechanism by which 
Treg preferentially expand is still unknown however it is believed that rapamycin 
induces apoptosis in TCR-activated T cells but Treg appear to be resistant. In 
conventional T cells the PI3K/mTOR survival signalling pathway is blocked by 
rapamycin leading to activation induced apoptosis (Zeiser et al., 2008). In 
addition the presence of rapamycin leads to differential expression of anti-
apoptotic Bcl-2 family of proteins – levels are increased in Treg and down 
regulated in conventional T cells leading to an increase in Bax and subsequent 
apoptosis (Strauss et al., 2009). In this study the optimal rapamycin 
concentration was decided to be 1nM. They stated any more than 10nM 
decreased expansion rates, and less than 1nM had no desirable effect, 
however this data was not reported. This study also used high concentration 
exogenous recombinant human IL-2 (1000IU/ml). They also confirmed that 
phenotypic characteristics were unaffected by rapamycin, measuring 
expression of CD25, Foxp3, CD62L, GITR, CTLA-4, CCR7, FAS and HLA-DR. 
Battaglia et al showed that, after proving rapamycin expanded murine Treg, it  
also promoted the expansion of human Treg (Battaglia et al., 2006).  
There are undoubtedly several factors which need to be taken into 
consideration for the in vitro culture of Treg. Within our lab a Treg expansion 
method has been developed which takes into account several aspects of the 
studies previously mentioned (Wang et al., 2009). This method uses high 
concentration IL-2 (500IU/ml), 100nM Rapamycin and CD3/CD28 T cell 
expander beads, initially 3 beads per cell but reduced to 1 bead per cell once 
cell numbers began to increase (Wang et al., 2009).  
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 The effect of cryo-preservation on Treg 3.1.3
The effects of cryo-preservation on the suppressive properties of Treg is 
becoming of more importance with the increasing use of cryo-preserved Treg in 
clinical trials (Brunstein et al., 2011). Despite the interest in the use of cryo-
preserved Treg for clinical use, little is known about the effects of cryo-
preservation on their potency. The ability to cryo-preserve Treg for use in in 
vitro studies would also be highly beneficial as it would allow for more 
experimental flexibility and efficient use of resources. To date no 
comprehensive study has tested the effects of cryo-preservation on the 
suppressive capacity of Treg. 
 Cryo-preservation of PBMC is commonly used for subsequent analysis, 
however many studies have reported cryo-preservation to be detrimental to 
some subpopulations of cells (Golab et al., 2013).  A study by Constantini et al 
reported a comparison of PBMC from HIV patients and healthy controls prior to 
and following cryo-preservation. They suggested that cryo-preservation could 
affect surface marker expression and also the proportion of cells within the 
PBMC. In the healthy controls they reported a decline in central memory 
(CD45RO+CD62L-) and naïve (CD45RA+CD62L+) cells and an increase in 
effector CD8+ cells (Costantini et al., 2003). This study made no mention of the 
proportion of Treg but raised questions as to the effects of cryo-preservation on 
cell populations within PBMC.  
In 2009 Elkord reported a decrease in the proportion of Treg following cryo-
preservation (Elkord, 2009). This study only investigated the percentage of 
cells, no assessment of their suppressive capacity was carried out and only 6 
healthy volunteer samples were used. A letter in direct response to this paper 
was then published stating that they had observed no such decrease in Treg 
percentage following cryopreservation and that this difference could be caused 
by differences in methodology (Van Hemelen et al., 2009). Despite differing 
results in the effect of cryo-preservation on Treg it was generally agreed that it 
was necessary to keep protocols consistent, so if a particular study used cryo-
preserved samples then it was important to always use previously cryo- 
preserved samples.   
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There is little in the literature as to the effects of cryo-preservation on the 
suppressive properties of isolated Treg. Peters et al, in 2008, reported 
successful isolation and expansion of clinical grade Treg; they also tested the 
suppressive capacity of Treg following cryo-preservation. It was observed that 
freshly isolated Treg required both a recovery period and expansion following 
thawing in order to retain their suppressive capacity; Treg which were expanded 
prior to cryo-preservation did not require a recovery period and were highly 
suppressive upon thawing (Peters et al., 2008). However in this study they only 
looked at the Treg capacity to prevent 3H thymidine incorporation of autologous 
naive CD4+CD25- cells. It is therefore necessary to test the effects of cryo-
preservation on the suppressive effects of Treg prior to routinely using them for 
further in vitro experiments.                                                                                                                                                      
 
The specific aims of this chapter were to:- 
 Optimise and validate a method for in vitro isolation and expansion of 
Treg. 
 Monitor the suppressive properties of Treg throughout ex vivo expansion. 
 Investigate the effects of cryo-preservation on Treg ability to mediate 
suppression of T cell allo-responses. 
 Compare the suppressive properties of donor or third party derived Treg 
in the context of HSCT. 
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 Methods 3.2
 Cell isolation and culture 3.2.1
The isolation of CD8+ cells, isolation and expansion of Treg and the 
generation of moDC was carried out as described previously (Chapter 2). Treg 
were cryo-preserved as previously described in 90% FCS and 10% DMSO. 
 Expansion rate and culture conditions for Treg 3.2.2
Treg were expanded as previously described. Calculation of cell yield and 
assessment of Treg stability were assessed by maintaining Treg in expansion 
culture for up to 5 weeks with regular cell counts and Foxp3 staining to assess 
purity. Culture medium was changed every 2-7 days when required. Treg were 
also expanded either in the presence or absence of rapamycin. 
 The effect of cryo-preservation on Treg 3.2.3
A summary of the methods used to test the effects of cryo-preservation is 
shown in Figure 3.2. Briefly detailed phenotypic analysis of Treg was carried out 
by flow cytometry prior to and following cryo-preservation. In order to ensure 
that the cryo-preservation of Treg did not affect their ability to suppress allo-
reactive CD8+ T cells Treg were tested fresh, following expansion, and then 
again after being cryo preserved for a minimum of 7 days. Suppressive capacity 
was assessed by measuring allo-stimulated CD8+ proliferation, activation, 
cytokine production and the extent of GvH reaction using the modified skin 
explant assay. 
 Use of third party Treg to suppress GvH reactions 3.2.4
A summary of the methods used to test the potency of third party Treg in 
ameliorating GvH reactions is shown in Figure 3.3 CD8+ T cells were allo-
stimulated as previously described, either in the presence of Treg from the 
same donor as the CD8+ T cells, or from a third party donor. The CD8+ T cell 
response to allo-stimulation was measured using CD8+ T cell activation and 
proliferation. In addition third party Treg were tested in the skin explant model, 
briefly responder PBMC were incubated with irradiated stimulator PBMC either 
in the presence or absence of third party Treg for 7 days. The responder PBMC 
were then incubated with small sections of skin (from the stimulator donor) 
which was then graded for cutaneous GvH damage as previously described. 
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Figure 3.2 The effects of cryo-preservation on Treg function. 
Cells were isolated from LRS cones. Some Treg were used fresh following expansion, 
other aliquots were cryo-preserved in 90% FCS 10% DMSO for a minimum of 7 days prior 
to use. Treg were added into MLR with ratios of 2:1, 4:1, 8:1 and 16:1 for proliferation 
assays and 2:1 and 4:1 for flow cytometry to measure activation markers. CD8
+
 T cell 
proliferation was measured by 3H-thymidine (3H-TdR) incorporation on D5. Activation 
markers were measured by flow cytometry (CD69 after 24 hours and CD25 after 5 days). 
Skin explant GVH reaction was carried out as previously described; briefly CD8+ cells 
were isolated from MLR on D7 by CD4 depletion of Treg and any remaining moDC. CD8 
cells were then incubated with small sections of skin (from the stimulator) for 3 days, 
which were then routinely fixed and H/E stained then graded according to the Lerner 
scale (Lerner et al., 1974).  
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Figure 3.3 The use of third party Treg to supress GvH reaction.  
Cells were isolated from LRS cones. CD8+ T cells and Treg were isolated from one 
donor, moDC were generated from a second donor and Treg isolated from the third 
donor. Treg were activated and expanded prior to use. Either autologous or third party 
Treg were added into mixed lymphocyte reactions at ratios of 4:1, 8:1 and 16:1. CD8 T 
cell activation was measured after 24 hours by expression of CD69, and after 5 days by 
expression of CD25. 3H-TdR incorporation on D5 was used to assess the capacity of 
Treg to supress CD8+ T cell proliferation. 
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 Results 3.3
Data included in this chapter has been published as a letter to the journal 
Transplantation 95;e68-70 (2013) Do cryopreserved regulatory T cells retain 
their suppressive potency? (Mavin et al., 2013). 
 Isolation and Expansion of Regulatory T cells 3.3.1
Treg were successfully isolated from LRS cones following CD4 negative 
enrichment and CD25Hi positive selection. The average Treg purity upon 
isolation, identified by Foxp3 expression, was 81.9%±2.17 SEM, rising to 
90.7%±1.52 SEM following expansion (Figure 3.4 & Figure 3.5).  
 
Figure 3.4 Successful isolation of Treg from LRS cones. 
Representative plots from multi-parameter flow cytometry analysis (n=35). Data shown 
includes analysis of PBMC before isolation, CD4 enriched lymphocytes, CD4 CD25
Hi
 
enriched cells and Treg after activation and expansion. Treg purity was calculated by 
gating on lymphocyte populations based on FSC and SSC then the CD3
+
CD4
+
 population. 
Within the CD4
+
 population both the CD4
+
 CD25
Hi
 and the the CD25
Hi
Foxp3
+
 populations 
are shown. Appropriate isotype controls were used to determine gate position.  
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 Rapamycin is required to maintain Foxp3 expression  3.3.2
To ensure that Treg were successfully expanded Foxp3 purity was routinely 
checked throughout expansion. Treg were expanded in RF10 with exogenous 
IL-2 and T cell expander beads. In the presence of rapamycin Treg increased in 
purity (p=0.0015) and maintained Foxp3 expression of over 90% for up to 3 
weeks in expansion culture and over 70% for up to 4 weeks (Figure 3.5). In the 
absence of rapamycin during expansion culture Treg purity decreased rapidly. 
This is consistent with the findings by Strauss et al (Strauss et al., 2007). This 
data confirms that the Treg isolation and expansion protocol used results in a 
highly pure population of Treg which were stable in expansion culture and 
therefore suitable for further use in in vitro studies. 
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Figure 3.5 Rapamycin maintains Treg phenotype during expansion. 
A. Rapamycin is required to maintain Treg purity; upon isolation purity was 80.6%. Purity 
increased to >95% during week 1 of expansion in the presence of rapamycin (n=1-26).   
B.  Purity of Treg upon isolation then following expansion in the presence of rapamycin 
(n=26) purity significantly increased from 81%±2.17 to 90%±1.52, p=0.0015. 
 
 Expression of Helios in freshly isolated/expanded Treg 3.3.3
Commonly the transcription factor Helios is used to differentiate between 
natural and induced Treg. It has been reported that naturally occurring thymus 
derived Treg express Helios and Treg induced in the periphery do not express 
Helios (Thornton et al., 2010). However, this appears to be controversial since 
there have been reports of induced Treg expressing Helios in vitro (Gottschalk 
et al., 2012). In the absence of any other known marker to differentiate between 
them Helios was used in this study to assess the proportion of induced and 
naturally occurring Treg during expansion. The percentage of Helios+ Treg seen 
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was in line with what is previously reported in the literature (Thornton et al., 
2010) and it remained consistent throughout Treg expansion (Figure 3.6). 
 
Figure 3.6 Helios expression in Treg cells throughout expansion culture.  
Representative plots (n=2). Prior to plots shown, gates were applied on live cells and 
Foxp3
+
 Treg. Gate position was determined using the appropriate isotype control. 
 
 Expansion rate of isolated Treg 3.3.4
The cell number and phenotype of Treg were monitored throughout 
expansion by cell counting and IC Foxp3 staining. Over 3 weeks of expansion 
culture, in the presence of IL-2, rapamycin and CD3/CD28 beads, cell numbers 
increased by an average of 57 fold ±18.6 SEM. Trypan blue dead cell exclusion 
dye was used to monitor cell viability (Figure 3.7). 
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Figure 3.7 Expansion of cultured Treg.  
Growth curve is shown for Treg expanded for up to 3 weeks (n=4-13). 
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 Treg prevent allo-moDC stimulated CD8+ T cell proliferation in a 3.3.5
dose dependent manner 
Mixed lymphocyte reactions (MLR) were used to assess the suppressive 
ability of Treg. As this study was to focus on the potential beneficial properties 
of Treg in ameliorating GVHD following HSCT allo stimulated CD8+ T cells were 
chosen to test Treg suppressive properties due to the prominent role of CD8+ 
cells in the pathophysiology of GVHD. 
Treg suppression of CD8+ T cell proliferation was measured using 3H-TdR 
incorporation (Figure 3.8), after 4 days the MLR were pulsed with 3H-TdR for a 
further 16 hours. The count per minute (cpm) recorded by CD8+ T cells alone 
was considered to be the background level. It was shown that Treg were able to 
suppress proliferation by allo-stimulated CD8+ T cells to a level not significantly 
different from background levels when used at a ratio of 2:1 CD8:Treg 
(p=0.100). As the number of Treg in the MLR decreased, to a ratio of 16 CD8 to 
1 Treg, the proliferation of CD8+ T cells increased but always remained 
significantly lower than allo-stimulated CD8+ T cells in the absence of Treg 
(p=<0.0001). 
 
Figure 3.8 Treg prevent allo-stimulated CD8
+
 T cell proliferation in a dose dependent 
manner.  
3H-TdR incorporation was used to measure CD8
+
 T cell proliferation; un-stimulated CD8
+
 
T cells and allo-moDC stimulated CD8
+
 T cells acted as negative and positive controls 
respectively ( ). Autologous Treg were present in a range of CD8:Treg ratios ( ). 
Suppression was seen to be greater with higher concentrations of Treg. Representative 
data is shown (n=5), triplicate MLR wells were analysed for each experiment (as indicated 
by error bars).  
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 Treg inhibit allo-moDC stimulated CD8+ T cell activation  3.3.6
Activation of CD8+ T cells following allo-moDC stimulation results in 
increased expression of activation markers CD69 and CD25, measured by flow 
cytometry (Figure 3.9). The early activation marker CD69 increased in 
expression 24 hours after allo-stimulation from 2.40%±0.59SEM to 
13.1%±1.34SEM, but in the presence of Treg (at a CD8:Treg ratio of 4:1) this 
early activation was reduced (only 6.36%±1.09SEM expression). After 5 days 
expression of CD25 increases from 0.34%±0.04SEM to 31.6%±2.77SEM, but 
was again suppressed in the presence of Treg (4.97%±0.94SEM). This data, 
along with Treg prevention of allo-moDC stimulated CD8+ T cell proliferation, 
confirms that the expanded Treg are highly suppressive and suitable for use in 
further studies. 
 
Figure 3.9 CD69 and CD25 suppression by Treg on allo-stimulated CD8
+
 T cells. 
Cells were gated on lymphocytes based on FSC SSC and then CD8
+
 T cells prior to 
representative plots shown. MLR were used to assess CD8
+
 T cell activation, CD8
+
 T cells 
alone were considered to be background expression and allo-moDC stimulated CD8
+
 T 
cells either in the presence or absence of autologous Treg at a ratio of 4:1 (n=5). 
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 Treg retain their suppressive properties in expansion culture 3.3.7
The suppressive capacity of Treg was measured at regular time points 
following isolation using 3H-TdR incorporation to ensure it was maintained 
throughout expansion. Suppressive capacity of the Treg increased following 1 
week of expansion culture, falling slightly in weeks 2 and 3 with a more marked 
decreased when Treg were expanded for more than 4 weeks (Figure 3.10). The 
decrease in suppressive capacity was more apparent when less Treg were 
present (8:1 and 16:1 CD8:Treg ratios).  
 The decrease in suppressive capacity of the Treg corresponded with a 
decrease in Foxp3 purity of the Treg (Figure 3.10 shown in red). This suggests 
that while the Treg express high levels of Foxp3 they will remain suppressive for 
several weeks in expansion culture and are therefore suitable for use in further 
in vitro studies. Because of the decrease in suppressive capacity associated 
with the decline in Foxp3 expression further functional studies were carried out 
using Treg expanded for only 2-3 weeks, with close monitoring of Foxp3 
expression levels. 
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Figure 3.10 Association of Treg Foxp3
+
 purity and their suppressive potency.   
CD8
+
 T cells were allo-moDC stimulated in the presence of 4:1 Treg ( ) 8:1 Treg (  ) or 
16:1 Treg ( ). Treg were freshly isolated and expanded and suppressive potency as 
assessed at 5 time points. Proliferation was measured by 3H-TdR incorporation. Levels 
of Treg suppression were calculated by subtracting background cpm (CD8
+
 T cells alone) 
and dividing by the positive control (CD8
+
T cells allo-stimulated with moDC). Values were 
then subtracted from 1 to give a suppression value. Each data point represents mean of 
3 replicates in one experiment. Treg Foxp3
+
 purity is shown in red ( ). 
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 Isolation based upon CD4+CD25Hi is sufficient for suppressive Treg 3.3.8
As previously described the use of CD4+CD25+ to isolate Treg may not be 
sufficient to achieve high purity, particularly in an inflammatory situation. Two 
commercially available Treg kits were compared, based upon purity following 
isolation, purity of expanded cells, expansion capacity and ability to suppress 
allo-stimulation in a MLR. Both kits, obtained from Stemcell Technologies, relied 
on CD25Hi immuno-magnetic positive selection following a negative 
RossetteSep enrichment. One kit uses CD4+ enrichment and the other 
CD4+CD127- enrichment.  
The purity of freshly isolated Treg was not significantly different between the 
two kits (Figure 3.11) and following activation and expansion of this isolated 
Treg the purity remained comparable between cells isolated by both kits; 
96.47%±0.56SEM for CD4+CD25Hi and 97.3%±0.91SEM for CD4+CD127-
CD25Hi. In addition to the purity of the cells the number isolated was 
investigated. From the same starting number the CD4+CD25Hi selection resulted 
in a higher yield than the CD4+CD127-CD25Hi selection (Figure 3.11). 
Throughout expansion the growth rate of Treg isolated by both methods was 
comparable, however the final cell number was much greater for the 
CD4+CD25Hi selected cells due to the higher starting number (p=0.049). 
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Figure 3.11 Selecting Treg by CD4
+
CD25
Hi
 results in greater yield without a reduction in 
purity following expansion.  
Foxp3 purity was assessed by flow cytometry and cell number was measured by cell 
counting using Trypan blue dead cell exclusion dye at regular points throughout Treg 
expansion. 
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To ensure both populations of Treg had equally potent suppressive capacity 
the ability of the cells to supress allo-stimulation of CD8+ T cells was assessed. 
The ability of the Treg to prevent allo-stimulated CD8+ T cell proliferation, 
measured by CFSE dilution, and activation by expression of CD25 and CLA 
was comparable between CD4+CD25Hi Treg and CD4+CD127-CD25Hi Treg 
(Figure 3.12). This supports current literature therefore was only carried out 
once. 
 
Figure 3.12 Treg suppression of allo-stimulated CD8
+
 T cell activation and proliferation 
was comparable between CD4
+
CD25
++
 and CD4
+
CD127
-
CD25
++
 isolation methods.  
Prior to plots shown live cells were selected (n=1).  
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 Cryopreservation of Treg has no effect on their phenotype, 3.3.9
expansion capacity and suppressive function 
In order to ensure that previously cryo-preserved Treg could be used in 
further experiments the phenotype and suppressive properties were tested prior 
to and following cryo-preservation. Cryopreservation was shown via several 
means to have no effect on the ability of Treg to prevent activation and 
proliferation of allo-stimulated CD8+ T cells. Firstly 3H-TdR incorporation 
(shown in Figure 3.13) was used to demonstrate that there was no difference in 
the prevention of allo-stimulated CD8+ T cell proliferation depending on whether 
the Treg were cryo-preserved or not (p>0.05). To ensure the robustness of this 
test, matched pairs of Treg with and without cryo-preservation were used in 
parallel tests.  
 
Figure 3.13 Treg dose dependant suppression of CD8
+
 T cell proliferation is unaffected 
by cryo-preservation of Treg prior to MLR.  
Proliferation was measured using 3H-TdR incorporation by allo-moDC stimulated CD8
+
 T 
cells in the presence of freshly expanded ( ) or cryo preserved ( ) Treg. Un-stimulated 
CD8
+
 T cells and allo-stimulated CD8
+
 T cells ( ) served as negative and positive 
controls. Error bars indicate mean±SEM of 9 individual tests of 3 independent 
experiments.  
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Secondly suppression of expression of activation markers and skin homing 
markers on CD8+ T cells by Treg was also unaffected by cryopreservation 
(Figure 3.14). The skin homing markers CLA and CCR10 were chosen because 
of their particular relevance to cutaneous GvHD (Tsuchiyama et al., 2009, Faaij 
et al., 2006). Suppression of the early activation marker CD69 (Figure 3.14a) 
and the late activation marker CD25 (Figure 3.14b) was comparable between 
freshly expanded and cryo-preserved Treg at a range of ratios. Treg 
suppression of CLA expression on the allo-stimulated CD8+ T cells was above 
85% regardless of whether the Treg were cryo-preserved or not (Figure 3.14c). 
Cryo-preserved Treg inhibition of CCR10 appeared lower; however, this 
difference was not statistically significant (Figure 3.14d). 
 
Figure 3.14 Suppression of expression of activation and skin homing on CD8
+
 T cells is 
unaffected by cryo-preservation of Treg.  
Percentage inhibition of activation and skin homing markers by CD8
+
 T cells in the 
presence of freshly expanded ( ) or cryo preserved ( ) Treg. Inhibition was calculated 
using un-stimulated CD8
+
 T cells (background levels) and allo-stimulated CD8
+
 T cells (in 
the absence of Treg) as reference samples. Error bars indicate mean±SEM a) 
Suppression of CD69 expression on CD8
+
 cells by Treg after 24 hours. b) Suppression of 
CD25 expression in CD8
+
 cells by Treg after 5 days. c) Suppression of CLA expression 
on CD8
+
 cells by Treg after 5 days. d) Suppression of CCR10 expression on CD8
+
 cells by 
Treg after 5 days (n=3). 
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Detailed phenotypic analysis of Treg was carried out by flow cytometry prior 
to and following cryopreservation. Foxp3 expression, CTLA-4 expression, LAP 
(TGFβ1) and IL-10 staining all showed no change in expression following cryo-
preservation (Figure 3.15). These markers were chosen due to their importance 
in both the function and phenotypic identification of Treg.  
 
Figure 3.15 Phenotype of Treg following cryo-preservation.  
Cells were routinely fixed and stained for both cell surface and intra-cellular markers, 
Representative histograms are shown (n=3) with freshly expanded (  ) cryo-preserved ( 
 ) and control (  ) 
 
Both the phenotypic and functional comparisons between freshly expanded 
and cryo-preserved Treg led to the conclusion that cryo-preserved Treg retain 
their suppressive potency. Therefore it is possible to use previously cryo-
preserved Treg for further in vitro functional studies.  
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  The use of third party Treg to ameliorate GvH reactions 3.3.10
Recent clinical trials have used third party Treg however the question 
remains whether the third party Treg are as effective at preventing GvHD as 
Treg autologous to the donor. In vitro functional tests were carried out to 
investigate the potency of third party Treg in comparison to Treg which were 
autologous to the CD8+ T cells. The ability of third party Treg to suppress allo-
stimulated CD8+ T cell proliferation was measured using 3H-TdR incorporation. 
Third party Treg were less potent at suppressing proliferation than autologous 
Treg (p=0.01, 0.03 and 0.01 for 2:1, 4:1 and 16:1 ratios respectively). Although 
less potent than autologous Treg, the third party Treg were able to significantly 
reduce proliferation at all ratios when compared to the CD8+ T cells allo-
stimulated in the absence of Treg (Figure 3.16). 
 
Figure 3.16 Treg dose dependant suppression of CD8
+
 T cell proliferation was not 
comparable between autologous and third party Treg. 
Proliferation was measured using 3H-TdR incorporation by allo-moDC stimulated CD8
+
 T 
cells in the presence of autologous ( ) or third party ( ) Treg. Un-stimulated CD8
+
 T 
cells and allo-stimulated CD8
+
 T cells ( ) served as negative and positive controls. 
Error bars indicate mean±SEM of 9 individual tests of 3 independent experiments. 
In addition the suppressive capacity of third party Treg was measured by the 
activation status of the CD8+ T cells after 24 hours and 5 days of allo-
stimulation. Levels of CD69 suppression were comparable between autologous 
and third party Treg (Figure 3.17 p=0.78 and 0.62 for 2:1 and 4:1 respectively). 
Late activation was assessed via expression of CD25, autologous and third 
party Treg supressed CD25 expression to the same extent at a 2:1 ratio of 
CD8:Treg (p=0.23) however, when less Treg were present at the 4:1 ratio the 
third party Treg were less potent at supressing CD25 expression (p=0.03) 
although they do show potent expression when compared to allo-stimulation in 
the absence of Treg. 
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Figure 3.17 Treg dose dependant suppression of CD8
+
 T cell activation by third party 
Treg. 
Activation was measured by flow cytometry for CD69 at 24 hours and CD25 after 5 days 
of allo-stimulation in the presence of autologous ( ) or third party ( ) Treg. Un-
stimulated CD8
+
 T cells and allo-stimulated CD8
+
 T cells ( ) served as negative and 
positive controls. Error bars indicate mean±SEM of 4 independent experiments. 
 
Finally the potency of third party Treg was assessed in the skin explant 
model. Irradiated PBMC were used to stimulate donor PBMC in a 7 day MLR 
either in the presence or absence of third party Treg, these cells were then 
incubated with small sections of skin obtained from the stimulator before being 
fixed and assessed for GvH damage. In the presence of Treg (Figure 3.18C) 
the severity of damage was greatly reduced compared to when Treg were 
absent during the MLR phase (Figure 3.18B). This is in line with previously 
published work using Treg autologous to the PBMC. 
 
Figure 3.18 Third party Treg are able to prevent cutaneous GvH damage in human skin 
explant model.  
Sections were graded according to the Lerner scale (Lerner et al., 1974). Representative 
images from 3 independent experiments.  
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 Discussion 3.4
This work demonstrates successful isolation, expansion and 
cryopreservation of highly purified populations of suppressive regulatory T cells 
from human peripheral blood samples, and has therefore provided a basis for 
studies carried out in the following chapters. The isolation and expansion rates 
seen are consistent with previously published data. Peters et al saw a 30 fold 
expansion in 10 days of expansion culture (Peters et al., 2008). This is a lower 
fold expansion, but also a shorter expansion time than in this study. Hoffmann 
et al report a much higher Treg expansion of up to 40 000 fold over a period of 
3-4 weeks (Hoffmann et al., 2004). In this expansion protocol they used a co-
culture containing CD32+ L cells to achieve such high cell numbers. In the 
absence of the helper cells a lower expansion rate was seen of 2775 fold 
increase over 4 weeks. The overall fold increase in cell number seen in this 
study may appear much lower however the cells were expanded for a shorter 
time period (Hoffmann et al., 2004). Conversely it has been reported that some 
donor Treg may be suppressive in the absence of activation and expansion; 
Hagness et al reported that in 54% of healthy donors Treg were spontaneously 
suppressive in a contact dependent APC independent manner (Hagness et al., 
2012). Prolonged expansion of Treg was seen to be associated with a reduction 
in Foxp3 expression and suppressive capacity. It is therefore important to 
consider the balance between cell number and cell function. An increase in cell 
number may come at the cost of reduced suppressive function. 
Detailed flow cytometry analysis of isolated and expanded Treg was carried 
out. Freshly isolated Treg were seen to have slightly lower CD4 expression than 
the CD4+CD25neg/intermediate population, this could be due to their slightly smaller 
size prior to expansion (according to forward and side scatter flow cytometry 
analysis) in line with previous reports (Hoffmann et al., 2004). High levels of 
Foxp3 expression was seen along with other functional markers including LAP-
(TGFβ), CTLA-4 and IL-10. All these markers have previously been associated 
with Treg suppressive function and confirm the successful isolation and 
expansion of Treg (Tang and Bluestone, 2008).  
Although Foxp3 is considered to be the gold standard identifier and master 
regulator of Treg development and function it can be transiently expressed in 
activated conventional T cells (Wang et al., 2007). Assessment of the 
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methylation status of the Foxp3 locus enables discrimination between Treg and 
conventional T cells which are transiently expressing Foxp3 (Baron et al., 
2007). Therefore further investigation into the methylation status of the Foxp3 
locus could provide further insight into the purity and stability of the ex vivo 
expanded Treg used in this study.  
The stability of Treg is of great importance when considering the routine use 
of Treg in the clinic and has been the subject of much debate (Sakaguchi et al., 
2013).  Under some inflammatory conditions Treg may become unstable and 
loose Foxp3 expression becoming pathogenic T cells (Zhou et al., 2009, 
Hansmann et al., 2012).  It is thought that Treg induced in the periphery are less 
stable and therefore more likely to lose Foxp3 expression, ideally only thymus 
derived natural Treg would be isolated and expanded.  
Helios has commonly been used to identify the difference between nTreg 
and iTreg. However recent reports have drawn attention to the possibility that 
Helios may not be able to accurately differentiate between the populations 
(Thornton et al., 2010, Gottschalk et al., 2012, Akimova et al., 2011). In the 
absence of any other known marker at the time, to differentiate between them, 
Helios was used in this work to assess the proportion of induced and naturally 
occurring Treg during isolation and expansion. It was seen that the proportions 
of Helios+ and Helios- cells remained consistent throughout isolation and 
expansion. Helios has been shown, in mouse models, to induce epigenetic 
silencing of the IL-2 gene locus, thereby preventing Treg production of IL-2 
(Baine et al., 2013). Interestingly IL-2 signalling coincided with lower levels of 
Helios expression and reduced suppressive capacity (Baine et al., 2013). These 
results would suggest that Helios levels could be down-regulated due to a 
negative feedback loop during expansion, however no such down-regulation in 
Helios expression was seen. 
Bruder et al reported the transmembrane protein neuropilin-1 (Nrp-1) as 
strongly and constitutively expressed in murine Treg (Bruder et al., 2004). 
Recent work using mouse models proposed that Nrp-1 is expressed on nTreg 
at higher levels than on iTreg, therefore potentially differentiating between the 
two populations (Weiss et al., 2012, Yadav et al., 2012). Unfortunately is has 
been reported that in humans Nrp-1 is not a marker of Foxp3 Treg, but rather a 
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general activation marker for human T cells (Milpied et al., 2009). It may still be 
possible to use Nrp-1 as a marker to differentiate between nTreg and iTreg in 
the future however more work would be needed to ensure that it is an accurate 
way of separating the two populations. 
There are few reports on the effects of cryopreservation on isolated Treg. 
However there have been conflicting reports as to the effect of cryopreservation 
on percentages of Treg within PBMC. Elkrod, in 2009, suggested the 
percentage of Treg in PBMC were significantly reduced following 
cryopreservation, however Van Hemelen et al provided evidence to the contrary 
(Elkord, 2009, Van Hemelen et al., 2009). An additional study reported that 
mRNA expression of Treg associated markers such as Foxp3, CTLA-4 and 
TGF-β in total PBMC was unchanged following cryopreservation (Kivling et al., 
2009). These studies focused on the effects of cryo-preservation on un-isolated 
Treg and demonstrated that the effects of cryopreservation need to be 
thoroughly investigated prior to routine use of Treg as an ‘off the shelf’ reagent 
for therapeutic use. 
Peters et al stated that the cryopreservation of isolated Treg reduced their 
suppressive capacity unless they were expanded after thawing, however they 
showed that expansion prior to cryopreservation did result in Treg able to 
suppress autologous CD4+CD25- proliferation. The results described in this 
chapter are in line with those published by Peters et al (Peters et al., 2008). In 
addition the results have demonstrated a comparable suppressive potency on 
cryopreserved Treg across a much wider spectrum including their ability to 
modulate activation, proliferation and cytokine production of allo-reactive CD8+ 
T cells. Taken together the results offer an assurance that cryopreserved Treg 
can be used in further in vitro functional tests enabling reduced cost, reduced 
workload and increased consistency. Furthermore the results provide the first in 
vitro evidence with particular relevance to their potential use in the prevention of 
GVHD following allogeneic HSCT. In the context of this work the ability to 
cryopreserve Treg without any adverse effects on the cells is advantageous as 
it allows for extra flexibly in experimental design, more efficient use of available 
resources and the ability to generate a stock supply of Treg.  
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The use of third party Treg as a therapeutic option has reached clinical trials 
however questions still remain as to the potency of third party Treg in 
comparison to autologous Treg. This work has demonstrated that third party 
Treg are highly suppressive and are able to prevent GvH reaction in vitro, 
however they appear to have less potency than autologous Treg, especially at 
lower Treg ratios. The successful and safe use of third party Treg to ameliorate 
GvH has been seen in xenogenic models of GvHD (Parmar et al., 2014) as well 
as in the clinic (Brunstein et al., 2011). This creates the possibility to generate a 
stock supply of ‘off the shelf’ Treg for use in the clinic, potentially improving 
transplant outcomes and providing a readily available source of Treg for 
research purposes.  
In summary this chapter shows the isolation and expansion of Treg which 
are able to suppress a range of allo-reactive responses relevant to graft-versus-
host disease. In addition the results show that it is possible to cryo-preserve 
Treg following expansion without adversely affecting their phenotype or 
suppressive capacity. This work has provided a basis for further assessment of 
the role of Treg in preventing GvHD following HSCT.  
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4 Chapter 4 - Treg modulation of CD8+ T cell migration into 
skin as a mechanism of preventing GVHD 
 Introduction 4.1
Previous work carried out within our group has demonstrated that ‘donor’ 
Treg, when present during priming of effector cells, are able to prevent 
cutaneous GvH tissue damage (Wang et al., 2009). Work presented in this 
chapter, aimed to further investigate the mechanism behind this protective 
effect. It is well reported in the literature that Treg are able to prevent GvHD but 
what mechanisms might be responsible? Extensive research has been carried 
out in murine models to model leukocyte migration in GvHD and the effect of 
Treg may have on this migration, however, currently no such information exists 
for human GvHD. Murine models have the advantage that experimental GvHD 
can be designed and performed as study aim desires whereas in the human 
setting this is not possible. The present study investigated the effect of Treg on 
CD8+ T cell migration in humans using various in vitro functional tests including 
an unique human GvHD ex vivo skin explant model. 
 Donor T cell migration in GvHD 4.1.1
The migration of donor T cells following HSCT is extremely important in the 
patho-physiology of GvHD as histopathologic diagnosis of GvHD requires the 
presence of T cells in the target tissue (Lerner et al., 1974). Extensive research 
has led to the inclusion of effector T cell migration into target tissues as a fourth 
criterion following the classical Billingham concept requiring 3 prerequisites for 
GvHD to occur (Sackstein, 1993, Sackstein, 1995). In GvHD the cytotoxic 
responses against host tissues are mediated by the donor T cells, with the 
recruitment of other effector cells following the initial damage. The most 
effective approach to prevent GvHD remains total depletion of T cells from the 
graft, although this in itself presents alternative problems such as increased 
incidence of relapse (Blazar et al., 2012). Modulation of allo-reactive T cell 
trafficking has been identified as means of ameliorating GvHD (Blazar et al., 
2012).  
In order for T cells to reach their target tissues they must migrate from the 
vascular system into the tissues via a highly regulated process controlled by 
various adhesion molecules and chemokines. Typically T cell migration can be 
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divided into two key processes; firstly extravasation where the cells move from 
the vessel lumen into the tissue and secondly chemotaxis of cells through the 
tissue driven by a concentration gradient of chemokines.  
An established multistep model has been used to describe leukocyte 
extravasation (Butcher, 1991, Springer, 1994); firstly cells tether and roll along 
the endothelial surface (Figure 4.1). Rolling leukocytes then become activated 
following exposure to chemokines, cytokines and other pro-inflammatory 
molecules. This causes activation-dependent increase in integrin adhesive 
capacity, resulting in firm adhesion of the cells. In skin interactions between E-
selectin and cutaneous lymphocyte antigen (CLA) result in the T cells rolling 
along the vascular wall, continuously sampling the endothelium environment. 
Interactions between a chemokine receptor on the T cell, such as CCR4, and its 
ligands CCL17/22, being produced by either the endothelium or skin cells, 
causes activation and up-regulation of integrins on the T cell (such as LFA-1, 
CD11a/CD18, αLβ2) and binding to their ligands (ICAM-1, CD54) on the 
endothelium resulting in firm adhesion of the T cell (Chong et al., 2004). 
Transmigration of the cell into the tissue then takes place, but less is known 
about this process (Wysocki et al., 2005).  
 
Figure 4.1 Summary of leukocyte extravasation.  
Transient interactions between selectins mediate tethering and rolling of cells. When 
cells are then activated by chemokines leading to firm arrest and then transmigration. 
Image taken from www.mpi-muenster.mpg.de.  
Following extravasation cells then move through the tissue driven by a 
concentration gradient of chemokines. In order for T cells to infiltrate the skin 
during GVHD they must complete each stage of migration, therefore blocking 
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just one stage of this process could be enough to prevent migration into the skin 
and consequently reduce cutaneous GvHD following HSCT. This provides a 
possible mechanism for the action of Treg in the prevention of GvHD by 
interfering with at least one stage of T cell migration. The functions of many of 
the components in this process are discussed in more detail with particular 
relevance to GvHD. 
4.1.1.1 Selectins and their ligands in GvHD 
The initial capture and rolling of leukocytes is mediated by selectins 
interacting with carbohydrate epitopes of their ligands in a calcium dependent 
manner (Sperandio, 2006). There are 3 members of the selectin family, L-
Selectin (LECAM-1/LAM-1/CD62L), E-Selectin (ELAM-1/CD62E) and P-Selectin 
(GMP-140/PADGEM) each of which is able to mediate rolling in vitro and in 
vivo. It is their different expression patterns which determines which part of the 
inflammatory response they are involved in (Kansas, 1996). L-selectin is 
predominantly expressed on neutrophils and monocytes along with other 
immature hematopoietic cells and upon activation of leukocytes L-selectin is 
rapidly lost (Kansas, 1996). E-selectin is expressed on endothelium in response 
to inflammatory responses and in human skin expression can be persistent due 
to differential polyadenylation of the E-selectin transcript (Chu et al., 1994). In 
murine models E-selectin has been shown to slow leukocyte rolling and 
therefore aids leukocyte adhesion in the inflammatory microenviroment (Kunkel 
and Ley, 1996). P-selectin is expressed by both endothelium and platelets, it is 
stored in Weibel-Palade bodies and α-granules respectively and these granules 
rapidly fuse with the cell membrane upon stimulation which exposes P-selectin 
on the cell surface, P-selectin is then rapidly internalized and either recycled or 
shed. Like E-selectin, transcription of P-selectin is briefly induced by 
inflammatory stimulus such as IL-1, LPS or TNFα making it likely to be 
expressed both early and late in the immune response (Kansas, 1996). Murine 
studies have shown the importance of selectins in the pathogenesis of GvHD; 
Lu et al demonstrated that the absence of P-selectin in transplanted mice 
resulted in a reduction in experimental GvHD due to reduced allo-reactive T cell 
trafficking to inflamed target tissues (Lu et al., 2010).  
Skin homing T cells can be identified by their expression of CLA, a 
carbohydrate epitope predominantly presented on P-selectin glycoprotein 
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ligand-1 (PSGL-1), which serves as a receptor for vascular selectins 
(Fuhlbrigge et al., 1997). CLA+ T cells can bind both E- and P- selectins  and 
therefore acting as a homing receptor to skin (Borges et al., 1997). CLA is found 
on most infiltrating T cells in almost all skin diseases (Kupper and Fuhlbrigge, 
2004, Fuhlbrigge et al., 1997). CLA+ T cells also typically express the 
chemokine receptor CCR4 which can lead to the arrest of rolling lymphocytes. 
CLA expression allows T cells to interact with E-selectin expressed on 
endothelial cells which mediates rolling and tethering of the cells but it is its 
interactions between chemokines and their receptors which cause the activation 
and diapedesis (Kunkel and Butcher, 2002).  
4.1.1.2 Chemokines and chemokine receptors in GvHD 
Chemokines are a large family of 8-12kDa proteins which function in the 
migration of leukocytes (Moser et al., 2004). This section will focus on the 
function of chemokines as leukocyte chemo-attractants, but it is worth noting 
that chemokines have also been shown to influence other processes such as 
hematopoiesis, angiogenesis and immune cell activation (Wysocki et al., 2005). 
They can be divided into four families based upon the position of N-terminal 
cysteine residues; most are found in the CC and CXC sub-families with a few in 
the CX3C and C sub-families (Murphy et al., 2000, Murphy, 2002). Chemokine 
receptors are a family of 7-transmembrane domain G-protein coupled receptors 
(GPCRs) which elicit downstream cell signalling. There is a high level of 
redundancy in the chemokine system with chemokines interacting with several 
receptors and receptors interacting with several chemokines. The role of a few 
key chemokine/chemokine receptors will be discussed with relevance to GvHD. 
CXCR3 and its ligands 
Various mouse models have been used to investigate the role of 
chemokines in the pathophysiology of GvHD. One of particular interest is 
CXCR3, an inflammatory chemokine receptor which guides T cell migration by 
interacting with 3 IFNγ inducible ligands CXCL9 (monokine induced by gamma-
IFN, MIG), CXCL10 (interferon-induced protein of 10kDa, IP-10) and CXCL11 
(interferon-inducible T-cell alpha chemoattractant, I-TAC) (Kanda et al., 2007). 
Although all 3 ligands bind to CXCR3 they have been shown to work 
redundantly, synergistically, collaboratively and antagonistically in vivo (Groom 
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and Luster, 2011). The chemokine receptor CXCR3 is important in gut 
pathogenesis of GvHD. Using either wild type or CXCR3(-/-) donor cells it was 
shown that there was reduced pathology and CD8+ T cell infiltration into the gut 
when the T cells did not express CXCR3 (Duffner et al., 2003). In addition gene 
expression analysis of cutaneous GvHD in mouse models showed that the 
ligands CXCL9 and CXCL10 were up-regulated in mouse ears within 1 week of 
transplantation (Sugerman et al., 2004). A more recent study showed long term 
use of a CXCR3 blocking antibody in murine models ameliorated GvHD by 
reducing effector T cell migration into target tissues without adversely affecting 
the beneficial GvL  effect (He et al., 2008).  
There is a significant volume of evidence demonstrating the importance of 
CXCR3 in the development of GvHD in mouse models of HSCT. Piper et al 
showed through serum analysis, T cell phenotyping and immunohistochemistry 
that CXCL10-CXCR3 interactions cause the recruitment of T cells into the sites 
of inflammation in human aGvHD (Piper et al., 2007). Interestingly they showed 
that only CXCL10 (but not CXCL11) –CXCR3 interactions were important in 
pathogenesis by recruitment of CXCR3+ T cells into the skin. CXCR3 may also 
play an important role in the pathogenesis of chronic GvHD by causing CD4+ T 
cell migration to the skin (Croudace et al., 2012). Undoubtedly CXCR3 
interactions with its ligands is important in the pathogenesis of GvHD in both 
mouse models and in humans following transplantation and will therefore be 
investigated as a potential mechanism for Treg mediated suppression of GvHD.  
CCR10 and CCR4 and their ligands  
It is thought that CCR4 and CCR10 function redundantly in T cell recruitment 
into the skin (Xiong et al., 2012). CCR10 interactions with its ligand CCL27 are 
important chemokine receptor/chemokine interactions for the migration of 
lymphocytes to the skin (Morales et al., 1999). CCR10 has an additional ligand, 
CCL28, which is produced by mucosal epithelial cells and is also able to 
support migration through CCR3 (Pan et al., 2000). Although important in 
homing to other tissues CCL28 expression will not be discussed further in this 
section due to the lack of its expression in skin. 
Expression of CCL27 is increased with keratinocytes in patients with 
dermatitis or psoriasis and the majority of skin infiltrating lymphocytes 
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expressed CCR10 (Homey et al., 2002).   CCL27 is secreted and immobilized 
on the extra-cellular matrix it is in its active form, creating a concentration 
gradient to guide the T cells through the tissue. Interference of the CCR10-
CCL27 pathway also impaired lymphocyte recruitment into skin (Homey et al., 
2002).  In a cohort of transplant patients those with GvHD,  had a higher 
number of CD4+CCR10+ in their peripheral blood, and that after resolution of 
GvHD these numbers reduced back to normal levels, supporting the 
involvement of CCR10-CCL27 interactions in the pathology of GvHD. Of note 
CCR10 expression is more common on CD4+ T cells than CD8+ T cells (Faaij et 
al., 2006). The CCR4-CCL17 pathway is believed to recruit the lymphocytes 
while the CCR10-CCL27 pathway guides them through the epidermis (Faaij et 
al., 2006). 
4.1.1.3 Integrins in GvHD 
Integrins are a family of cell adhesion molecules which are important in the 
attachment of cells to the extracellular matrix and also in cell-cell interactions. 
The family contains 24 heterodimeric members consisting of non-covalently 
associated α and β subunits (Takada et al., 2007). There are resemblances 
between members of the α subunits and the β subunits but there is no 
homology between the α and β subunits (Barczyk et al., 2010). With particular 
importance to T cell migration in GvHD, integrins function in the tethering and 
rolling of leukocytes. On circulating leukocytes most integrins exist in low affinity 
states and upon stimulation conformation changes and clustering leads to 
increased affinity of integrins (Wysocki et al., 2005). Interactions such as those 
between chemokines and chemokine receptors can elicit “inside-out” signalling 
which is able to rapidly cause a conformational change in the integrin at the 
same time as causing clustering (Wysocki et al., 2005). Figure 4.2 contains a 
representative diagram of the structure of integrins, taken from Barczyk et al 
2010, showing both the α and β chain domains and arrangement (Barczyk et 
al., 2010) 
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Figure 4.2 Representative diagram of integrin heterodimer.  
Half of α subunits contain an αI domain and all integrins contain a βI domain. (Barczyk et 
al., 2010). 
 
The migration of effector CD8+ T cells into skin during GvHD is a highly 
complex process; the effector cells themselves must express the necessary 
skin homing markers, they then must interact with the selectins and integrins 
and then transmigrate into the tissue before completing chemotaxis through the 
tissue. Disruption of this process presents a possible mechanism for the 
amelioration of GvHD following transplantation. 
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The specific question asked in this chapter is whether Treg prevention of 
GvH tissue damage is associated with blocking effector cell migration into 
tissue. This question will be addressed via examining: 
 Association between the number of infiltrating CD8+ T cells in target 
tissue and the severity of GvH histopathology of the tissue 
 Treg modulation of CD8+ T cell infiltration and GvH tissue destruction 
 Treg modulation of tissue homing receptor (CLA and CXCR3) expression 
by effector T cells 
 Treg modulation of chemo-attractants (CXCL9, CXCL10 and CXCL11) 
expression in target tissue 
 Treg modulation of migratory functions including CLA-mediated adhesion 
and CXCR3-mediated chemotaxis of allo-reactive CD8+ T cells  
 Treg modulation of production and gene expression of IFNγ, a key 
inducer of CXCR3 ligands 
 Examining PBMC skin homing marker expression in a small clinical 
cohort 
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 Methods 4.2
General methods used for the work presented in this chapter are included in 
Chapter 2. Additional techniques are described below; including methods used 
to measure T-cell adhesion and migration. 
 In vitro adhesion assay using the cellix platform 4.2.1
The cellix platform is a flow based adhesion assay used to measure Treg 
prevention of CD8+ T cell adhesion to E selectin under flow conditions. In brief 
the cellix platform consists of a Biochip fitted onto a microscope stage in a 
temperature controlled environment. The Biochip contains micro channels 
which are able to mimic in vivo capillary flow rates when fluid is passed through 
them by the nanopump. Images and videos are recorded by a camera attached 
to the microscope for further analysis (Figure 4.3). 
 
Figure 4.3 Cellix Platform used to measure CD8 adhesion to E-selectin under flow 
conditions.  
A) labelled image of the cellix platform (image from www.cellixltd.com). B) Image of a 
Biochip showing micro-channels. C) Still image of cells passing through the micro-
channels. 
Biochips were coated over-night at 4ºC with 100μg/ml E selectin (R&D 
Systems). Non-specific binding was monitored using 1% BSA (Sigma) as a 
control channel. Mixed lymphocyte reactions (MLR) were set up with allo-
stimulated CD8+ T cells either in the presence or absence of autologous Treg 
as previously described. After 5 days the cells were harvested and subjected to 
MACS CD4 depletion to remove Treg and any remaining moDC, leaving only 
the CD8+ cells (Miltenyi Biotech). The CD8+ T cells were then re-suspended at 
2x106cells/ml in RF10 and were passed through the micro channels at 1 
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dyne/cm2 mimicking in vivo capillary flow rates. Following subsequent washes 
only CD8+ T cells expressing CLA would remain adhered to the channels. The 
mean number of cells adhered was analysed by DuoCell software. Flow 
cytometry was also carried out to assess CLA expression on the CD8+ T cells 
as previously described (Chapter 2).  
 Measuring cell migration using the Transwell system 4.2.2
T cell migration towards CXCR3 ligands CXCL9, CXCL10 and CXCL11 was 
measured using a Transwell chemotaxis assay. Effector CD8+ T cells (MLR 
cells as previously described depleted for CD4+ Treg and remaining moDC) 
were loaded into the upper chambers (5x105 per well) of 96 well plates with 
5μm filters. The lower well contained RPMI with 1% BSA and 18nM of the 
appropriate chemokine (Figure 4.4). Plates were incubated for 1 hour at 37ºC 
and then the cells which had migrated to the lower well were collected and 
counted using Neubauer cell counting chamber as previously described.  
 
Figure 4.4 Diagrammatic representation of Transwell chemotaxis assay. 
CD8
+
 effector cells (  ) were loaded into the upper well and appropriate chemokine ( ) 
into the lower well. 
 
 Automated Immunohistochemistry staining using Ventana system 4.2.3
Immunohistochemistry for CD8 (Dako, Cambridge) CXCL10 (PeproTech, 
Rocky Hill, NJ) and CXCL11 (Santa Cruz Biotechnology, Santa Cruz, CA) was 
performed on 3μm thick, formalin-fixed and paraffin-embedded skin sections 
using benchmark autostainer (Benchmart XT; Ventana Medical Systems) with 
the UltraView and the iView DAB detection kit (Ventana Medical Systems, 
Roche, Switzerland). Negative controls were stained without the primary 
antibodies. Cells stained positive or negative for CD8+, CXCL10+ and CXCL11+ 
cells were manually counted across epidermis and primary dermis. The 
percentage of positively stained cells was calculated from the total number of 
cells in the tissue section. 
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 Results 4.3
All work presented in this chapter was performed using ex vivo expanded 
Treg with high purity and potent suppressive functionality as shown in the 
previous chapter. In addition data included in this chapter has been published in 
the journal Transplantation, 15, 456-64 (2012) Regulatory T Cells Inhibit CD8+ 
T-Cell Tissue Invasion in Human Skin Graft-Versus-Host Reactions (Mavin et 
al., 2012). 
 Treg inhibit CD8+ effector T cell infiltration and reduce cutaneous 4.3.1
GvH tissue destruction 
A unique human GvHD skin explant model was used to assess tissue injury 
caused by allo-stimulated CD8+ T cells either in the presence or absence of 
Treg. The severity of cutaneous tissue destruction following the skin explant 
was scored according to the well-established Lerner grading system (Lerner et 
al., 1974). Histopathological changes in each section were graded by two 
independent evaluators.  
Control skin sections incubated in either skin explant medium only or with 
un-activated CD8+ T cells showed minimal tissue injury, all being grade I 
according to the Lerner scale (Figure 4.5a&b). Incubation with allo-stimulated 
CD8+ T cells resulted in a high grade of tissue injury, all being graded III or IV 
(Figure 4.5c). When the CD8+ T cells were allo-stimulated in the presence of 
Treg this resulted in a significant down-regulation in the severity of  tissue injury 
(p<0.0001) with 5 out of the 17 having grade II damage and the remaining 12 
only grade I injury (Figure 4.5d). Late addition of the Treg, at the skin explant 
stage only, showed no inhibition of tissue injury, with all sections having grade II 
damage or above, suggesting that Treg need to be present during priming of 
the CD8+ T cells to prevent GvH damage (Figure 4.5e) in line with previous 
findings (Wang et al., 2009). 
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Figure 4.5 Treg reduce the capacity of CD8
+
 T cells to cause a cutaneous GVH response. 
Cumulative results and representative images of GVH damage of skin sections incubated 
with either (a) medium, (b) un-stimulated CD8
+ 
T cells, (c) allo-stimulated CD8
+
 T cells, (d) 
allo-stimulated CD8
+
 T cells in the presence of Treg and (e) allo-stimulated CD8
+
 T cells 
with Treg present during the skin explant (effector) phase only. Grading of damage is 
according to the Lerner scale (Lerner et al., 1974) from 4-11 independent experiments, 
sections were tested in duplicate where possible. 
 
In addition, the number of infiltrating CD8+ T cells was calculated as a 
percentage of cells in each section after staining by immuno-histochemistry. 
Control skin sections cultured with medium only showed low numbers of 
residual CD8+ T cells 2.6%±0.77SEM and minimal tissue injury (Figure 4.6a). 
CD8+ T cells allo-stimulated in the absence of Treg showed a high number of 
infiltrating CD8+ T cells, 24.7%±3.66SEM (Figure 4.6b). The presence of Treg 
during CD8+ T cell allo-stimulation resulted in a significant reduction in the 
number of infiltrating CD8+ T cells down to only 11.56%±1.79SEM (p=0.01) 
(Figure 4.6c). Delayed addition of the Treg, adding them at the skin explant 
stage rather than the MLR, showed no inhibitory effect on CD8+ T cell migration 
into the skin further demonstrating that Treg need to be present during the initial 
allo-stimulation for them to be beneficial in protecting against CD8+ T cell 
infiltration (Figure 4.6d).   
The grade of histopathological damage and the number of infiltrating CD8+ T 
cells in the skin sections showed a highly significant correlation. As the number 
of infiltrating CD8+ T cells increased the severity of tissue damage also 
increased with the more CD8+ T cells in skin sections showing the higher GvH 
grade III (Figure 4.7). 
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Figure 4.6 Treg prevent tissue infiltration by CD8
+
 T cells.  
Cumulative and representative staining of skin infiltrating CD8
+
 T cells. Skin sections 
were incubated with either (a) medium only, (b) allo-stimulated CD8
+
 T cells, (c) allo-
stimulated CD8
+
 T cells in the presence of Treg and (d) allo-stimulated CD8
+
 T cells with 
Treg present during the effector phase only. Horizontal lines indicate median values of 7-
11 independent experiments. **P<0.01 n=11-13 for each experimental condition. 
 
Figure 4.7 Severity of GvH damage increased as the number of infiltrating CD8
+
 T cells 
increased.  
Cumulative (left) and representative (right) data. The number of infiltrating CD8
+
 T cells 
was calculated following IHC and grading of sections was carried out according to the 
Lerner scale. Negative staining control is shown where no primary antibody was used. 
n=7-21 for each grade of severity. 
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 Treg reduce expression of skin homing receptors on effector cells 4.3.2
In order for cells to migrate from circulation into the skin they must express 
the appropriate skin homing receptors, therefore CXCR3 and CLA was 
measured on the CD8+ T cells following allo-stimulation either in the presence 
or absence of Treg by multi-parameter flow cytometry. CD8+ T cell surface 
expression of the chemokine receptor CXCR3 was up regulated from 
background levels of 28.84%±5.22SEM to 55.98%±4.88SEM upon allo-
stimulation (p=0.0021). In the presence of Treg during allo-stimulation CXCR3 
expression, although higher than background levels, was significantly reduced 
to 40.84%±6.44SEM (p=0.0098) when compared to the level of expression in 
the absence of Treg (Figure 4.8A).   
In addition the expression of CLA was also assessed on resting CD8+ T cells 
and allo-stimulated CD8+ T cells in the presence and absence of Treg and, in 
concordance with the results seen with CXCR3 expression, CLA  was 
significantly increased upon allo-stimulation and in the presence of Treg this 
expression was significantly reduced (Figure 4.8B). Mean background 
expression of CLA was 4.79%±1.47SEM which increased to 31.44%±4.63SEM 
following allo-stimulation (p=0.0004). Allo-stimulation in the presence of Treg 
resulted in a highly significant inhibition of CLA expression with only 
9.62%±SEM of allo-stimulated CD8+ T cells expressing CLA (p=0.0011). 
 
Figure 4.8 Treg reduce skin homing receptor expression.  
Representative flow cytometry plots - gated on live CD8
+
 T cells prior to plots shown- and 
cumulative graphs showing mean±SEM of skin homing receptor expression on un-
stimulated CD8 cells , allo-stimulated CD8 cells  and allo-stimulated CD8 cells in the 
presence of Treg  of A) CXCR3 (n=10) and B) CLA (n=9) respectively. **P<0.01, 
***P<0.0001 
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Next the gene expression of CXCR3 and CLA was assessed using qPCR, 
with GAPDH used to normalise the Ct values, each sample was assessed in 
triplicate as normal protocol dictates. The levels of gene expression for both 
CXCR3 and CLA were not seen to significantly change following allo-stimulation 
of CD8+ T cells (p=0.16 and 0.08 for CXCR3 and CLA respectively). It was 
therefore unsurprising that gene expression was not significantly reduced in the 
presence of Treg (p= 0.08 and 0.87) (Figure 4.9).  
 
 
Figure 4.9 Gene expression of A) CXCR3 and B) CLA measured by qPCR and normalized 
to GAPDH. 
a) un-stimulated CD8
+
 T cells c) allo-stimulated CD8
+
 T cells and (c) allo-stimulated CD8
+
 
T cells in the presence of Treg. n=8 and error bars indicate mean±SEM.  
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 Treg reduce expression of CXCR3 ligands in the target tissue  4.3.3
Having seen that the presence of Treg during allo-stimulation causes a 
reduction in cell surface expression of the chemokine receptor CXCR3, the 
levels of CXCR3 ligands (CXCL10 and CXCL11) were then assessed in the 
skin sections by immunohistochemistry. Levels of CXCL10+ cells were 
calculated as a percentage of cells in each section. In skin sections incubated in 
medium only the background expression of CXCL10 was 40.5%±4.4SEM 
(Figure 4.3.10A). When allo-stimulated CD8+ T cells were added into the skin 
explant the number of CXCL10 expressing cells increased to 70.2%±3.26SEM 
and were significantly reduced to 48.9%±2.76SEM in the presence of Treg 
during CD8+ T cell priming. Late addition of Treg, in the effector phase only (day 
8), did not result in a decrease in CXCL10.  
 
Figure 4.10 Treg reduction in expression of CXCR3 ligands in the skin explant assay. 
Levels of CXCL10 (A) and CXCL11(B) were measured as a percentage of cells following 
immuno-histochemistry for (a) medium only, (b) allo-stimulated CD8
+
 T cells, (c) CD8
+
 T 
cells allo-stimulated in the presence of Treg and (d) allo-stimulated CD8
+
 T cells with 
addition of Treg at the effector phase only. Cumulative (left) showing overall CXCL10 and 
CXCL11 levels. Representative (right) staining shows positive staining in relation to 
histopathological damage with higher magnification inserts. 
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A similar pattern of CXCL11 expression was seen in the skin sections with 
the exception of the late addition of Treg. Medium alone background expression 
was 47.7%±1.36SEM (Figure 4.10B). Incubation with allo-stimulated CD8+ T 
cells resulted in an increase to 69.6%±1.73SEM of cells expressing CXCL11, 
and when the CD8+ T cells were allo-stimulated in the presence of Treg there 
was a highly significant reduction in expression, with only 52.9%±1.42 of cells 
expressing CXCL11. When Treg were added during the effector phase only, 
unlike CXCL10 expression, there was a significant reduction in the levels of 
CXCL11 to only 58%±2.74SEM. 
When the percentage of both CXCL10 and CXCL11 expressing cells was 
correlated with the grade of histological damage in the skin sections there was a 
highly significant relationship with higher the CXCL10 (Figure 4.11A) or 
CXCL11 (Figure 4.11B) expressing cells correlating with greater the severity of 
damage. 
 
Figure 4.11 Correlation between percentage of cells expressing CXCR3 ligands and 
severity of tissue damage following skin explant assay.  
Data shown is from 7 independent experiments and duplicate sections were used when 
possible. Horizontal bars indicate median values *p<0.05, ****p<0.0001. 
In addition to receptor expression on the effector cells and the presence of 
ligand in the skin sections skin explant culture supernatants were collected and 
analysed by CBA flex analysis for levels of secreted CXCL9 and CXCL10. For 
both chemokines there was a significant decrease in protein concentration in 
the supernatant when Treg were present during allo-stimulation of CD8 cells 
(Figure 4.12A). As the severity of damage to the skin increased so did the 
concentration of CXCL9 and CXCL10 in the culture supernatants (Figure 
4.12B). 
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Figure 4.12 The presence of Treg during priming resulted in a reduction in CXCR3 
ligands secreted into skin explant supernatant. 
This reduction in CXCR3 ligands correlated with the severity of tissue destruction. A skin 
explant supernatants from skin sections incubated with allo-stimulated CD8
+
 T cells ( ), 
allo-stimulated in the presence of Treg ( ) and allo-stimulated with the addition of Treg 
at the effector stage only ( ) were analysed by CBA flex for CXCL9 and CXCL10. B 
Culture supernatants were grouped according to severity of tissue damage and plotted 
against concentration of CXCL9 and CXCL10. *P<0.05 **P<0.01, ***P<0.0001 n=7-18. 
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 Treg reduce effector cell adhesion to E selectin under flow 4.3.4
conditions 
E-selectin is the ligand for CLA and is important in the migration of 
leukocytes out of the blood vessels and into surrounding tissue (Wysocki et al., 
2005). Section 4.3.2 showed that CLA expression on allo-stimulated CD8+ T 
cells was reduced in the presence of Treg. To test the functional importance of 
this reduction, with particular relevance to cutaneous GvHD, the cellix platform 
was used to assess CD8+ T cell adhesion to E-selectin under flow conditions. 
The cellix platform is able to mimic in vivo flow rates found in capillaries and is 
therefore a good in vitro model of leukocyte tethering.  
When unstimulated CD8+ T cells were passed through the E-selectin coated 
micro-channels 5.26±0.67SEM cells adhered per field (Figure 4.13). The 
number of adherent allo-stimulated CD8+ T cells increased to 20.31±1.76SEM 
(p<0.0001) and when Treg were present during allo-stimulation of the CD8+ T 
cells there was a highly significant reduction in the number of adherent cells per 
field to 7.41±0.74SEM (p<0.0001) (Representative images (left) and cumulative 
results (right) Figure 4.13). The results demonstrate that Treg mediated 
reduction in CLA expression on allo-stimulated CD8+ T cells gives rise to a 
functional reduction in the ability of the CD8+ T cells to adhere to E-selectin 
under flow conditions. 
 
 
 
Figure 4.13 Treg mediated suppression of skin homing receptors resulted in a reduced 
capacity of CD8
+
 T cell adhesion.   
Representative still images (left) and cumulative results (right) from 9 individual tests 
from 3 independent experiments. Un-stimulated (  ), allo-stimulated (  ) and allo-
stimulated in the presence of Treg (  ) CD8
+
 T cells were passed through E-selectin 
coated micro-channels. Adherant cells, which remained attached when channels were 
rinsed with medium, were counted using DuoCell software.  
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 Treg reduce effector cell migration towards CXCR3 ligands 4.3.5
The effect of Treg during allo-stimulation upon the migratory capacity of 
CD8+ T cells was assessed using a Transwell system. In section 4.3.2 allo-
stimulation was shown to increase CXCR3 expression of CD8+ T cells, which 
was suppressed in the presence of Treg. The Transwell assay was used to 
confirm that this change in CXCR3 expression had a functional implication in 
the migration of CD8+ T cells. The chemokine ligands for CXCR3 were added 
into the lower wells and the cells into the upper wells, after 1 hour the number of 
migrated cells was calculated as a fold increase above background migration 
(where no chemokine was present in the lower well).  
Migration towards CXCL9 by un-stimulated CD8+ T cells was 3.52±0.75SEM 
fold higher than background migration. When the CD8+ T cells were allo-
stimulated migration increased to 6.95±0.96SEM fold above background and in 
the presence of Treg this fold increase of cell migration was significantly 
decreased to less than that observed for un-stimulated CD8+ T cells; 
2.88±0.57SEM (Figure 4.14).  
Migration towards CXCL10 by un-stimulated CD8+ T cells was 
2.71±0.23SEM fold higher than background, allo-stimulated CD8+ T cells 
migrated by a fold increase of 7.17±0.60SEM, compared to only 3.97±0.53 
when allo stimulated in the presence of Treg. A similar pattern was seen for the 
third CXCR3 ligand CXCL11; un-stimulated CD8 only showed a 2.72±0.57 fold 
increase, allo-stimulated CD8+ T cells a 9.17±1.02SEM fold increase and in the 
presence of Treg only 4.38±0.90SEM fold increase, a significant reduction. 
Although the CXCR3 ligands have been reported to act to work redundantly, 
synergistically, collaboratively and antagonistically in vivo (Groom and Luster, 
2011) in this experimental setting they all showed the same pattern of Treg 
mediated inhibition. In the case of all 3 ligands CD8+ T cell migration was 
significantly increased upon allo-stimulation. When Treg were present during 
CD8+ T cell allo-stimulation this increase in migration was significantly impaired 
confirming an in vitro functional effect of the changes observed in CXCR3 
expression. 
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Figure 4.14 The presence of Treg decreased CD8
+
 cell migration.  
Migration towards CXCR3 ligands CXCL9 (left), CXCL10 (middle) and CXCL11 (right) was 
assessed using a Transwell assay Un-stimulated (  ), allo-stimulated (  ) and allo-
stimulated in the presence of Treg (  ). Migration towards each chemokine was 
calculated as a fold increase above background migration (when no chemokine was 
present). ** indicates p<0.01 n=6. 
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 IFNγ production is reduced at all levels 4.3.6
IFNγ is a highly important cytokine in the patho-physiology of GvHD and 
interestingly it is able to induce expression of CXCL9-11, the ligands for the 
chemokine receptor CXCR3. The capacity of allo stimulated CD8+ T cells, in the 
presence or absence of Treg, to produce IFNγ was measured using 
PMA/Ionomycin stimulation followed by intra-cellular staining. The capacity of 
the CD8+ T cells to produce IFNγ upon stimulation was significantly down 
regulated when Treg were present during allo-stimulation from 32.72±4.52SEM 
to only 14.23±3.22SEM, p=0.0019 (Figure 4.15).  
 
Figure 4.15 The presence of Treg during allo-stimulation resulted in reduced capacity to 
produce IFNγ. 
CD8
+
 T cells allo-stimulated in the absence  or presence  of Treg were stained for 
their capacity to produce intracellular IFNγ. Representative plots shown were gated on 
CD8
+
 T cells prior to assessment of IFNγ; cumulative bar chart shows mean±SEM for 9 
independent experiments. 
In addition the supernatant from the skin explant cultures were tested for 
IFNγ levels using CBA flex. A highly significant down regulation of IFNγ 
secretion was seen when Treg were present during allo-stimulation, p<0.0001 
(Figure 4.16A). The levels of IFNγ in the skin explant supernatant was 
correlated with the severity of histopathological damage seen with lower grades 
of damage correlates with significantly less IFNγ in the supernatant than 
medium or high grades (Figure 4.16B).  
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Figure 4.16 IFNγ secreted into skin explant supernatant was measured using CBA flex 
analysis.  
A) supernatant was collected from skin sections cultured with either allo-stimulated CD8
+
 
T cells  or allo-stimulated in the presence of Treg . B) Correlation between the level 
of IFNγ secreted into the skin explant supernatant and the pathophysiological grade of 
damage to the skin. 
 
Levels of IFNγ gene expression were measured with qPCR. Samples were 
tested in triplicate and normalised to GAPDH. IFNγ expression was calculated 
as a fold increase in expression relative to un-stimulated CD8+ T cells. 
Expression of IFNγ was significantly reduced in the presence of Treg 
(p<0.0001) (Figure 4.17).  
 
Figure 4.17 Relative IFNγ gene expression measured with qPCR, normalized to GAPDH. 
Un-stimulated CD8
+
 T cells alone were used as the reference group to calculate relative 
gene expression, data from 8 independent experiments. ***P<0.0001.  
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 Association between skin homing T cells and cutaneous GvHD in a 4.3.7
small clinical cohort 
CLA and CCR10 bearing lymphocytes have been implicated in the 
development of GvHD (Tsuchiyama et al., 2009, Faaij et al., 2006). Following 
on from the in vitro work showing CLA+ CD8+ T cells were potent inducers of 
cutaneous GvH, T cell populations in PBMC following matched HSCT were 
assessed for their levels of skin homing markers. This data was then correlated 
with the GvHD status of the patient following transplantation. 
Serial samples of peripheral blood were collected following transplantation 
as previously described (Chapter 2). Multi-parameter flow cytometry was carried 
out on the samples and analysed according to the gating strategy shown in 
Figure 4.18.  
 
Figure 4.18 Gating strategy used to assess skin homing T cell populations in PBMC.  
Flow cytometry was carried out using BD Canto II and analysed using FlowJo (TreeStar). 
First live T cells were identified, followed by SSC-A and SSC-H to ensure only single cells 
were analysed. Further sequential gating separated CD4
+
 and CD8
+
 cells then levels of 
CLA, CCR10 and CXCR3 were assessed. Gates were positioned according to appropriate 
isotype controls. 
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The patient cohort (80 samples from 24 donors) was split into those with no 
GvHD, acute GvHD only and de novo chronic GvHD. Patients with both acute 
and chronic GvHD were not included in this study. The levels of circulating 
CLA+ CD4+ T cells was seen to be significantly higher in patients with aGvHD 
than those without up to 100 days post transplantation (Figure 4.19). There was 
then a decline in levels back down to pre-transplant levels, with a second, 
however not statistically significant (p=0.0571), peak at 9 months post 
transplantation. The kinetic pattern of CLA expression on CD8+ T cells was 
similar but to a much lesser extent. Patients who developed de novo cGvHD 
showed a sharp increase in CD4+CLA+ T cells from as early as day 28 post 
transplantation which remained significantly high throughout the 12 month 
period. The CLA expression on CD8+ T cells remained comparable with or 
without cGvHD at all time points observed. 
 
Figure 4.19 Expression of CLA on CD4
+
 and CD8
+
 T cells in serial samples following 
transplantation.  
Plots indicate mean±SEM for 3-9 samples at each time point. Statistical significance was 
assessed by Mann-Whitney U tests. 
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CCR10 has also shown to be of importance in skin homing in GvHD 
therefore levels of CCR10 were also investigated on the patient samples. There 
was a trend showing increased CCR10 expression on both CD4+ and CD8+ T 
cells in patients with acute GvHD, however this was not statistically significant 
(Figure 4.20). CCR10+ T cells in patients who developed chronic GvHD were 
elevated on CD4+ T cells, however this difference did not achieve statistical 
significance. 
 
Figure 4.20 Expression of CCR10 on CD4
+
 and CD8
+
 T cells in serial samples following 
transplantation.  
Plots indicate mean ±SEM for 3-9 samples at each time point, Statistical significance was 
assessed by Mann-Whitney U tests. 
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The levels of CXCR3 expressing cells within CD4+ and CD8+ T cells from 
the patient cohort was also assessed (Figure 4.21). A significant decrease in 
CD4+ T cells expressing CXCR3 was seen in patients who developed aGvHD at 
28 days post transplantation (p=0.0095). There was also a trend towards higher 
CD8+CXCR3+ cells at 3 months post transplantation in patients with aGvHD 
(p=0.0932) and a statistically significant increase at 12 months post 
transplantation, p=0.0317. Patients who developed cGvHD had increased levels 
of CD4+CXCR3+ cells 12 months post transplantation (p=0.0286) and increased 
CD8+CXCR3+ cells 6 months post transplantation (p=0.0051) when compared 
to patients who did not develop GvHD. 
 
Figure 4.21 Expression of CXCR3 on CD4
+
 and CD8
+
 T cells in serial samples following 
transplantation.  
Plots indicate mean ±SEM for 3-9 samples at each time point, Statistical significance was 
assessed by Mann-Whitney U tests. 
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In addition to the level of skin homing receptor expression, the Treg content 
of PBMC was assessed in the patient samples (Figure 4.22). At each time point 
there was no difference in the number of Treg cells in patients with aGvHD 
compared to those patients without GvHD. Patients who developed cGvHD did 
have an increased Treg content at 6 months post transplantation (p=0.0205). 
Figure 4.22 Treg content of the CD4
+
 T cell population in serial samples following 
transplantation.  
Plots indicate mean ±SEM for 3-9 samples at each time point, Statistical significance was 
assessed by Mann-Whitney U tests. 
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 Discussion  4.4
The beneficial role of Treg in ameliorating GvHD has been convincingly 
demonstrated using mouse models (Hoffmann et al., 2002, Edinger et al., 
2003), in vitro studies (Wolf et al., 2007, Rezvani et al., 2006) and early stage 
clinical trials (Brunstein et al., 2011, Di Ianni et al., 2011). Undoubtedly Treg 
have an important role in the prevention of GvHD but there are still questions as 
to the exact mechanism of action. Protection against GvHD has been 
associated with modulation of various immunological events during the 3 phase 
pathophysiology of GvHD (Trenado et al., 2006, Wang et al., 2009, Taylor et al., 
2004, Ermann et al., 2005) however, until now it was not known if this was also 
the case in humans. The research conducted in this chapter focuses on the 
more recently proposed fourth criteria for GvHD pathogenesis which refers to 
the requirement for effector cells to migrate to the target tissues and plays an 
important role in the development of GvHD. 
Results presented in this chapter provide the first human in vitro evidence 
that Treg are able to prevent cutaneous GvH reaction by blocking the migration 
of effector T cells into the target tissues. The results have shown that addition of 
Treg during effector T cell priming resulted in a blockade of effector cell 
migration into the skin and therefore a reduction in cutaneous histopathological 
damage. Late addition of Treg, after allo-stimulation, did not cause a reduction 
in effector cell infiltration or GvH damage verifying that Treg must be present 
during priming to have the most potent effect, previous work from within our 
group has also shown late addition of Treg resulted in a loss of their ability to 
suppress T cell activation, proliferation and cytolytic function (Wang et al., 
2009). This is reinforced by work in mouse models where it has been shown 
that Treg with the capacity to home to secondary lymphoid tissue are more 
potent inhibitors of GvHD, supporting our evidence that Treg presence during 
allo-stimulation provides superior protection (Ermann et al., 2005, Taylor et al., 
2004).  
Interactions between CLA and E-selectin are crucial in the movement of 
effector cells from the circulation into the skin and are therefore of great interest 
in the pathophysiology and the potential role of Treg in ameliorating GvHD 
(Kunkel and Butcher, 2002). The presence of Treg resulted in a highly 
significant down-regulation of CLA expression on allo-stimulated CD8+ T cells. 
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The functional effect of this down regulation was seen in the highly significant 
reduction on the ability of CD8+ effector cells to adhere to the CLA ligand E-
selectin under flow conditions. The cellix platform used accurately models the 
flow conditions and shear forces which are seen in vivo, however, unfortunately 
it is beyond the remit of the skin explant model to conclusively demonstrate the 
Treg modulation of CD8+ effector cell extravasation by impairing E-selection 
CLA interactions. The in vitro data suggests that in vivo initiation of the 
migration cascade by interactions between CLA and E-selecin could be 
inhibited in the presence of Treg resulting in the failure of effector cells to 
extravasate into target tissue. 
The molecular pathway by which Treg mediate a reduction in cell surface 
expression of CLA on CD8+ effector cells remains to be elucidated. To examine 
whether Treg suppression of CLA involves down-regulation of relevant genes 
which governs their expression qPCR was carried out, as CLA is a 
carbohydrate epitope it was the levels of the protein backbone, PSGL-1 mRNA, 
which were measured. Unexpectedly we found comparable levels of PSGL-1 
mRNA expression on CD8+ T cells regardless of allo-antigen stimulation. 
Consequently the presence of Treg did not result in any changes in PSGL-1 
gene expression. CLA is formed via post-translational glycosylation of PSGL-1 
by FuncTVII an α(1,3)-fucosyltransferase, found in leukocytes which express 
CLA (Fuhlbrigge et al., 1997). Therefore it is possible that allo-stimulation, and 
consequently Treg modulation of allo-stimulation, affects either the function or 
expression levels of FuncTVII thereby affecting downstream cell surface 
expression of CLA. Further experiments could examine the levels of FuncTVII 
mRNA and protein within the CD8+ T cells, potentially providing further insight 
into the molecular pathways leading to Treg mediated suppression of CLA 
expression on the surface of allo-stimulated CD8+ T cells. 
Further support for the role of Treg in modulation of CD8+ T cell migration as 
a mechanism for the prevention of GvHD came from the observation that 
reduced CXCR3 expression on allo-stimulated, in the presence of Treg, CD8+ 
effector cells lead to a functional impairment of their migration. CXCR3 is a well-
known receptor in the recruitment of effector T cells into the skin (Mohan et al., 
2005). Early intervention of Treg was seen to impair in vitro CD8+ T cell 
migration towards all three CXCR3 ligands with similar efficiency. Each of the 3 
107 
CXCR3 ligands have been shown to transduce different signals, dependent on 
distinct intracellular domains of CXCR3 therefore it is possible that Treg 
influence several pathways of signal transduction (Colvin et al., 2004). Further 
investigations to examine the signal transduction pathways could be carried out 
to elucidate the effect of Treg on CXCR3 signalling in response to CXCL9-11. 
The presence of Treg not only reduced CD8+ effector T cell expression of 
CXCR3 but also the levels of CXCR3 ligands were reduced at the site of tissue 
damage. As CXCR3 guides activated T cells in to sites of cutaneous 
inflammation through interactions with its ligands CXCL9-11 reduction in both 
CXCR3 expression and its ligands is of great interest in the role of Treg in 
preventing GvHD. Although this study did not investigate levels of CXCR3+ 
infiltrates into the skin explant, Piper et al observed large numbers of CXCR3+ 
cells in dermal infiltrates of patients with GvHD (Piper et al., 2007), supporting 
our observation that Treg mediated reduction of CXCR3 expression on effector 
T cells and of CXCR3 ligand expression at the target tissue could results in 
decreased severity of cutaneous damage in the skin explant model.  
The three IFNγ inducible ligands of CXCR3 are potent chemo-attractants 
which are produced by activated keratinocytes in skin (Flier et al., 2001), in 
particular CXCL10 has already been shown to be increased in the serum of 
patients with GvHD following transplantation (Piper et al., 2007). The results in 
this chapter showed a close relationship between the severity of GvH tissue 
damage in the skin explant model and the levels of CXCL10 and CXCL11 
detected by immunohistochemistry, and significantly Treg mediated a reduction 
in CXCL10 and CXCL11 levels detected in the skin. In addition the levels of 
CXCL9 and CXCL10 in the skin explant supernatants were lower in the 
presence of Treg. This Treg mediated reduction in CXCR3 ligands may be 
attributed to the reduction in IFNγ by the CD8+ T cells.  
Similarly, to CLA, gene expression was carried out to attempt to clarify the 
mechanism by which Treg caused a reduction on cell surface expression. 
Again, surprisingly, there were comparable levels of CXCR3 mRNA present 
following allo-stimulation and therefore the presence of Treg during allo-
stimulation also had no effect on level of CXCR3 mRNA expression, suggesting 
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control of cell surface expression for CXCR3 must also occur post-
transcriptionally. 
Additional evidence that CXCR3 expression on CD8+ effector T cells is 
significant in the pathology of GvHD is provided by a study in murine models 
using CXCR3-/- donor grafts, they showed a marked reduction in CD8+ T cell 
infiltration into the gut of recipients associated with improved survival (Duffner et 
al., 2003). A more recent study used administration of a CXCR3 neutralizing 
antibody to reduce CD8+ T cell migration into GvHD target organs, ameliorating 
GvHD without adversely affecting GvL (He et al., 2008). However, the use of 
chemokine blocking molecules remains a significant challenge in the clinical 
setting (Proudfoot et al., 2010, Schall and Proudfoot, 2011). The use of Treg 
may therefore provide an exciting alternative therapeutic option for the 
prevention of chemokine driven migration of effector cells to the target tissue 
and therefore amelioration of GvHD. 
Treg mediated reduction in the expression of skin homing markers along 
with reduced IFNγ production by effector cells and a decrease in CXCR3 
ligands in the the skin, taken together this suggests that in vivo Treg modulation 
of effector cell migration forms an important role in the mechanisms by which 
Treg have a beneficial role in the prevention of GvHD following HSCT. Treg 
modulation of both the CXCR3 and CLA migration pathways shows the 
suppressive effect that Treg have on distinct but synergistically acting pathways 
involved in the migration of effector cells to target tissue in GvHD. Treg 
mediated reduction of CLA levels would interfere with CD8+ T cell rolling which 
directly impairs effector T cell extravasation whereas a decrease in CXCR3 
expression impedes the capacity of the cells to migrate through the tissue 
following extravasation. 
Results presented in this chapter support our proposed mechanism by which 
Treg are able to prevent cutaneous GvHD following HSCT (Figure 4.23). The 
presence of Treg during allo-stimulation causes the CD8+ T cells to have lower 
surface expression of skin homing markers CLA and CXCR3 and also a 
reduced capacity to produce IFNγ. The reduction in IFNγ production also 
causes CXCR3 ligands CXCL9-11 to be produced in lower quantities. The 
combination of less IFNγ, CXCR3, CLA and CXCL9-11 results in a lower 
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number of infiltrating effector cells into target tissue and lower histopathological 
damage in vitro which in the clinic would result in lower incidence and/or 
severity of GvHD. In the absence of Treg the effector cells are activated 
following allo-stimulation, expressing high levels of skin homing markers and 
producing high levels of IFNγ which in turn leads to the production of CXCL9-
11, resulting in more tissue invasion and more severe GVH response. 
 
Figure 4.23 Proposed mechanism of Treg action in preventing cutaneous GvHD. 
Once the importance of skin homing receptors had been demonstrated in 
vitro, clinical samples were investigated to examine any correlation between 
skin homing markers on circulating T cells and the GvHD status of the patient. 
Reports on patient PBMC phenotyping following transplantation are plentiful in 
the literature, therefore only a small scale patient study was carried out. Results 
obtained in this study are in concordance with previously reported data. The 
increase in CLA expression on the circulating CD4+ T cells may be informative 
as an indicator for acute and chronic GvHD. It has previously been reported that 
the CLA+ T cell fraction increases 3-7 days prior to onset of GvHD and could be 
potentially used as a biomarker (Tsuchiyama et al., 2009) . The expression of 
CLA+ on CD8+ T cells was increased in patients with GvHD, in vitro CLA+CD8+ 
cells are potent inducers of cutaneous GvHD, therefore it is not unexpected that 
patients with aGvHD have increased numbers of circulating CD8+CLA+ cells. 
This demonstrates the importance of skin homing markers in the clinical setting, 
supporting the proposed mechanism by which Treg are able to prevent GvHD 
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by reducing T cell migration into target tissues. Levels of CCR10+ circulating 
cells were not increased in patients with GvHD, possibly because they had 
already migrated into the target tissue at the time when the blood samples were 
collected. Levels of Treg in the peripheral blood of post-transplant patients have 
been reported to be decreased in aGvHD, but increased in cGvHD (Wolf et al., 
2007, Ukena et al., 2011, Zorn et al., 2005) however in this small cohort of 
patients there was no difference between the groups of patients, possibly due to 
the small numbers of samples from a heterogeneous cohort of patients. 
Taken together the results from this chapter have shown that Treg 
modulation of skin homing receptor expression on effector cells is an important 
mechanism for the prevention of GvHD. Also results from a small scale study of 
patient samples have shown that increasing numbers of circulating T cells 
expressing skin homing markers can be associated with both acute and chronic 
GvHD at specific times post transplantation and that in some cases, such as 
CD4+ T cell expression of CLA and CXCR3 at day 28 post transplant, could be 
predictive of GvHD. 
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5 Chapter 5 - Treg induced impairment of DC function and its 
impact on GvH reactions 
 Introduction 5.1
Results presented in Chapter 4 have highlighted two important issues. 
Firstly, Treg mediated blockade of effector T cell migration into GvHD target 
tissues contributes to their protective role and is a potential mechanism of 
action (Mavin et al., 2012). Secondly, Treg mediated protection requires their 
presence during effector T cell priming. This has led to the hypothesis that Treg 
modulation of DCs could be a key mechanism by which Treg exert their 
protective role in GvHD. Results presented in this chapter focused on how Treg 
conditioning of moDC was able to drive them towards a semi-mature, 
tolerogenic status. The Treg mediated changes in DC phenotype and function 
resulted in an impaired ability to stimulate allo-reactive effector T cells and 
therefore induced less cutaneous GvH tissue damage.  
 Dendritic cells and in vitro generated DCs 5.1.1
Dendritic cells (DCs) are a population of highly potent and specialised 
antigen presenting cells which lack expression of lineage markers CD3, CD14, 
CD19, CD20 and CD56. Since their discovery in 1973 the role of DCs has been 
increasingly characterised (Steinman and Cohn, 1973). DCs are involved in 
both the innate and adaptive immune response, and they are responsible for 
maintaining the balance between tolerance and immunity (Banchereau et al., 
2000). Human dendritic cells are a heterogeneous population of cells with 
several distinct sub-populations, broadly defined as myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs).  
Due to the difficulties in isolating large numbers of DC from human 
peripheral blood various methods have been developed to generate DCs in 
vitro. Human DCs can be generated from CD34+ hematopoietic progenitor cells 
by culturing with GM-CSF and TNFα (Caux et al., 1992). More recently Flt3-L 
and thrombopoietin have been shown to generate DC from CD34+ progenitors 
(Chen et al., 2004). However monocyte-derived DCs are most commonly used 
in aiding immuno-biological research (Wang et al., 2009, Mavin et al., 2012) and 
development of DC-based immunotherapies for cancers (Schuler-Thurner et al., 
2002, Di Nicola et al., 2009), autoimmune diseases (Harry et al., 2010) and 
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transplantation rejection (Macedo et al., 2013). The method used to generate 
DCs in vitro depends on the experimental requirements; GM-CSF is able to 
reliably produce large numbers of monocyte derived DCs (moDC) and Flt-3L is 
able to more accurately mimic in vivo development of DCs (Merad et al., 2013).  
In vitro generation of moDCs has been established for 20 years (Sallusto 
and Lanzavecchia, 1994). Monocytes are available in sufficient numbers to be 
isolated by immuno-magnetic separation or FACS sorting from peripheral blood. 
Incubation of isolated monocytes with GM-CSF and IL-4 results in a moDC 
population similar to a CD1a+ dermal DC (Merad et al., 2013). GM-CSF is 
currently considered to be a critical factor for DC development under steady 
state and inflammatory conditions (van de Laar et al., 2012). Intra-cellular 
signalling from GM-CSF can occur through JAK/STAT, MAPK, PI3K and NFκB 
to direct pathways inducing differentiation into moDC. Although the role of IL-4 
in the differentiation into moDCs was initially unclear (Sallusto and 
Lanzavecchia, 1994) it is now believed that IL-4 functions to inhibit the growth of 
macrophages (Menges et al., 2005). These moDC are able to respond to a 
variety of pathogen-associated molecular patterns (PAMPS) through toll like 
receptors (TLRs). LPS stimulates moDC maturation through TLR-4 (Anderson 
et al., 2008), although moDC are also reported to be able to respond to 
stimulation from TLR7, TLR8 and TLR9 (Lombardi et al., 2009, Hoene et al., 
2006). LPS acts through the TLR-4 signal transduction pathway, in either the 
MyD88 dependent or independent pathways (Kurt-Jones et al., 2000). LPS 
maturation results in a decrease in antigen processing and an increase in 
migratory capacity of moDC resulting in DCs able to promote expansion and 
differentiation of naïve T cells into effector cells (Joffre et al., 2009). moDCs 
were used throughout this study to stimulate allo-reactive CD8+ T cells or drive 
naïve CD4+ T cell polarisation. 
 Tolerogenic DC 5.1.2
It has been well recognised that DCs also have tolerogenic properties. 
Generation of tolerogenic DCs (TolDC) either in vitro or in vivo has been 
uncovered as a potential mechanism for the induction or maintenance of 
tolerance post transplantation (Ezzelarab and Thomson, 2011).  TolDCs have 
also been designated as alternatively activated DCs (Anderson et al., 2008), 
modified DCs (Sato et al., 2003a) and regulatory DCs (Sato et al., 2003b). 
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TolDCs can occur naturally, often in immune-privileged sites such as the lung, 
eye or intestine (Svajger and Rozman, 2014). Additionally TolDCs can be 
generated in vitro by genetic engineering or controlling culture conditions with 
cytokines, growth factors and pharmacological agents (Hackstein and 
Thomson, 2004). The presence of these additional immuno-suppressive signals 
facilitates the development of TolDCs which are able to actively promote 
tolerance through the presence of inhibitory signals as well as lacking 
expression of co-stimulatory signals (Steinman et al., 2003). The key 
phenotypic features of TolDCs include expression of surface HLA molecules, 
low expression of co-stimulatory molecules CD80/CD86 and low secretion of IL-
12p70 (Morelli and Thomson, 2007).  
One important characteristic of TolDC is their ability to migrate towards 
CCL19 due to their expression of high levels of CCR7, this allows them to home 
to lymph nodes and exert their tolerogenic effects in vivo (Anderson et al., 
2008). TolDCs are able to secrete indoleamine 2,3-dioxygenase (IDO) and 
induce regulatory T cells while promoting the death of effector cells via 
apoptosis (Morelli and Thomson, 2007). Additionally they express the immuno-
suppressive molecules IL-10 and TFGβ which can lead to the induction of 
peripherally induced Treg (Lan et al., 2006, Wakkach et al., 2003). TolDCs are 
able to secrete heme oxygenase-1 (HO-1), which prevents maturation of other 
DCs and has been shown to induce tolerance in solid organ transplantation and 
prevent rejection (Soares et al., 1998). TolDC are also able to act in a contact 
dependent manner through the action of PDL-1 (Brown et al., 2003), HLA-G 
(Carosella et al., 2011) and Fas/FasL amongst others (Griffith et al., 1995). 
 Treg interactions with dendritic cells  5.1.3
Dendritic cells are one of the many cell types known to be influenced by 
Treg and therefore these interactions are of significant interest when 
considering the mechanisms by which Treg modulate GvH reactions. There is 
evidence to suggest that in murine models Treg are able to supress responder 
T cells indirectly through the modulation of DCs (Onishi et al., 2008, Fallarino et 
al., 2003). Interactions between human Treg and moDC have also been shown 
to severely affect the ability of the DC to stimulate and activate CD4+ T cells 
(Misra et al., 2004). More recent studies have demonstrated the ability of Treg 
to induce a semi-mature phenotype in DCs (Bayry et al., 2007); inducing down-
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regulation of co-stimulatory molecules, and reduced capacity to induce allo-
stimulation of CD4+ T cells while increasing expression of CCR7 and HLA-DR. 
Additionally it has been shown that, as well as monocyte derived DC, Treg are 
able to modulate the function of ex vivo sorted myeloid DC (Houot et al., 2006). 
Studies have shown that this semi-mature phenotype induced by Treg to be 
modulated through several different mechanisms. Firstly, activated Tregs 
express high levels of Lymphocyte-activation gene-3 (LAG3) which is related to 
the CD4 protein and binds HLA-class II molecules with a high affinity (Huang et 
al., 2004). LAG-3 is required for maximum Treg suppression, when it binds to 
class II molecules LAG-3 causes ERK mediated recruitment of SHP1 resulting 
in prevention of immature DC maturation and poor immuno-stimulatory capacity 
of human CD4+ T cells and murine CD8+ T cells (Bayry et al., 2007, Liang et al., 
2008). Secondly, interactions between the co-inhibitory receptor CTLA-4 
constitutively expressed on the Treg, and its ligands CD80/CD86 expressed on 
the DC, are able to modulate the action of the DCs (Vignali et al., 2008). CTLA-
4 is able to capture its CD80/86 ligands from other cells via trans-endocytosis 
and degrade them, resulting in reduced capacity for co-stimulation (Qureshi et 
al., 2011). In vitro blockade of CTLA-4 does not appear to reduce Treg function, 
however in vivo CTLA-4 blockade nullifies Treg mediated suppression in 
several mouse models of inflammation (Tang and Bluestone, 2008). Thirdly, 
Treg have been shown to promote secretion of IDO by DCs (Grohmann et al., 
2003). IDO is an enzyme commonly associated with pregnancy and immune 
evasion that acts by local depletion of tryptophan (Mellor and Munn, 2004). The 
deprivation of tryptophan leads to starvation of T cells, increasing apoptosis and 
preventing further local T cell proliferation. This Treg promotion of IDO 
expression in DCs has been shown to depend on interactions between CTLA-4 
and CD80/86 (Fallarino et al., 2003). Although CTLA-4 and IDO provide 
important mechanisms of Treg modulation of DC, it has been shown through 
blocking CTLA-4 and IDO that these interactions are not functioning in the 
generation of semi-mature Treg conditioned moDC (Amarnath et al., 2010). 
In addition IL-10 has been shown to play a significant role in Treg 
modulation of DC function in a mouse model through a MARCH1 dependent 
mechanism (Chattopadhyay and Shevach, 2013). MARCH1 is an E3 ubiquitin 
ligase found to degrade CD86 and class II expression on the cell surface by 
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ubiquitination and internalisation (Tze et al., 2011). However, it remains 
unknown if Treg are also able to modulate human DC functions through 
increasing expression of MARCH1 via IL-10. 
It is not only regulation of DCs by Treg which is important in the 
maintenance of tolerance but also DC regulation of Treg.  Figure 5.1 shows a 
mechanism proposed by Darrasse-Jeze et al by which Treg and DC are 
involved in a regulatory feedback loop (Darrasse-Jeze et al., 2009). Previously it 
had been shown that the peripheral Treg population expanded following 
treatment with Fms-like tyrosine kinase 3 ligand (Flt-3L) (Swee et al., 2009), 
and that loss of Treg increases DC numbers in a Flt-3L dependent manner (Liu 
et al., 2009). Treg are also able to regulate DC through the action of TGFβ and 
IL-10, but conversely DC are also able to regulate Treg in the presence of TGFβ 
(Sela et al., 2011). This illustrates the highly complex bi-directional regulation 
between Treg and DC, which results in the maintenance of tolerance. 
 
Figure 5.1 Homeostatic feedback loop between Treg and DCs (Darrasse-Jeze et al., 2009). 
 
 Regulatory DC and Treg conditioned DC in GvHD 5.1.4
DCs have a critical role in the pathophysiology of aGvHD as previously 
discussed. Various interventions specifically targeting DCs for the prevention 
and/or treatment of GvHD have been summarised in a recent review (Stenger 
et al., 2012). Despite advances in the understanding of the key features and the 
role of regulatory DCs in modulating autoimmunity, little is known in the current 
literature with regard to their effect on CD8+ T cell mediated allo-reactive 
immune responses, particularly in the context of GVHD in humans. 
Observations from one group have reported that administration of IL-10 and 
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TGFβ treated DCs protected mice from aGvHD and leukemia relapse (Sato et 
al., 2003b) as well as decreased incidence and severity of cutaneous cGvHD 
(Fujita et al., 2007). To date, no convincing evidence is available demonstrating 
whether Treg treated DCs are able to ameliorate human GvHD, although one 
report has demonstrated the GvHD protection by Treg treated DC’s in a 
xenogenic GvHD model (Amarnath et al., 2010).  
This chapter aimed to address whether Treg treatment of DC reduced CD8+ 
T cell activation, proliferation and subsequent GvH damage. This question will 
be addressed via examining the following; 
 The phenotype and morphology of Treg treated moDC. 
 The ability of Treg treated moDC to induce allo-reactive CD8+ T cell 
activation and proliferation. 
 The capacity of CD8+ T cells stimulated by Treg treated moDC to 
induce GvH tissue damage reaction in the skin explant model. 
 Changes in naïve T cell polarisation induced by Treg treated moDC.  
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 Methods 5.2
The experimental outline for results presented in this chapter as illustrated in 
Figure 5.2. The majority of methods are presented in Chapter 2; additional 
methods used only in this chapter are described below.  Unless otherwise 
stated all data presented in this chapter was generated using a 3:1 ratio of 
Treg:moDC.  
 
Figure 5.2 Summary of the experimental outline for results presented in this chapter.  
Phenotype was assessed by flow cytometry, antigen uptake by FITC dextran and 
morphology by cytopsin. T cell activation, proliferation, cytokine secretion, polarisation 
and the skin explant were all assessed following MLRs using third party responder cells.   
118 
 Generation of moDC 5.2.1
Immature and mature moDC were generated according to standard 
protocols with IL-4 and GM-CSF. Treg conditioned moDC were generated by 
the addition of (unless otherwise stated) 3 Treg per 1 moDC on day 3 of 
generation, summarised in Figure 3.3. Prior to functional and phenotypic 
analysis Treg were separated from the Treg-moDC by cell sorting. For cell 
sorting Treg were identified by positive expression of CD3 and the Treg-moDC 
negative CD3 expression. 
 Antigen uptake assay 5.2.2
Antigen processing was measured by FITC-dextran uptake (Sigma-Aldrich). 
5x104 immature, mature or Treg treated moDC were incubated for 1 hour at 
37˚C or 4˚C in RF10 with 1mg/ml FITC dextran uptake. Cells were then 
extensively washed in cold FACS buffer and then the amount of FITC dextran 
was analysed by flow cytometry. Dead cells were excluded from analysis based 
on positive staining for either 7AAD or DAPI. 
 Assessment of cell morphology 5.2.3
Cytospin was used to assess the morphology of the moDC, 1x104 immature, 
mature and Treg conditioned moDC (following the removal of Treg) were spun 
in a cytospin centrifuge at 400g for 4 minutes onto coated microscope slides. 
Slides were then left to air dry before fixation in methanol for 15 seconds.  Cells 
were then stained with geimsa red and blue for 10 and 45 seconds then rinsed 
in distilled water. Images were then taken using Axio imager. 
 Naïve T cell polarisation 5.2.4
Naïve CD4+ T cells were isolated from PBMC using RoboSep automated 
CD4+ selection kit (StemCell technologies). Naïve CD4+ cells were incubated 
with either immature, mature or Treg-moDC for 6 days in RF10 at a ratio of 10 
naïve cells per 1 moDC. Cells were then rested in RF10 supplemented with 
25IU/ml IL-2 for a further 4 days. After resting, cells were either stained for IC 
levels of cytokines following PMA/Ionomysin stimulation, stored as cell pellets 
for RNA extraction or stimulated at a 1:1 ratio with CD3/CD28 T cell expandor 
beads for 24 hours and the culture supernatants were stored for CBA flex 
analysis of cytokine secretion. 
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 Results 5.3
 Generation of Treg-moDC 5.3.1
Immature, mature and Treg conditioned moDC (Treg-moDC) were 
successfully generated by culturing CD14+ monocytes in RF10 supplemented 
with GM-CSF and IL-4 for 7 days. CD14+ monocytes were successfully isolated 
from PBMC by miltenyi MACS technology to a high purity (Figure 5.3a). 
Monocyte and DC status were closely monitored by their expression of 
appropriate cell surface molecules. Following 6 days of culture the monocytes 
lost expression of CD14 and gained CD1a as expected indicating their 
differentiation into immature moDC (Figure 5.3b). DC maturation was induced 
by the addition of LPS for a further 24 hours. DC maturation status was 
confirmed by expression of DC maturation markers CD83/CD40, increased 
expression of co-stimulatory molecules CD80/CD86 and expression of the 
antigen presenting molecule HLA-DR.  
 
Figure 5.3 Steps in the generation of Treg-moDC.  
a) Isolation of CD14
+
 monocytes from PBMC, left prior to isolation and right post 
isolation. b) On D0 cells were CD14
+
CD1a
-
 (left) and following culture cells had lost CD14 
and gained CD1a (right). c) and d) DC maturation was confirmed by expression of CD80, 
CD86, CD83 and HLA-DR. Representative data shown (n=10-22).  
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Timing of Treg addition 
To identify the most appropriate time window to add Treg into the DC culture 
the phenotype profiles of Treg-conditioned moDC generated by adding Treg on 
either day 3 or day 6 were compared. LPS maturation was carried out on day 6 
for both conditions. By the time Treg were added on day 3 of moDC culture over 
80% of cells had already lost expression of CD14 and gained expression of 
CD1a suggesting the changes observed are due to modulation of moDC 
maturation rather than due to prevention of the monocytes differentiating into 
moDC. Adding Treg on day 3 resulted in a population of moDC which had 
decreased expression of CD83, DC86 and CD40 (Figure 5.4).  This suggests 
these cells may have been resistant to LPS maturation. On the other hand, 
adding Treg on day 6 resulted in a population of moDC which expressed high 
levels of CD83, HLA-DR, CD86 and CD40 suggesting that these cells were not 
LPS maturation resistant and Treg need to be present for a longer time period 
to effectively condition the moDC. 
 
 
Figure 5.4 Late addition of Treg does not prevent LPS maturation of moDC.  
Representative histograms show expression of maturation markers, measured by flow 
cytometry. Immature (  ) mature (  ) and day 6 Treg conditioned (  ). Data 
representative of 2 independent experiments. 
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Titration of Treg dose  
Based on day 3 addition of Treg to the DC culture we next compared the 
phenotypic profile of DCs treated with titrated numbers of Treg ranging from 3:1 
to 0.5:1 for DC:Treg ratios. Untreated moDC served as a control. A clear dose 
response was observed (Figure 5.5). A 3:1 ratio resulted in the greatest 
inhibition of maturation, with maturation marker MFI values similar to that of 
immature moDC. In addition, this ratio closely mimicked in vivo conditions 
therefore the ratio of 3 Treg :1 moDC was used throughout this work. 
 
Figure 5.5 Treg prevent moDC maturation in a dose dependent manner.  
Treg were added on day 3 at a range of ratios and MFI of maturation markers was 
assessed by flow cytometry. Bars indicate mean values from 2 independent experiments. 
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Removal of Treg from DC cultures 
In order to carry out investigations into the functional capacities of the Treg 
conditioned moDC it was important to remove the Treg ensuring the functional 
results obtained were solely due to Treg mediated changes in moDC properties 
without a direct Treg effect on the T cells or DC-T cell interactions. Initially CD3 
MACS separation was performed however the efficiency of the Treg depletion 
was poor (data not shown). Therefore cell sorting was used to remove Treg. 
Cells were stained with anti-CD3 APC and then sorted based on FSC and SSC 
along with negative expression of the T cell marker CD3, the gating strategy 
used for sorting is shown in Figure 5.6A. It was also important to ensure the 
process of sorting did not adversely affect the Treg conditioned moDC therefore 
detailed phenotypic analysis prior to and after sorting was carried out. 
Expression of CD80, CD83, HLA-DR and CD86 was unchanged following cell 
sorting (Figure 5.6B) 
 
Figure 5.6 Cell sorting to separate Treg-moDC from the remaining Treg.  
A) Gating strategy for cell sorting, moDC were selected based on FSC SSC profile, and 
then single cells (SSC-A vs SSC-H) followed by cells not expressing CD3. B) 
Representative Histograms of cell surface maturation markers on Treg-moDC pre-sorting 
( ) and post sorting ( ) (n=10). 
Data from this pilot study was used as the basis for the experiments 
performed in this chapter.  
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 Treg conditioned DC exhibit immature phenotype 5.3.2
The effect of Treg conditioning on the LPS maturation of moDC was 
assessed by flow cytometry and analysed using mean fluorescence intensity of 
several maturation markers. Both immature and un-treated mature moDC were 
used as comparisons throughout. As expected, immature moDC expressed low 
levels of CD80, CD83, HLA-DR, CD86 and CD40 on their cell surface. Upon 
maturation with LPS expression of all of these markers significantly increased 
confirming that the moDC had a mature phenotype (Figure 5.7).  
The phenotype of the Treg conditioned moDC was semi-mature, levels of 
CD80, CD83 and CD86 were much lower than that of the mature moDC 
however levels were also significantly higher than the immature moDC. Levels 
of CD40 on the Treg conditioned moDC were not significantly different from that 
of the immature moDC (p=0.0890) but it did show a trend towards higher CD40 
expression on Treg-moDC. Levels of HLA-DR on the Treg-moDC were similar 
to that of the mature moDC (p=0.6357).  
Overall the addition of Treg on day 3 of moDC generation resulted in a 
significant change in the phenotype of the moDC following exposure to LPS, as 
assessed by flow cytometry. The cells appeared to have a semi-mature moDC 
phenotype, consistent with previous publications (Misra et al., 2004, Bayry et 
al., 2007). 
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Figure 5.7 Treg modulation of moDC maturation.  
Cumulative (Top) and representative (Bottom) expression of surface markers CD80, 
CD83, HLA-DR, CD40 and CD86, determined by flow cytometry on immature, mature and 
Treg-moDC. Graph shows mean ±SEM for n=20-22. Mann-Whitney U values are shown.  
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Following the finding that early addition of Treg was important the next 
question was to assess if the effect of Treg on moDC maturation was contact 
dependent. Previous work has suggested that Treg modulation of DC is contact 
dependent however due to the complex nature of Treg and DC interactions the 
requirement for contact between the moDC and Treg was further assessed 
using Transwell assays. moDC were generated in the lower well and Treg 
added to the upper well on day 3. When there was no direct cell-cell contact 
between the moDC and Treg expression of CD80, CD83, CD86, HLA-DR and 
CD40 increased to a level similar to that of moDC matured in the absence of 
Treg (Figure 5.8). When there was direct cell-cell contact Treg conditioned 
moDC retained an immature-like phenotype following LPS maturation. This 
showed that in this experimental setting Treg modulation of moDC maturation 
occurred in a contact dependent manner and future experiments were carried 
out with direct cell-cell contact between the moDC and Treg. 
 
Figure 5.8 Treg need direct cell-cell contact to influence moDC maturation in response to 
LPS.  
moDC were Treg conditioned with direct cell-cell contact (top panel ) and in a Transwell 
system without direct cell-cell contact (bottom panel). Representative histograms show 
expression of maturation markers, measured by flow cytometry. Immature DC (  ) 
mature DC (  ) and Treg conditioned DC (  ). Data representative of 2 independent 
experiments. 
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 Treg conditioned moDC express markers associated with immune 5.3.3
modulatory function 
The cell surface expression of TGFβ is an effective mechanism employed by 
various cell types with immuno-modulatory properties. Levels of LAP-TGFβ 
expressed on the cell surface of the moDC were measured by flow cytometry. 
LAP-TGFβ is the latent form of TGFβ which can be activated by proteases, a 
pH change or through the action of integrins (Tran, 2012). Expression levels of 
LAP-TGFβ were similar on the immature and mature moDC, however the Treg 
conditioned moDC had increased levels of cell surface TGFβ when compared to 
the mature moDC (p=0.0396). In addition Treg conditioned moDC showed a 
trend towards higher expression of CCR7 when compared to the mature moDC, 
although this was not statistically significant. 
 
Figure 5.9 Treg moDC express increased levels of LAP-TGFβ and CCR7 on their cell 
surface.  
Left– representative histogram and right- cumulative levels of expression analysed by 
flow cytometry. Live cells were selected prior to histograms shown. N=4-6. Paired t test 
values shown 
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 Treg conditioned moDC secrete lower levels of cytokines 5.3.4
Mature DCs produce high levels of the pro-inflammatory cytokines IL-6 and 
IL-12p70 (Lutz and Schuler, 2002) therefore levels of IL-6, IL-12p70 and 
additionally the anti-inflammatory cytokine IL-10 were measured in the culture 
supernatants following generation of moDC and Treg-moDC.  
Levels of IL-6 were low in the supernatant collected from immature moDC; 
143pg/ml±102SEM (Figure 5.10A). The levels of IL-6 secreted by Treg-moDC 
were higher than that those of the immature moDC, but significantly lower than 
that secreted by non-Treg treated mature moDC, 702pg/ml±444SEM and 
12703pg/ml±4208SEM respectively (p=0.02, Mann-Whitney U test). The IL-6 
detected in the Treg-moDC was assumed to originate from the moDC rather 
than the Treg as IL-6 levels were below the detectable range in the Treg alone 
control culture.  
Compared to mature moDC, the Treg conditioned moDC produced 
significantly lower IL-10, 141pg/ml±77.7SEM and 5.43pg/ml±2.16SEM, 
respectively (p=0.0317) (Figure 5.10B). The levels of IL-10 produced by the 
Treg-moDC was comparable to that produced by immature moDC 
(6.72pg/ml±3.55SEM) and the levels of IL-10 detected for Treg only were very 
low (0.48pg/ml±0.18SEM), therefore it can be assumed that the majority of the 
IL-10 present in the Treg-moDC culture was derived from the Treg-moDC.  
Treg-moDC produced 4.65pg/ml±4.27SEM of IL-12p70 which was 
significantly less than mature moDC (530pg/ml±242SEM) (p=0.0079, Mann-
Whitney U test). IL-12p70 was not detectable when Treg were cultured alone 
and immature DC only produced 0.56pg/ml±0.56SEM (Figure 5.10C).  
 
 
Figure 5.10 Treg-moDC produce lower levels of pro-inflammatory and anti-inflammatory 
cytokines.  
Cell culture supernatants were collected on day 7 of moDC generation and analysed by 
CBA flex. Data acquired on FACS Canto II and analysed with FCAP array. Error bars 
indicate SEM, n=5 independent experiments. ND not detectable. 
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 Treg conditioned moDC have a morphology similar to immature 5.3.5
moDC 
Further to assessment of cell surface maturation markers on the moDCs 
cytopsins with giemsa staining were carried out to assess the morphology of the 
cells. The Treg treated moDC appeared to have a morphology which was 
similar to the immature moDC rather than the mature moDC (Figure 5.11). 
Therefore this data supports that obtained from flow cytometry for maturation 
markers. 
 
Figure 5.11 Treg treated moDC retain an immature-like morphology following treatment 
with LPS.  
Immature, mature and Treg conditioned moDC were stained with giemsa red and blue, 
images representative of 5 independent experiments. 
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 Treg conditioning results in impaired antigen processing by moDC 5.3.6
Once it was established that Treg conditioning affected both the phenotype 
and morphology of moDC further testing was carried out to investigate the effect 
Treg had upon the functional properties of moDC. FITC dextran uptake was 
used to measure the antigen processing capacity of the moDC. Unsurprisingly 
immature moDC took up the greatest amount of FITC dextran, which was 
significantly higher than that shown for mature and Treg conditioned moDC (p= 
0.0038 and 0.0063 for mature and Treg conditioned moDC respectively). 
Interestingly, immature moDC also lost their ability to uptake FITC dextran when 
treated with Treg (p=0.0474) (Figure 5.12). 
Although the Treg conditioned moDC had what appeared to be an immature 
phenotype and morphology, the amount of FITC dextran uptake was not 
significantly different from that of mature moDC. As antigen processing is 
typically carried out by immature moDC Treg treated immature moDC were 
included as an additional control. These cells were generated as the normal 
Treg treated moDC but without the addition of LPS for the final 24 hours of 
culture. These cells, when analysed by flow cytometry, appeared to be 
immature according to levels of maturation marker expression but again had 
reduced FITC dextran uptake compared to untreated immature moDC. This 
provides evidence that the presence of Treg results in a reduced capacity of 
moDC to process antigen rather than just arresting maturation. 
 
Figure 5.12 Treg treated moDC have impaired FITC dextran uptake.  
Antigen processing was calculated by the amount of FITC dextran take up by immature (
), mature ( ), Treg conditioned ( ) and Treg conditioned immature ( ) moDC, measured 
by flow cytometry. N=3-8 for each condition.  
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 Treg conditioned moDC exhibit a reduced capacity to stimulate 5.3.7
allogeneic CD8+ T cell activation and proliferation 
Following transplantation the allo-stimulation and proliferation of donor 
effector cells is crucial for the development of GvHD. Therefore the capacity of 
Treg conditioned moDC to induce allogeneic CD8+ T cell activation and 
proliferation was investigated. CD8+ T cell activation was measured by levels of 
CD25 expression on the cell surface after 5 days of allo-stimulation. 
Unstimulated CD8+ T cells showed minimal CD25 expression 
(0.73%±0.12SEM). Stimulation of the CD8+ T cells with immature moDC 
resulted in 30%±4.54SEM of cells becoming activated, and stimulation with 
mature moDC resulted in the highest levels of CD8+ T cell activation with 
40%±2.17SEM of cells expressing CD25. Following stimulation with Treg 
conditioned moDC only 26%±3.19SEM of cells expressed CD25, a significant 
decrease compared to mature moDC (p=0.0090). As expected the CD8+ T cells 
which were allo-stimulated with mature moDC in the presence of Treg showed 
low levels of activation (only 6%) as reported in Chapters 3 and 4 and this was 
significantly lower than the Treg conditioned moDC (p=0.0085) (Figure 5.13). 
 
Figure 5.13 Treg-moDC have a reduced capacity to induce allo-stimulated CD8+ T cell 
activation.  
A) Representative plots and B) cumulative data (a) unstimulated CD8+ T cells, CD8+ T 
cells stimulated with (b) immature ( ), (c) mature ( ), (d) Treg conditioned ( ) and (e) 
mature moDC in the presence of Treg ( ), measured by flow cytometry. Treg conditioned 
moDC (Treg-moDC).  
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The levels of CD8+ T cell proliferation was assessed by CFSE dilution over 5 
days. Unstimulated CD8+ T cells showed background levels of proliferation of 
only 0.3%±0.09SEM. Upon stimulation with immature and mature moDC 
proliferation levels were 20%±5.12SEM and 30%±5.02SEM respectively. The 
Treg treated moDC resulted in only 23%±3.85SEM of CD8+ T cells proliferating, 
a significant reduction compared to the untreated mature moDC (p=0.0467) 
(Figure 5.14). Again the CD8+ T cells allo-stimulated in the presence of Treg 
showed significantly less proliferation (5.06%±1.23SEM) than the CD8+ T cells 
stimulated by Treg conditioned moDC (p=0.0085). 
 
Figure 5.14 Treg-moDC have a reduced capacity to induce allo-stimulated CD8
+
 T cell 
proliferation.  
A) representative and B) cumulative data for (a) unstimulated CD8
+
 T cells, CD8
+
 T cells 
stimulated with (b) immature ( ), (c) mature ( ), (d) Treg conditioned ( ) and (e) mature 
moDC in the presence of Treg ( ), measured by flow cytometry.  Previously to plots 
shown, gates were applied on live CD8
+
 cells. Treg conditioned moDC (Treg-moDC). 
 
Increased CD8+ T cell activation is associated with increased CD8+ T cell 
proliferation for immature, mature and Treg conditioned moDC. Treg treatment 
of moDC results in an impaired capacity to induce CD8+ activation and 
proliferation which is an important factor in the pathogenesis of aGvHD 
induction following HSCT.  
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 Treg conditioning of moDC prior to MLR results in reduced GvH 5.3.8
severity in the skin explant model 
To examine the capacity of Treg conditioned moDC to induce allo-stimulated 
effector CD8+ T cell mediated GvH reactions an in vitro human skin explant 
model was used. This model has been used for studying GvHD in humans for 
20 years and is considered to closely mimic the type of skin lesions observed in 
clinical GvHD. 
As reported in Chapter 4 skin sections incubated in medium only, with 
unstimulated third party CD8+ T cells or CD8+ T cells stimulated in the presence 
of Treg have the lowest levels of GvH damage, only being grade I (Figure 5.15 
a, b and f). When immature or mature moDC were used to allo-stimulate the 
CD8+ T cells the majority of skin sections exhibited grade III damage (Figure 
5.15 c and d). Interestingly when the CD8+ T effector cells were allo-stimulated 
with Treg conditioned moDC grade I tissue injury was observed in 2 out of 3 
independent experiments, and grade II in the other (Figure 5.15e) – this was a 
significant reduction in the level of damage induced by untreated mature moDC 
(p=0.038) and not significantly different to the CD8+ cells allo-stimulated in the 
presence of Treg (p=0.423). 
 
Figure 5.15 Treg-moDC have a reduced capacity to induce allo-stimulated CD8+ T cell 
mediated cutaneous GvH damage.  
A) Cumulative and B) Representative data for skin sections incubated with (a) medium 
alone ( ), (b) unstimulated CD8
+
 T cells ( ), CD8
+
 T cells stimulated with (c) immature ( ), 
(d) mature ( ), (e) Treg conditioned ( ) and (f) mature moDC in the presence of Treg ( ), 
sections were graded according to the Lerner scale as previously discussed (Lerner et 
al., 1974). Treg conditioned moDC (Treg-moDC). 
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 Treg impair moDC function partially through a MARCH1 dependent 5.3.9
mechanism 
A recent publication provided evidence that in a mouse model Treg 
impairment of DC function occurred through a IL-10/MARCH1 dependent 
mechanism (Chattopadhyay and Shevach, 2013). Therefore the levels of CD86 
and MARCH1 gene expression were assessed to investigate if Treg modulation 
of moDC was also occurring via this mechanism.  
As previously discussed, the expression of CD86 was increased, following 
LPS treatment, on the cell surface of mature moDC and this increase was 
impaired in the Treg conditioned moDC (Figure 5.16A and section 5.3.2). CD86 
gene expression was seen to correlate with the cell surface protein expression 
levels, with significantly more CD86 mRNA detectable in the mature moDC 
(Figure 5.16B). Based on the nature of MARCH1 regulation of CD86 expression 
in that higher MARCH1 expression leads to lower CD86 expression, it was 
expected that if regulation was occurring via a MARCH1 dependent manner that 
high levels of CD86 would associate with low levels of MARCH1 mRNA. In the 
immature moDC high levels of MARCH1 were detected when CD86 was low 
and in mature moDC when CD86 expression was high MARCH1 expression 
was low as expected (Figure 5.16C). Interestingly the MARCH1 expression did 
not mirror CD86 expression exactly. In the Treg conditioned moDC levels of 
CD86 protein and mRNA were decreased but the MARCH1 expression was 
significantly higher than the mature moDC, suggesting the decreased 
expression of CD86 may be occurring via a partially MARCH1 dependent 
mechanism. 
 
Figure 5.16 Treg impair moDC function through a MARCH1 independent mechanism.  
A) Protein expression of CD86. Gene expression of B) CD86 and C) MARCH1 was 
assessed by qPCR and normalised to GAPDH. cDNA was generated by random hexamer 
priming from RNA isolated from immature ( ), mature ( ), and Treg-conditioned ( ) moDC 
and analysed by qPCR. Duplicate wells were assessed from 4 independent experiments 
and analysed by Mann-Whitney U tests.  
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 Naïve T cell polarisation by Treg conditioned moDC 5.3.10
The ability of Treg-moDC to polarise naïve T cells was assessed using re-
stimulation assays to measure cytokine production associated with T cell 
polarisation. Naïve T cells were stimulated for 6 days then rested for a further 4 
days. The polarised cells were then stained for intracellular levels of the typical 
Th1 and Th2 cytokines, IFNγ and IL-4 following PMA and ionomycin stimulation. 
The capacity of the Treg-moDC polarised naïve CD4 cells to produce IFNγ 
(15.5%±4.64SEM) was not statistically different to that of naïve T cells polarised 
by mature moDC (20.8%±2.78SEM); however although not significant, there 
was a trend towards lower levels of IFNγ producing cells (Figure 5.17A). The 
capacity of the polarised cells to produce IL-4 was significantly higher when the 
naïve cells were polarised with the Treg-moDC (4.35%±0.37SEM) compared to 
that by mat-moDC (2.5%±0.30SEM) suggesting increased presence of Th2 
cells (Figure 5.17A&B). Levels of IL-10 and IL-17a were also tested; 
unfortunately they failed to yield meaningful results due to technical difficulties 
(data not shown). 
 
Figure 5.17 Cytokine production following naïve CD4
+
 T cell polarisation.  
The capacity to produce Th1 and Th2 cytokines is altered when naïve CD4
+
 cells are 
polarised by Treg-moDC. A cumulative and B representative data for naïve T cell 
polarisation. Naïve CD4
+
 T cells were stimulated with immature ( ), mature ( ), and Treg-
conditioned ( ) moDC for 6 days then rested for a further 4 days before staining for 
levels of IC IFNγ and IL-4. Data generated from 1-2 repeats of 4 independent experiments. 
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In addition to IC staining (following PMA/Ionomysin stimulation) to detect the 
capacity of the polarised naïve cells to produce Th1/Th2 type cytokines, the 
secretion of cytokines into the culture supernatant was measured using CBA 
flex. After 6 days stimulation and 4 days resting 1x105 cells were re-stimulated 
with CD3/CD28 beads at a 1:1 bead to T cell ratio for 24 hours and the 
supernatant was collected. The results of CBA flex are shown in Figure 5.18. 
Secreted levels of IFNγ were significantly lower when the naïve cells were 
stimulated with Treg-moDC, 2163pg/ml±378SEM compared to when stimulated 
with mature moDC, 3182pg/ml±37SEM (p=0.021). Levels of IL-4, were not 
detectable when the naïve cells were stimulated with mat-moDC, but when 
polarised by Treg-moDC 0.18pg/ml±0.1SEM was detected. IL-17a was also not 
detectable when cells were polarised by mat-moDC, however it was present at 
low levels in those polarised by Treg-DC, 1.44pg/ml±0.84SEM. Due to the low 
levels of IL-4 and IL-17a detected during this assay it was not possible to draw 
firm conclusions. Levels of IL-10 secreted by the polarised cells were increased 
when the cells were polarised by Treg-moDC compared to the mat-moDC 
(770pg/ml±252SEM compared to 175pg/ml±45.5SEM).  
 
Figure 5.18 CBA analysis of secreted cytokines after re-stimulation assay.  
Data was collected on Canto II and analysed using FCAP array software. Mann-Whitney U 
tests values are shown. Data generated from 1-2 repeats of 3 independent experiments. 
ND=not detectable.  
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Due to the increased levels of the regulatory cytokine IL-10 in the 
polarisation culture supernatant the expression of intracellular Foxp3 was 
assessed to examine polarisation towards a Treg phenotype. Naïve cells 
polarised by mature moDC had a mean Foxp3 expression of 9.7%±2.07SEM 
whereas the Treg-moDC polarised cells had a significantly higher expression of 
Foxp3 with 15.0%±2.15SEM (Figure 5.19). 
 
Figure 5.19 Treg conditioned moDC show a trend towards increased polarisation towards 
Foxp3 Treg phenotype.  
Left-representative and right-cumulative plots, data obtained from 2 repeats of 4 
independent experiments. Cells were harvested and stained for Foxp3 expression after 
re-stimulation assays. Prior to plots, gates were applied to select lymphocytes.  
In addition to examination of the cytokine profile to assess naïve T cell 
polarisation the expression of master transcription factors were measured using 
qPCR. Levels of TBX21 (Th1), GATA-3 (Th2) and Foxp3 (Treg) mRNA were all 
unchanged regardless of the moDC used to polarise the naïve cells (Figure 
5.20). RORC, the transcription factor associated with Th17 cells was up-
regulated in cells polarised by Treg-moDC.  
 
Figure 5.20 Gene expression of Th1, Th2, Th17 and Treg transcription factors.  
mRNA was isolated after naive T cell polarisation by im-moDC, mat-moDC and Treg-
moDC. Gene expression was measured by qPCR and normalised to GAPDH. Paired t test 
values shown, n=4.  
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 Discussion 5.4
Accumulating evidence has shown the potential of modified DCs such as 
TolDC or regulatory DC for therapeutic use (Ezzelarab and Thomson, 2011, 
Stenger et al., 2012, Harry et al., 2010). However the studies carried out in this 
chapter were not intended to generate a new population of regulatory DCs to 
aid in the prevention or treatment of GvHD. Rather this was a proof of principle 
study which aimed to further investigate Treg mediated impairment of DC 
function and its impact on the amelioration of GvH reactions. Data presented in 
this chapter shows the first multi-parameter functional analysis of the effects of 
Treg conditioning on moDC including assessment of their phenotype, 
morphology, cytokine production, antigen uptake and ability to polarise naïve T 
cells. Furthermore the impact of Treg mediated changes in moDC on allo-
reactive CD8+ T cell induced GvHD target tissue damage was also examined, 
for the first time using an in vitro human GvH skin explant model. 
Treg conditioned moDC (Treg-moDC) were generated based on a 
previously published protocol (Bayry et al., 2007) with further refinement to 
confirm the optimal conditions such as the timing and dose of Treg. The 
successful generation of Treg-moDC gave assurance as to the reliability and 
reproducibility of the results reported in this chapter.  
Results presented in this chapter have shown that for Treg to drive moDC 
towards a tolerogenic status direct cell-cell contact was required.  Contact 
dependent regulation of DCs has also been reported in ex vivo mouse models 
where Treg form aggregates on/around dendritic cells, preventing their 
maturation (Onishi et al., 2008). The formation of these aggregates was 
dependent on leukocyte function-associated antigen-1 (LFA-1) expression by 
Treg cells; however the actual inhibition of maturation was dependent on CTLA-
4 as well as LFA-1. Interestingly Onishi et al also reported that Treg were able 
to out-compete naïve T cells to form these aggregates, which suggests in vivo 
Treg are also able to outcompete the naïve T cells, blocking their access to DCs 
thereby preventing their activation.  
Data presented in this chapter suggests that the regulation of DC phenotype 
function may occur, at least partially, in a MARCH1 dependent mechanism. This 
is supported by data from a recent publication that reported antigen specific 
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iTreg were able to modulate DC function through an IL-10/MARCH 1 dependent 
mechanism (Chattopadhyay and Shevach, 2013). The maturation marker CD83 
promotes MHC class II and CD86 expression by blocking IL-10 driven 
MARCH1-dependent ubiquitination and degradation of MHC class II and CD86 
(Tze et al., 2011). Further investigation would be required to confirm the 
requirement for Treg derived IL-10 in this human in vitro model. 
In this study the in vitro generated Treg-moDC have shown remarkably 
consistent phenotypic and functional profiles. Treg-DC expressed lower levels 
of maturation and co-stimulation molecules (CD83, CD40, CD80 and CD86) 
and comparably high levels of HLA-DR when compared to mature moDC. This 
finding suggests that Treg-moDC acquired a phenotype profile that overlaped 
the features of immature and mature DCs. This partially resembles the features 
of semi-mature DC, a new concept proposed by Lutz et al based on data 
obtained from murine bone marrow derived DC (Lutz and Schuler, 2002), which 
challenges the bimodal concept of DC status with an immature tolerogenic  
status and a mature immunogenic status. The partially mature status indicated 
by high level expression of HLA-class II and co-stimulation molecules was 
required to establish tolerance (Lutz and Schuler, 2002). Interestingly the levels 
of maturation and co-stimulation markers expressed on Treg-DC were not only 
significantly lower than those expressed on mature moDC but also significantly 
higher than those on immature moDC, suggesting the maturation status of 
Treg-moDC was distinctively different from both immature and mature DC, 
which has added to the theory of a the semi-mature DC.  The high level of HLA-
DR expression on Treg-moDC allows Treg-moDC to engage the T cells but a 
low expression of co-stimulatory molecules would give rise to a reduced or 
failed second signal resulting in T cell anergy/apoptosis (Alegre et al., 2001).  
Treg-moDC also expressed an increased level of CCR7 which is a 
chemokine receptor responding to the ligands CCL19 and CCL21 (Forster et 
al., 2008). CCR7 expression is important for tolerance induction in vivo due to 
its ability to guide the cells with immuno-modulatory properties, such as TolDC 
and Treg, into lymph nodes (Garrod et al., 2006, Forster et al., 2008). However 
the increased CCR7 expression on Treg-moDC was not likely to have 
contributed to the data reported in this chapter, due to in vitro nature of the 
experiments. On the other hand, the observed increase in expression of LAP-
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TGFβ on Treg-moDC may have played an important role in the promotion of 
tolerance. TGFβ is able to promote tolerance via the induction of Foxp3 in naïve 
T cells (Chen et al., 2003). 
The phenotype and functional properties of Treg-moDC closely resemble 
that of TolDC (Svajger and Rozman, 2014). It is worth noting that TolDC are not 
a distinct DC subset, identifiable by specific markers, but rather a functional DC 
status induced by the biological environment, such as inhibitory cytokines or 
immunosuppressive drugs (Hackstein and Thomson, 2004). TolDC exert either 
a modulatory or inhibitory function towards immune responses.  The data 
presented in this chapter have shown that Treg-moDC fit the description of 
TolDC. The key point is that most TolDC induced by cytokines (Svajger and 
Rozman, 2014)  or pharmacological agents (Harry et al., 2010) were generated 
for their potential therapeutic use (Ezzelarab and Thomson, 2011, Stenger et 
al., 2012) whilst this work was conducted to underpin the hypothesis that Treg 
induced development of TolDC plays a key role in Treg mediated protection 
from GvHD. 
Treg-moDC and im-moDC share similar properties, however they are not 
interchangeable. Immature moDC have been shown to induce T cell tolerance 
in vitro (Lutz and Schuler, 2002). However immature DC are unstable, upon 
stimulation with LPS or other endogenous TLR-4 ligands such as heat shock 
proteins 60 and 70 (Ohashi et al., 2000, Vabulas et al., 2002) they mature, 
increasing expression of maturation makers and co-stimulatory molecules, 
hence switching their immune tolerogenic properties to immune-stimulatory 
properties. Data presented in this chapter has shown that Treg-moDC were 
resistant to LPS maturation and retain their low levels of co-stimulatory 
molecules and maturation markers  following LPS stimulation which is 
consistent with the properties of Treg-moDC generated in previous studies 
(Misra et al., 2004, Bayry et al., 2007). LPS stimulation of TLR-4 requires 
interactions between several molecules including LPS binding protein (LBP), 
CD14, MD-2 and TLR-4 (Lu et al., 2008). TLR-4 signal transduction occurs 
through MyD88 dependent and independent pathways. These findings could be 
strengthened by exploring the molecular pathways underlying Treg mediated 
resistance to LPS maturation. 
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Along with decreased expression of co-stimulatory molecules and increased 
expression of immuno-modulatory molecules Treg-moDC were shown to 
secrete low levels of the pro-inflammatory cytokines IL-6 and IL-12p70. This 
was in line with the cytokine secretion of semi-mature DC derived from mouse 
bone marrow and from human TolDC (Lutz and Schuler, 2002, Anderson et al., 
2008). Unexpectedly the IL-10 levels secreted by Treg-moDC were significantly 
lower than that of mature moDC. This could be due to the timing of cell culture 
supernatant collection. Measuring DC cytokines following resting and re-
stimulation should be performed to confirm the current findings. 
In addition to modulation of moDC phenotype and morphology, Treg 
conditioning also impaired the functional capacity of moDC. Antigen uptake in 
Treg-moDC (both those which had received LPS stimulation those which had 
not received LPS stimulation) was significantly decreased when compared to 
the non-Treg treated immature moDC, suggesting that Treg are not solely 
arresting the maturation of moDC but also actively regulating the functions of 
the moDC. Similarly LPS stimulated Treg-moDC exhibited a significantly 
diminished capacity to stimulate activation and proliferation of CD8+ effector T 
cells when compared to the non-Treg treated mature moDC, although this effect 
was not as potent as when Treg were present during the allo-stimulation. 
Previous publications have shown that Treg-moDC had reduced ability to 
stimulate both autologous and allogeneic CD4+ T cell proliferation (Misra et al., 
2004, Bayry et al., 2007). Treg-moDC were also less able to stimulate allo-
reactive CD8+ T cell proliferation in a humanised mouse model of GvHD 
(Amarnath et al., 2010). This data provides the first evidence of Treg modulation 
of immature moDC antigen uptake and impairment of efficient allo-stimulation of 
human CD8+ effector T cells by Treg-moDC. 
Furthermore the results have shown, for the first time, that allo-reactive 
CD8+ effector T cells stimulated by Treg-moDC induced significantly less severe 
cutaneous GvH damage than those stimulated by non-Treg treated mature 
moDC. This observation was supported by the recent humanised mouse study 
in which Treg-moDC had limited capacity to induce T cell proliferation and 
therefore protected against xenogenic GvHD (Amarnath et al., 2010).  
141 
The observed Treg-moDC protection against GvHD target tissue damage 
was further strengthened by the findings that Treg-moDC skewed naïve T cell 
polarisation from Th1 towards Th2 accompanied with a trend towards increased 
Treg lineage. Th1 type responses are dominant in the pathophysiology of 
aGvHD (Ferrara et al., 2009) and therefore Treg modulation of DC resulting in 
skewing of naïve T cells away from a Th1 phenotype may contribute to Treg 
prevention of GvHD. It is well established that TolDC are able to induce Treg in 
the periphery as a mechanism for maintaining peripheral tolerance (Sela et al., 
2011, Svajger and Rozman, 2014) and therefore may further contribute to 
protection against GvHD.  In addition the Treg-moDC showed a trend towards 
increased naïve T cell differentiation into a Th17 type phenotype with 
significantly increased RORC mRNA, however the IL-17a secretion data was 
inconclusive. Th17 cells have been shown to be sufficient but not necessary to 
induce lethal GvHD, although IL-17 producing cells can also be suppressive 
(Carlson et al., 2009, Coghill et al., 2011, Pesenacker et al., 2013).  
Due to difficulties in isolating sufficient numbers of DC from peripheral blood 
moDC were used in this study. Ideally for clinical significance these results need 
to be confirmed using relevant sub-sets of DC sorted directly from human blood 
or tissues. CD1c+ dermal DC are the most prominent population of human DC 
and their role as potent stimulators as naïve T cells (Collin et al., 2013) would 
make them interesting to study in this skin explant model following Treg 
conditioning. 
The potent effect Treg have been shown to have on the functional capacity 
of moDC provides insight into the mechanism by which Treg are able to prevent 
GvHD post HSCT. Questions still remain as to the signalling pathways which 
are involved in the Treg modulation of DCs. TolDC have been shown to have 
down-regulated components of the NF-κB signalling pathway caused by Dex 
and VitD3 (Matasic et al., 1999, Xing et al., 2002) therefore it would be 
interesting to further investigate the NF-κB signalling pathway in Treg 
conditioned moDC.  
Data presented in this chapter provides the first comprehensive phenotypic 
and functional profiling of Treg-moDC in relation to human GvH reactions. The 
magnitude of GvH modulation appears to be less potent when only the moDC 
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are Treg conditioned than when Treg modulation is persistent over the entire 
allo-stimulatory process. This suggests that the most effective Treg modulation 
is likely to require the multidimensional effects of Treg including induction of 
tolerogenic DCs and direct suppression of the effector T cells including blocking 
of effector T cell migration. 
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6 Chapter 6 – In vitro and in vivo investigation into the 
potential impact of Treg on GvL effects 
 Introduction 6.1
In vivo murine models and early clinical trials have reported Treg protection 
against GvHD without compromising GvL (Edinger et al., 2003, Di Ianni et al., 
2011, Brunstein et al., 2011). A large volume of in vitro research, including our 
own, has demonstrated beyond doubt that Treg potently down-regulate GvH 
responses (Wang et al., 2009, Mavin et al., 2012, Edinger and Hoffmann, 2011) 
however, a certain level of GvH responses are required to achieve the 
beneficial GvL effect (Kolb, 2008). Increased frequency of Treg was also shown 
to correlate with CML relapse after HSCT (Nadal et al., 2007). Due to the 
conflicting nature of the current literature available and the fact that detrimental 
GvHD and beneficial GvL share a common immuno-biology the research 
presented in this chapter was conducted to evaluate the potential impact of 
Treg on GvL effects. This was carried out using in vitro cellular assays and 
assessment of Treg content in patient peripheral blood and occurrence of 
relapse post transplantation.  
 Graft-versus-leukaemia; historical perspectives 6.1.1
The beneficial GvL effect was first described when it was observed that 
patients who suffered with GvHD incurred a lower incidence of relapse (Weiden 
et al., 1979). Disparities in major or minor histocompatibility antigens between 
the donor and the recipient not only lead to GvHD but also to tumour 
eradication. The importance of the GvL effect became more evident when T cell 
depletion was introduced to prevent GvHD, patients who received T cell 
depleted grafts had an increased risk of leukaemia relapse compared to those 
who received un-depleted grafts (Horowitz et al., 1990). The effectiveness of 
GvL was further recognised by the observation that with donor lymphocyte 
infusion following a relapse post HSCT could induce remission. This lymphocyte 
infusion is able to induce remission, most potently in chronic myelogenous 
leukaemia (CML) patients, and also to a lesser extent in those patients with 
acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) 
amongst others (Kolb, 2008). Consequently the current goal of HSCT is to allow 
for sufficient GvL effect without permitting the development of GvHD; this is 
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particularly important in the case of non-myeloablative conditioning regimens 
which rely on the GvL activity of the graft to eradicate tumour cells (Martino et 
al., 2002).  
 Natural Killer cells and allo-reactive CD8+ T cells in the graft-versus-6.1.2
leukaemia effect 
The GvL effect is mainly mediated by allo-reactive donor CD8+ T cells and 
NK cells. The allo-reactive CD8+ T cells mediated GvL, is allo-antigen specific 
via adaptive immunity whereas the NK cells act through an innate non-antigen 
specific mechanism. 
Both natural killer (NK) cells and allo-reactive CD8+ cytotoxic T lymphocytes 
(CTL) are important in the protection against pathogens and transformed cells 
(Caligiuri, 2008, Vivier et al., 2011). Both populations mediate cytotoxicity 
through the release of granzyme and perforin, activation of death receptor 
pathways (Fas/TRAIL) along with the production of a range of cytokines. 
However, the control of cytotoxicity occurs in a very different manner. 
Regulation of NK function is a balance between activation and inhibition signals 
caused by the binding of various ligands to NK cell surface receptors (Caligiuri, 
2008).  Inhibitory killer immunoglobulin-like receptors (KIR) expressed on the 
surface on NK cells recognise MHC class I molecules, allowing the NK cells to 
recognise ‘self’. Engagement of the inhibitory KIR with their ligands occurs at a 
higher affinity than the activation receptor, meaning that the inhibitory signal will 
predominate (Hsu and Dupont, 2005). When a cell is altered by infection or 
leukaemic transformation it may cause an alteration in expression of MHC class 
I molecules which can be recognised by the diverse repertoire of NK cells 
(Caligiuri, 2008). In this case the absence of an inhibitory signal and the 
presence of a ligand in an activation KIR can result in NK mediated cytotoxicity. 
It has long been established that NK cells are beneficial in HSCT, promoting 
engraftment and amplifying the GvL effect through ‘missing self’ recognition 
(Ruggeri et al., 2006). A study by Ruggeri et al reported a highly significant 
survival advantage following HSCT if the donor was NK-allo-reactive, meaning 
the donor possessed a KIR ligand which was missing in the recipient (Ruggeri 
et al., 2007). This NK-allo-reactivity means donor NK cells would become 
activated due to the ‘missing self’ expression of a MHC class I molecule and 
mediate cytotoxicity, lysing the host leukaemia cells. 
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On the other hand, donor-derived allo-reactive CD8+ CTL mediate the GvL 
effect in an allo-antigen specific manner by recognising the disparate HLA class 
I antigens expressed on residual host leukemic cells then initiating allo-reactive 
immune responses. The ability of donor CD8+ CTL to eliminate recipient 
leukemic cells is mediated mainly by activated DCs of recipient origin 
(Chakraverty et al., 2006, Merad et al., 2013) although donor derived DCs could 
also contribute via indirect allo-antigen presentation (Shlomchik, 2007). In HLA 
matched HSCT it is the differences in miHA between donor and recipient which 
are responsible for the GvL effects (Bleakley and Riddell, 2004).  
 Treg and leukaemia relapse in HSCT 6.1.3
There are a number of publications associating Treg and leukaemia relapse, 
however the majority of the research has been conducted in relation to the role 
of Treg in tumour immunity in an autologous system (Ersvaer et al., 2010, Ustun 
et al., 2011). Research with regard to the effect of Treg on GvL in the HSCT 
setting was mainly carried out in murine models. Early studies investigating the 
infusion of Treg in the prevention of GvHD reported that Treg were able to 
prevent GvHD without affecting GvL in mice (Edinger et al., 2003, Trenado et 
al., 2003). In the human setting there is limited information available, the early 
stage clinical trials which administrated Treg to high risk HSCT patients 
revealed no change in relapse/GvL compared to historical cohorts of patients 
who did not receive Treg infusions (Brunstein et al., 2011, Di Ianni et al., 2011). 
However, there are also opposing results showing that higher Treg content post 
HSCT in patient peripheral blood is associated with a higher incidence of CML 
relapse (Nadal et al., 2007). Furthermore, a small scale clinical trial studying the 
safety and efficacy of Treg depleted DLI has demonstrated that Treg depletion 
of the graft improved the GvL effect of DLI which was associated with improved 
survival (Maury et al., 2010). Undoubtedly more investigation is required into the 
effect Treg may have on the GvL effect following an allogeneic HSCT. 
The specific questions asked in this chapter aimed to further investigate 
whether Treg were able to impair GvL reactions and therefore impact on 
leukaemia relapse. This was addressed by examining and analysing the 
following: 
 The effect of Treg on NK cell functions in vitro. 
146 
 The impact of Treg on allo-reactive CTL cytotoxicity in vitro. 
 The Treg content in patient peripheral blood at various time points 
post-transplant 
 The association between Treg content in post-transplant patient 
peripheral blood and the clinical outcome of leukaemia relapse. 
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 Methods 6.2
 Maintenance and generation of target cells 6.2.1
To examine the non-allo-specific cytotoxicity mediated by NK cells and the 
allo-reactive CTL mediated cytolytic functions K562 cell line and PHA blasts 
were used as respective target cells. The PHA blasts were autologous to the 
moDC used to prime the CD8+ CTLs. The K562 cell line was maintained in 
general purpose RF10 media; cells were regularly split to maintain log phase 
expansion for use in assays. PHA blasts were generated by culturing PBMC at 
1x10^6 cells/ml in RF10 with 5μg/ml PHA and 50IU/ml IL-2 for 6 days.  
 Generation of effector cells 6.2.2
NK effector cells, generated by negative enrichment, were cultured in RF10 
with 100IU/ml IL-2 overnight either in the presence or absence of 1:1 ratio of 
Treg. Prior to functional testing Treg were removed by CD3 MACS depletion. 
NK cells were then assessed for their functional capacities using IC staining for 
IFNγ production, NKG2D cell surface expression and co-culture with K562 
target cells (Figure 6.1A). CTL effector cells were generated using a priming 
MLR. CD8 cells were allo-stimulated either in the presence or absence of Treg 
for 6 days at a ratio of 4 CD8 to 1 Treg, unstimulated CD8 cells served as a 
control. Treg were depleted with CD4 MACS depletion prior to functional 
testing. Primed CTL were then assessed for levels of perforin and granzyme 
expression along with their ability to degranulate and induce target cell death 
(Figure 6.1B). 
 Assessment of target cell death and effector cell degranulation 6.2.3
To assess the functional abilities of NK cells they were added to 96 well U-
bottomed plates with a range of K562 ratios in RF10. If required CD107a 
antibody (a marker for degranulation) was added at this point. Plates were then 
spun down to ensure cell-cell contact between K562 and NK cells, and then 
incubated at 37ºC for 2 hours to measure degranulation and 3 hours to 
measure target cell death. Both degranulation and cell death were measured by 
flow cytometry. Gating strategies are shown in section 6.3.1.The ability of CTL 
to degraunlate and cause target cell death was also assessed by flow 
cytometry. Briefly CD8+ T cells either unstimulated, allo-stimulated or allo-
stimulated in the presence of Treg were cultured in a 96 well plate with a range 
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of ratios of PHA blasts, and spun down. The co-cultures were incubated for 2 
hours in RF10 supplemented with 25IU/ml IL-2. Gating strategies and 
assessment of target cell death and effector cell degranulation are discussed in 
section 6.3.1. 
 
Figure 6.1 Experimental designs to test the effect of Treg on effector cell functions.  
A. NK cells were incubated overnight in presence/absence of Treg. Treg were the 
removed prior to functional testing either by IC staining, cell surface staining of co-
culture with K562 target cells. 
B. CD8
+
 T cells were primed in MLRs and assessed for their functional capacity. PHA 
blasts generated form the same donor as the moDC were used as target cells to measure 
degranulation and target cell death 
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 Results 6.3
Results presented in this chapter showed the impact of Treg on the GvL 
effects of NK cells and cytotoxic T lymphocytes at a cellular level. Also 
considered is the potential association between the numbers of Treg in serial 
patient samples post transplantation and the incidence of leukaemia relapse. 
 Methodology development 6.3.1
Results in this section have shown that the optimization of methods used to 
measure the effect Treg have had on the cytotoxicity of NK cells and CD8+ T 
cells in vitro. The methods developed were adapted from two previous studies 
(Kim et al., 2007, Jardine et al., 2012). 
Isolation of NK cells 
NK cells were successfully isolated from normal healthy donor PBMC by 
MACS depletion of non-NK cells using an antibody cocktail of biotin conjugated 
antibodies against T cells, B cells, Stem cells, DCs, monocytes, granulocytes 
and erythroid cells (Miltenyi). The average NK cell purity post isolation was 
90.3%±1.21SEM based on double staining for CD3 and CD56 (Figure 6.2) 
 
Figure 6.2 Isolation of NK cells from PBMC.  
Data collected in BD Canto II and analysed with FlowJo version 7.6 (TreeStar). Data 
representative of PBMC before isolation and NK cell fraction after isolation in 10 
independent experiments. 
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Maintenance of K562 cell line in culture 
The kinetics of K562 growth was monitored with 3 starting cell 
concentrations of 0.1x10^6 cells/ml, 0.25x10^6 cells/ml and 0.5x10^6 cells/ml. 
The results showed that the log phase expansion of K562 cells appeared to be 
between 48 hours and 96 hours of culture (Figure 6.3). To ensure the 
consistency of the functional tests, particular attention was given to maintain the 
target cells in log phase growth prior to being used in functional assays. 
 
Figure 6.3 Representative K562 growth curve.  
K562 were seeded at 0.1x10^6 cells/ml ( ), 0.25x10^6 cells/ml ( ) and 0.5x10^6 cells/ml (
). Cell number was assessed at regular time points. Error bars represent duplicate cell 
counts. 
 
Gating strategies to assess target cell death and effector cell 
degranulation 
Traditionally radioactive 51Chromiun release assays were used to quantify 
target cell death, measuring 51Chromium released from lysed cells (Morales and 
Ottenhof, 1983). Despite this becoming the ‘gold standard’ for measuring 
cytotoxicity its use is often undesirable due to the hazardous nature of 
radioactive materials. Additionally the use of a flow based assay allows for 
target cell death to be quantified at a single cell level. The multi-parameter 
nature of flow cytometry allows for further sample analysis such as effector cell 
degranulation. Previous publications have reported that flow based assays do 
correlate well with the more traditional 51Chromium release assays (Kim et al., 
2007). 
The K562 cell line is a human chronic myelogenous leukemia cell line, 
positive for the Philadelphia chromosome and commonly used as a target cell in 
NK assays (Lozzio and Lozzio, 1975). K562 cells do not express HLA-ABC 
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which makes them very susceptible to NK cytotoxicity due to their ‘missing self’ 
status. This provides a good marker to separate the K562 cells from the effector 
cells by staining for HLA-ABC (Class I). HLA-ABC staining resulted in a good 
separation between the K562 target cells and the NK effector cells. 7AAD 
staining was also used to accurately identify dead cells within the K562 
population (Figure 6.4A). NK cells were identified as CD56+CD3-, NK cell 
degranulation was measured with CD107a staining and NKG2D expression was 
measured on the NK cells (Figure 6.4B). CD107a (lysosome-associated 
membrane protein-1) is a well reported functional marker of both NK and CTL 
cell cytotoxicity, as degranulation occurs CD107a is transported to the cell 
surface allowing antibody binding (Aktas et al., 2009, Alter et al., 2004).  
 
Figure 6.4 Gating strategies to assess NK cell function.  
A) Target cells were selected based on negative expression of HLA-ABC then viability 
assessed by 7AAD staining. B) effector cells were selected based upon CD56
+
CD3
-
 and 
then assessed for CD107a expression and NKG2D. Appropriate isotype controls were 
used to determine gating strategies. 
The target cells used to assess CTL killing ability were PHA blasts 
generated over 6 days from the same donor as the moDC used to stimulate the 
CD8+ T cells. Target cells were subsequently separated from the effector cells 
by staining them with different dyes prior to co-culture (Figure 6.5). Target cells 
were stained with CD3-PerCPcy5.5 and effector cells with CD8-APC. Target 
cells could then be selected and assessed for viability with DAPI staining. Live 
effector cells were assessed for expression of CD107a.  
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Figure 6.5 Gating strategies to assess CTL function.  
Target cells were selected based on positive PerCPcy5.5 staining and effector cells were 
selected based on positive APC staining. Target and effector cells were then assessed 
for viability and degranulation (CD107a) respectively. Gate position was determined by 
appropriate isotype control. 
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 Treg modulation of NK cell functions 6.3.2
The effect of Treg on NK cell mediated target cell death was assessed by 
treating NK cells with Treg cells at a 1:1 ratio overnight in RF10 with IL-2 to 
stimulate the NK cells. Treg were then removed prior to functional testing of NK 
cells with K562 target cells at a range of ratios. After 3 hours co-culture with the 
NK cells stimulated with or without Treg, target cell death was detected with 
7AAD staining. Due to inter-experimental variation in the background viability of 
the K562 cells, the fold increase in cell death above background cell death of 
K562 only culture was used to standardise NK cell mediated cytotoxicity (Figure 
6.6). A significant decrease in target cell death was observed at all NK:K562 
ratios for the NK cells treated with Treg compared to untreated NK cells. The 
fold increases in target cell death were 3.07±0.34SEM vs 1.82±0.28SEM, 
4.63±0.49SEM vs 2.32±0.35SEM and 10.32±1.9SEM vs 3.76±0.69SEM  for 
untreated and Treg-treated NK cells at 1:1, 2:1 and 5:1 NK-K562 respectively 
(p=0.041, 0.015 and 0.004 for 1:1, 2:1 and 5:1 respectively).  
 
Figure 6.6 Treg treatment impaired NK cell mediated target cell death.  
Untreated NK cells ( ) and Treg treated NK cells ( ) were co-cultured with a range of 
K562 cells for 3 hours. K562 viability was measured with 7AAD and calculated as fold 
increase over K562 only death. A) Representative plots, prior to plots shown gates were 
applied to target cells. B) Cumulative data from 6 normal donors. 
 
 
In addition to target cell death, NK cell degranulation was analysed as a 
measurement of NK cell function.  When CD107a is silenced it inhibits NK cell 
cytotoxicity therefore it is an integral part of NK cell functioning (Krzewski et al., 
2013). In the absence of any target cells the NK cells did not degranulate 
154 
(0.60%±0.09SEM) and there was no difference between the Treg treated and 
untreated NK cells (p=0.83) (Figure 6.7). After 2 hours of co-culture with K562 
target cells the percentage of degranulating NK cells was significantly 
decreased for NK cells that had been treated with Treg compared to untreated 
NK cells with 31.6%±2.71SEM vs 17.9%±1.24SEM, 26.1%±1.86SEM vs 
17.3%±1.51SEM and 19.3%±1.87SEM vs 11.88%±0.94SEM at 1:1, 2:1 and 5:1 
NK:K562 ratios respectively (p= 0.0002, 0.0005 and 0.0020 for 1:1, 2:2 and 5:1 
respectively). Interestingly untreated NK cells exhibited a clear dose response, 
while Treg treated NK cells appeared to have less of a dose response to 
decreasing numbers of target cells. 
 
Figure 6.7 Treg treatment reduces NK cell degranulation.  
Untreated NK cells ( ) and Treg treated NK cells ( ) were co-cultured with a range of 
K562 cells for 2 hours. CD107a expression was assessed by flow cytometry. A) 
Representative plots, prior to plots shown, gates were applied to live effector cells, upper 
row effector cells only, lower row effector:target ratio of 5:1. B) Cumulative data for 8 
normal healthy donors. 
 
NKG2D is an activating receptor expressed by NK cells, levels of NKG2D 
were measured on Treg treated and untreated NK cells prior to exposure to 
target cells. The MFI of NKG2D expression was significantly decreased for Treg 
treated NK cells (369.3±29.0SEM) compared to untreated (451.0±32.3SEM) 
(p<0.0001, paired t test) (Figure 6.8A&B). A significant decrease in NKG2D 
expression for Treg treated NK cells was also observed following exposure 
target cell ratios for untreated and Treg treated NK cells (411.7±46.4SEM vs 
341.8±35.2SEM, 430.0±47.5SEM vs 331.7±37.7SEM and 401.7±47.1SEM vs 
316.0±37.4SEM at 1:1, 2:1 and 5:1 ratios respectively. p=0.0412, 0.0040 and 
0.0092 respectively, paired t test) (Figure 6.8C). NKG2D expression had no 
dose response to NK:K562 ratios for both Treg treated and untreated NK cells.  
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Figure 6.8 NK cell reductions in NKG2D expression following Treg treatment.  
NKG2D expression was assessed by flow cytometry. A) Representative histogram, cells 
were previously gated on live NK cells B) Cumulative data, 4 measurements from 6 
normal healthy donors. C) NKG2D MFI of NK cells with and without Treg treatment 
following exposure to K562 target cells n=6.  
 
 
NK cells also produce IFNγ following stimulation which is able to influence 
the adaptive immune response (Vivier et al., 2011). The capacity of NK cells to 
produce IFNγ was assessed following Treg treatment and the results compared 
to untreated NK cells. Treg treated NK cells exhibited an impaired capacity to 
produce IFNγ following PMA and Ionomysin stimulation when compared to the 
untreated NK cells (15.1%±1.30SEM vs 22.9%±2.85SEM respectively 
p=0.0413, paired t test) (Figure 6.9). 
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Figure 6.9 NK cells had reduced capacity to produce IFNγ following Treg treatment. 
Untreated NK cells ( ) and Treg treated NK cells ( ) stimulated with PMA/Iono/BFA and 
stained for intracellular IFNγ. A) Representative plots, prior to plots shown gates were 
applied on CD8
+
 cells. B) Cumulative data. n=3 
 
  
157 
 Treg modulation of CTL functions 6.3.3
Cytotoxic T lymphocytes (CTL) are important mediators of the GvL effect 
and perforin and granzyme B are key components of CTL cytolysis machinery. 
To assess and compare CTL cytolytic function the levels of intra-cellular 
perforin and granzyme B were measured using flow cytometry. The results 
showed a significant decrease in granzyme B (6.6%±2.77SEM) in allo-reactive 
CD8+ T cells generated in the presence of Treg compared to those generated in 
the absence of Treg (32.6%±3.86SEM) (p<0.0001, paired t test). Perforin levels 
were also significantly decreased to 5.8%±1.94SEM in the allo-reactive CD8+ T 
cells generated in the presence of Treg, compared to those generated in the 
absence of Treg (33.8%±4.73SEM) (p=0.0003, paired t test) (Figure 6.10). 
 
Figure 6.10 The presence of Treg during allo-stimulation resulted in lower perforin and 
granzyme levels in CTL.  
CD8
+
 T cells were allo-stimulated in the absence (  ) or presence ( ) of Treg. 
Unstimulated CD8
+
 T cells served as a control (  ). A) Representative staining for 
granzyme and perforin, prior to plots shown gates were applied to CD8
+
 T cells. B) 
Cumulative data from 7-10 independent experiments. 
 
The ability of allo-reactive CD8+ T cells to induce target cell death was 
assessed at a range of effector:target cell ratios ranging from 5:1 up to 100:1. At 
every ratio there was a significantly higher target cell death when allo-reactive 
CD8+ T cells were generated in the absence of Treg compared to when Treg 
were present (p=0.013, 0.026, 0.030, 0.019 and 0.028 for 5:1, 10:1, 20:1, 50:1 
and 100:1 ratios respectively, paired t test). Allo-reactive CD8+ T cells 
generated in the presence of Treg resulted in a comparable target cell death to 
that of unstimulated CD8+ T cell control (Figure 6.11). 
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Levels of CD8+ T cell degranulation were also assessed following co-culture 
with PHA blast target cells. The CTL degranulation at a range of effector:target 
ratios was compared between allo-reactive CD8+ T cells generated in the 
absence or presence of Treg. The CTL degranulation level from un-stimulated 
CD8+ T cells at the same effector:target ratio served as a background control 
and a culture of CD8+ T cells alone without target cells was also included as an 
additional background control. CD8+ T cells cultured alone showed very low 
levels of degranulation at only 0.90%±0.31SEM. Additionally co-culture of un-
stimulated CD8+ T cells with the target PHA blasts exhibited less than 5% 
degranulation at all effector to target ratios. 
High levels of effector cell degranulation was observed in allo-reactive CD8+ 
T cells generated in the absence of Treg demonstrating a significantly 
decreased degranulation at all effector:target ratios except at the 100:1 ratio 
where sample size was too small to reach statistical significance (p=0.0034, 
p=0.0089, p=0.0012, p=0.0453 and p=0.0629 for 5:1, 10:1, 20:1, 50:1, and 
100:1 respectively). Indeed the allo-reactive CD8+ T cells generated in the 
presence of Treg showed degranulation levels as low as those of unstimulated 
CD8+ T cells.  
  
Figure 6.11 The presence of Treg during allo-stimulation resulted in decreased target cell 
death and effector cell degranulation.  
CD8 cells were allo-stimulated in the absence ( ) or presence ( ) of Treg. Unstimulated 
CD8 cells served as a control ( ). Data acquired from 2-4 independent experiments. Error 
bars indicate mean±SEM. A) CD8 cells were incubated with PHA blasts for 2 hours and 
target cell death measured using flow cytometry. Fold increase in cell death was 
calculated as the fold increase over background levels in the absence of any effector 
cells. B) Levels of CD107a were measured by flow cytometry after co-culture with a range 
of ratios of target cells for 2 hours. Gates were applied to live CD8
+
 effector cells.  
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Next we assessed whether Treg mediated inhibition of CD8+ T cell cytolytic 
function was reversible in the absence of Treg. Allo-reactive CD8+ T cells were 
generated in the presence or absence of Treg, along with an unstimulated 
control as with previous experiments. After 6 days of priming culture, CD8+ T 
cells primed in the presence of Treg were rested for 4 days in fresh medium 
following Treg depletion then tested for their ability to induce target cell death 
and degranulate. Preliminary data showed that allo-reactive CD8+ T cells 
previously generated in the presence of Treg regained a certain level of 
cytotoxic function as indicated by markedly higher levels of target cell death and 
effector cell degranulation than those of CD8 alone control (Figure 6.12) whilst 
they were identically low before the reverse culture (Fig 6.11A & 6.11B). Due to 
technical difficulties it was not possible to assess the degranulation of rested 
allo-reactive CD8+ T cells generated in the absence of Treg. 
 
Figure 6.12 Resting CTL following allo-stimulation and Treg deletion allowed them to 
recover effector cell characteristics.  
CD8
+
 T cells were allo-stimulated for 6 days in the absence ( ) or presence ( ) of Treg. 
Unstimulated CD8
+
 T cells served as a control ( ). Cells were then harvested and then 
Treg depleted. Cells were rested for 4 days then assessed for A) target cell killing and B) 
degranulation as previously described. N=3, error bars represent mean±SEM 
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 Association between Treg content of PBMC and leukaemia relapse 6.3.4
A small cohort of transplant patients was examined to investigate if there 
was any association between Treg levels in patient PBMC post HSCT and the 
incidence of relapse (see Table 2.6 for patient characteristics). The in vitro data 
presented in this chapter, along with other published literature, suggested that 
Treg do have the potential to impair the GvL effects, and therefore could have 
an impact on relapse. Clinical data was obtained from 30 patients who received 
HSCT between 2008 and 2010. Within the patient cohort 8 suffered from 
leukaemia relapse and the remaining 22 did not. Patients who received DLI 
were excluded from the analysis. 
The Treg content of serial PBMC samples from patients post HSCT were 
analysed by flow cytometry. The Treg content was measured as a percentage 
of CD4+ T cells which were also either CD25HIFoxp3+ or CD25HICD127Low. The 
normal range seen in healthy donors was between 3.7% and 9.0% (Figure 
6.13), with a mean value of 6.10%±0.63SEM. When comparing the Treg 
content of samples taken from all the patients at all the time points no significant 
difference was seen between those who relapsed and those who didn’t 
(p=0.9016). Patients who relapsed had an average Treg content of 
13.5%±2.20SEM and those who did not relapse 12.1%±1.13SEM. 
 
Figure 6.13 Treg content in the post HSCT patients.  
Treg content calculated as a percentage of the CD4
+
 T cells which were CD25
HI
Foxp3
+
 or 
CD25
HI
CD127
Low
. Samples from all time points post transplantation. Mann Whitney U 
values shown. Analysis of 30 patients and 7 normal donors. 
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Samples were then split into those taken early after transplant, at day 28 
and 3 months, and those which were taken late after transplant, at 6 months, 9 
months and 12 months. Early samples in the relapse group had a Treg content 
of 8.84%±2.20SEM while the no relapse group had a Treg content of 
10.1%±1.65SEM (p=0.779). When the samples from late post-transplant were 
considered again there was no significant difference (p=0.423) in the Treg 
content between those who relapsed (17.7%±3.98SEM) and those who did not 
relapse (13.5%±1.47SEM) (Figure 6.14).  
 
Figure 6.14 Treg content in early and late HSCT patient PBMC.  
Treg content calculated as a percentage of the CD4
+
 T cells which were CD25
HI
Foxp3
+
 or 
CD25
HI
CD127
Low
. Samples split into early (D28 and 3M) and late (6M, 9M and 12M) post-
transplant. Mann Whitney U test values shown. Analysis of 30 patients and 7 normal 
donors. 
 
Due to the importance of the GvL effect in AML patients, the Treg content of 
those patients who had an underlying AML diagnosis were separated out from 
the whole patient cohort. In total there were 14 AML patients, 3 who later 
relapsed and 11 who did not. When all the samples from all time points were 
analysed as one group there was a significant increase in the Treg content for 
the non-relapse group (12.3%±1.13SEM) than the relapse group 
(7.49%±1.51SEM) (p=0.46, Mann-Whitney U test) (Figure 6.15). Further 
analysis of the samples collected early (D28 and 3M) or later post-HSCT (6M, 
9M and 12M) revealed a similar trend in early post-transplant samples (Figure 
6.16). However, splitting samples into sub-groups reduced the sample size and 
hence reduced statistical power. 
162 
 
Figure 6.15 Treg content in AML patient cohort.  
Treg content calculated as a percentage of the CD4
+
 T cells which were CD25
HI
Foxp3
+
 or 
CD25
HI
CD127
Low
. Samples from all time points post transplantation Mann Whitney U test 
values shown. Analysis of 14 patients and 7 normal donors. 
 
Although not statistically significant (p=0.099) there was a trend for 
increased Treg content in the non-relapse (11.7%±1.77SEM) cohort compared 
to the relapse (5.46%±1.09SEM) cohort early after transplantation. When the 
samples collected later after transplant were considered there was no difference 
in Treg content between the relapse and the non-relapse cohorts (p=0.423). 
 
Figure 6.16 Early and late Treg content in AML patient cohort.  
Treg content calculated as a percentage of the CD4
+
 T cells which were CD25
HI
Foxp3
+
 or 
CD25
HI
CD127
Low
. Samples split into early (D28 and 3M) and late (6M, 9M and 12M) post-
transplant. Mann Whitney U test values shown. Analysis of 14 patients and 7 normal 
donors. 
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Further investigation showed that it was the 3 month time point which was 
the most interesting. At 28 days post transplantation no difference was seen 
between relapse and non-relapse in terms of Treg content (p=0.788) whereas 
at 3 months there was a trend towards higher Treg content in the no-relapse 
(15.4%±2.69SEM) patients when compared to the relapse patients 
(5.3%±1.32SEM) (p=0.064) (Figure 6.17). Sample size was very low with only 3 
samples available for AML patients who relapsed which may be the reason why 
statistical significance was not reached therefore further patient samples need 
to be tested before drawing any conclusions. 
 
Figure 6.17 Treg content at 28 days and 3 months post HSCT in AML patients.  
Treg content calculated as a percentage of the CD4
+
 T cells which were CD25
HI
Foxp3
+
 or 
CD25
HI
CD127
Low
. Samples split into D28 and 3M post-transplant Mann Whitney U test 
values shown. Analysis of 14 patients and 7 normal donors. 
 
. 
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 Discussion 6.4
Current research investigating the association between Treg and leukaemia 
relapse has been carried out in two distinct directions. One is assessing the 
frequency and function of autologous Treg in the peripheral blood or bone 
marrow of leukaemia patients against disease status or response to treatment 
(Shenghui et al., 2011, Yang and Xu, 2013). The other is dissecting the role of 
normal donor-derived allogeneic Treg infusion in GvHD and the GvL effect after 
HSCT. Research presented in this chapter is related to the later.  
Data obtained from in vitro experiments described in this chapter have 
demonstrated a Treg mediated reduction in the cytolytic capacity of allo-reactive 
CD8+ CTL, which confirms the observation in a previous report (Wang et al., 
2009). This finding was observed only when Treg were present during CD8+ T 
cell priming suggesting that ineffective activation and differentiation of CD8+ T 
cells could be one of the mechanisms leading to their reduced function 
(Andersen et al., 2006). Further study examining the effects of late Treg 
addition could strengthen this notion. 
The results also indicated that the observed decrease in CD8+ T cell cytolitic 
function is at least partly due to the dysfunction of cytolytic machinery resulting 
from the inability of CD8+ T cells to produce granzyme B and perforin. These 
cytotoxic proteins are pre-synthesised and released upon encounter with target 
cells. The perforin/ganzyme pathway requires binding of perforin followed by 
penetration of the cell granule (granzyme A and B) which leads to activation of 
the caspase cascade and cell cytolysis takes place (Goker et al., 2001). The 
fact that intra-cellular levels of granzyme B and perforin were significantly 
decreased suggests that Treg modulation was targeted at inhibiting synthesis of 
these cytolytic proteins rather than preventing their release following exposure 
to target cells. 
Preliminary data presented in this chapter has shown a possibility that Treg 
mediated loss of allo-reactive CD8+ T cell function may be partially reversible 
following removal of the Treg and subsequent resting of the CD8+ cells. This 
data requires further confirmation. Incorporating a re-stimulation step following 
Treg depletion and resting period may provide clearer evidence with regard to 
the reversibility of Treg mediated reduction in CD8+ T cell function. Nonetheless 
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this finding raised an interesting hypothesis that Treg infusion before or with 
HSCT may contribute more towards dampening down the very high magnitude 
early allo-reactive responses accountable for acute GvHD early post HSCT, but 
may have less influence on relatively lower magnitude and longer lasting allo-
reactive responses required for delivering the beneficial GvL effect. It has been 
suggested that a lower number of allo-reactive donor T cells are needed to 
induce a GvL effect than to cause GvHD (Dazzi et al., 2000). Interestingly 
several results reported in this chapter and Chapter 5 have demonstrated that 
Treg modulation often resulted in a diminished rather than abolished immune 
response. It is worth noting that the long term GvL effect mainly depends on 
allo-reactive T cells derived from engrafted donor haematopoietic stem cells 
whilst infused Treg will only be present for a short period of time as they are 
already differentiated mature T cells. 
The beneficial GvL effect is also mediated by NK cells. Treg mediated 
reduction in NK cell cytotoxic activity was detected in this study, along with 
reduced expression of the activating receptor NKG2D. However NK cell function 
was not completely negated. Therefore it is possible that in vivo Treg could 
impair but not completely abolish the NK cell mediated GvL effects. Other 
groups have also described Treg inhibition of NK functions through various 
mechanisms. Trzonkowski et al reported a contact dependent reduction in IFNγ 
production and cytotoxic activity by human NK cells in the presence of Treg in 
vitro but similarly Treg did not completely negate NK cell function (Trzonkowski 
et al., 2004). Treg have also been shown to inhibit murine NKG2D mediated 
cytolysis in a TGFβ dependent, IL-10 independent manner (Smyth et al., 2006). 
Data presented in this chapter has shown that Treg also induce a reduction in 
NKG2D expression on human NK cells in support of a previous report from 
Ghiringhelli et al (Ghiringhelli et al., 2005). Interactions between NKG2D and its 
ligands induces signalling through the adaptor molecule DAP10 inducing NK 
cell activation (Mincheva-Nilsson and Baranov, 2014). Therefore a Treg 
mediated reduction in NKG2D expression could result in less activating signals 
and therefore a decrease in NK cell activation. Although resting NK cells are 
cytotoxic, the strength of NK cell cytotoxicity greatly increases upon stimulation 
(Ralainirina et al., 2007). Consequently it is possible that the reason for the 
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decrease, but not negation, seen in NK cell function when cells were Treg 
treated was due to prevention of efficient NK cell activation. 
In this study IL-2 was used to stimulate the NK cells and Treg treatment was 
seen to have a significant effect on their function. Recent mouse studies have 
shown that Treg are able to modulate murine NK cell function through local IL-2 
deprivation (Sitrin et al., 2013, Gasteiger et al., 2013a, Gasteiger et al., 2013b). 
It is conceivable that during the Treg treatment the NK cells have access to 
lower levels of IL-2, compared to the untreated NK cells, and are stimulated to a 
lesser extent. Contradictory reports are available in the literature as to the role 
of Treg mediated IL-2 limitation on NK cell function. It has been reported in a 
previous human in vitro study that when NK cells were stimulated with either IL-
2 or IL-15, Treg had no effect on their IFNγ secretory capacity (Ghiringhelli et 
al., 2005). A more recent report, supporting data presented in this chapter, has 
shown that human NK cells in vitro are suppressed by Treg limitation of 
available IL-2 (Bachanova et al., 2014). Interestingly during systemic viral 
infection IL-12 and IL-18 can drive CD25 expression on NK cells, possibly 
allowing them to compete with Treg for IL-2 (Lee et al., 2012) so although IL-2 
can be important when investigating in vitro GvL effects it may be less so when 
assessing in vivo GvL effects of NK cells in a pro-inflammatory environment 
highlighting the difference in complexity between in vitro and in vivo settings.  
Data presented in this chapter has also shown that following exposure to 
target cells the level of NKG2D expression is decreased on both the Treg 
treated and untreated NK cells. A similar down regulation in NKG2D expression 
following exposure to target cells has been reported in CD8+ effector cells. 
Upon stimulation of CD8+ CTL expression of NKG2D lessened due to 
interactions between NKG2D and its ligand inducing endocytosis and 
degradation of NKG2D expression (Groh et al., 2002) possibly due to up-
regulation and subsequent shedding of NKG2D ligands by the CD8+ CTL 
(Maasho et al., 2005). It is possible that similar mechanisms regulating NKG2D 
expression on the NK cells following exposure to target cells are due to 
endocytosis and degradation following ligation. 
The in vitro data which demonstrated a possible partial impairment of 
cellular GvL functions was obtained under isolated conditions which are unlikely 
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to fully reflect the complexity of the therapeutic setting after HSCT. Therefore an 
analysis of a small clinical cohort was carried out to investigate if there was any 
association between increased Treg levels and relapse. Examination of serial 
patient PBMC samples showed no association between a higher Treg content 
and incidence of leukaemia relapse. Apart from this observation there is only 
one such study available in the literature reporting that higher frequencies of 
Treg correlated with leukaemia relapse (Nadal et al., 2007). It is not surprising 
that the findings from the two studies contradict with each other. The conflicting 
outcome could be due to technical and clinical variations. Firstly, Nadal and 
colleagues identified the Treg population based on CD4+CD25High phenotype 
only whereas this study defined Treg using a combined phenotype of 
CD4+CD25Hi plus either CD127Low or Foxp3+. It is well established that 
CD4+CD25Hi phenotype only is less reliable for identifying Treg as some 
activated conventional T cells may also express high levels of CD25 particularly  
in a pro-inflammatory environment, such as in the case of GvHD and infection 
(Liu et al., 2006). Secondly, the study presented in this chapter included a 
mixed cohort of patients whereas the observations from Nadal et al were based 
on an uniform cohort of patients with CML, which is particularly susceptible to 
the GvL effects of donor lymphocytes (Kolb, 2008) and therefore may be more 
sensitive to the effects of Treg impairment of GvL. Thirdly, Nadal et al correlated 
Treg content with molecular relapse which may be more sensitive than the 
clinical relapse which was used in this study. Fourthly, despite having an overall 
larger patient cohort, the Treg content in the Nadal et al study was examined at 
only one time point post HSCT with follow-up times ranging from just weeks to 
years post transplantation whereas this study was able to follow the Treg 
content of individual patients at regular time points for up to one year post 
HSCT. In addition other clinical variables such as GvHD status, conditioning 
regimens and DLI could also contribute to the discrepancy between the two 
studies. Both studies have their shortcomings; however they are the only such 
observations available in the current literature. Therefore a well-designed 
prospective study with large longitudinal series may provide more informative 
conclusion. 
Taken together, based on the data and discussion presented in this chapter, 
along with the work of others, it is possible to hypothesise that the use of Treg 
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infusion as a clinical procedure to mitigate GvHD may not result in a substantial 
loss of beneficial GvL effects post HSCT. However, the final verdict lies in the 
long-term clinical outcome of patients with leukaemia who have received Treg 
infusion as part of their HSCT procedure. Two clinical trials, included allogeneic 
Treg infusion as part of their HSCT procedure, for either a heterogeneous or a 
mainly AML patient cohort, have reported no increased incidence of relapse 
when compared to a historical cohort based on a two year follow-up (Brunstein 
et al., 2011, Di Ianni et al., 2011). One of these clinical trials has recently 
published a follow-up study, including an additional second cohort of patients, 
reporting that adaptive therapy with Treg and conventional T cells prevents 
relapse in patients with acute leukaemia (Martelli et al., 2014). Although these 
are only small scale trials they have provided assurance that Treg can be used 
to supress GvHD without serious concerns in compromising the beneficial GvL 
effects. It is encouraging that no increased leukaemia relapse was observed in 
early clinical trials of Treg infusion. However longer term follow-up and further 
investigations are required before considering Treg as a routine immunotherapy 
for GvHD.  
Furthermore the role of Treg in the GvL effect post HSCT remains to be fully 
elucidated. If indeed Treg do permit the GvL effect while preventing GvHD, it is 
important to understand how they are able to target GvHD but spare the GvL 
effect. Research in murine models has demonstrated that bone marrow stromal 
cells are able to neutralise Treg suppressive capacities, hence impede any 
potential adverse impact the Treg may have on a GvL effect (Martelli et al., 
2014). Further investigations are required to establish if these could also be the 
case in human HSCT. 
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7 Chapter 7 - Concluding remarks 
Despite substantial advances in HSCT, aGvHD still remains a significant risk 
post transplantation. The use of Treg for the prevention of GvHD is an 
appealing prospect and early stage clinical trials have shown promising results; 
reducing the incidence of aGvHD without adversely effecting transplant 
outcome in terms of relapse, transplant related mortality and engraftment 
(Brunstein et al., 2011). To date, the mechanisms by which Treg exert their 
function in protecting against GvHD are not fully elucidated. In addition, the 
important question of whether Treg mediated GvHD protection is at the cost of 
sacrificing the beneficial GvL effect remains largely unexplored. This project 
aimed to further investigate the mechanisms of action underlying Treg mediated 
protection against GvHD and to explore the potential impact of Treg therapy on 
the GvL effect following HSCT. 
Due to the rarity of Treg, effective isolation and ex vivo expansion is a 
prerequisite for any Treg functional study. Data presented in Chapter 3 has 
demonstrated the robustness of the techniques used for Treg 
isolation/expansion and confirmed the potency of their immunosuppressive 
property. More importantly the data has provided further evidence 
demonstrating that in vitro expanded Treg can be cryopreserved without 
damaging their suppressive capacity (Mavin et al., 2013). This observation has 
not only allowed for more efficient use of resources with a reduced workload 
and increased consistency in functional research but also provided valuable 
information supporting the feasibility of using cryopreserved Treg in clinical trials 
especially where multiple infusions are required. If Treg were to be used 
routinely in a clinical setting the ability to store Treg prior to transfusion is 
critical, especially looking into the future considering the use of Treg as an ‘off 
the shelf’ cellular reagent. However, before Treg treatment becomes a routine 
clinical approach standard protocols need to be established to isolate, expand 
and store Treg under conditions that meet the requirements of regulatory bodies 
such as the Human Tissue Authority and the Medicines and Healthcare 
products Regulatory Agency. It would strengthen the quality control of 
expanded Treg to monitor the methylation status of the CNS2 element within 
the Foxp3 promoter region in the future as an indicator of Treg stability. 
170 
One of the highlights of this research is to have revealed a previously under-
appreciated potential mechanism underlying Treg mediated protection against 
GvHD. Data presented in Chapter 4 has provided the first evidence in a human 
experimental setting that Treg are able to prevent cutaneous GvH tissue 
damage by blocking effector T cell invasion into target tissues (Mavin et al 
2012). The data has further confirmed that Treg mediated impairment of effector 
cell migration into GvHD target tissue is associated with decreased expression 
of skin homing receptors on CD8+ effector T cells paired with reduced 
expression of the counterpart chemo-attractant ligands in the target tissue. It is 
fully appreciated that the role of Tregs in GvHD is complex and multifactorial. 
However the findings of this research have provided a valuable piece of 
evidence linked into a very complicated mechanistic network by which Tregs 
exert their protection of GvHD. Further research into Treg modulation of effector 
T cell invasion into other GvHD target tissues could be of value. Additionally the 
impact of Treg on alternative, IFNγ independent, skin homing mechanisms 
could be considered, such as interactions between the chemokine receptor 
CCR10 and its ligand CCL27. Furthermore it is also worth considering the 
effects Treg may have on the CD8+ effector T cells. Both murine and in vitro 
human studies have reported Treg modulation of CD8+ effector T cells in an 
APC independent manner (Piccirillo and Shevach, 2001, Trzonkowski et al., 
2004).  
To date no human evidence is available directly demonstrating the impact of 
Treg treated moDC on modulating GvHD. Data presented in Chapter 5  has 
shown, for the first time in an in vitro human GvHD skin explant model, that allo-
reactive CD8+ T cells stimulated with Treg treated moDC are less able to induce 
severe GvH target tissue damage. This could result from the overall outcome of 
multi-factorial modulation by Treg, including weakening of DC priming, blocking 
effector T cell migration and IFNγ secretion as well as diminishing the ability of 
CD8+ T cells to synthesise cytotoxic proteins such as granzyme B and perforin. 
The reduced ability of Treg treated moDC to prime allo-reactive CD8+ effector T 
cells is closely related to Treg mediated multi-parameter impairment of moDC 
both phenotypically and functionally. Furthermore the data also provides the 
first evidence in humans suggesting that Treg driven development of a 
tolerogenic status in moDC involves a MARCH1 dependent mechanism (Mavin 
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et al. manuscript in preparation). Further investigation into the requirement for 
Treg derived IL-10 in MARCH1 regulation could provide further insight into 
regulation of co-stimulatory molecules on Treg-DC. Interestingly the presence of 
Treg throughout the allo-stimulation process resulted in the magnitude of 
suppression being markedly greater than that when only the DC were treated 
with Treg, suggesting that the most potent Treg modulation is likely to rely on 
multiple regulatory mechanisms, influencing DCs and effector cells 
simultaneously. Further investigations are required to establish the molecular 
mechanisms by which Treg are able to drive DCs into a tolerogenic status and 
therefore induce a less severe cutaneous GvH reaction. This could be further 
investigated with gene expression profiling using PCR arrays. The findings in 
this research could also be strengthened by exploring molecular pathways, 
such as the NF-κB signalling pathway underlying Treg mediated resistance to 
LPS maturation.  
Despite the large amount of literature available relating to the beneficial 
effects of Treg protection against GvHD following HSCT, the effects of Treg on 
GvL are relatively unexplored. The findings from both in vitro experiments and 
clinical sample analysis presented in Chapter 6 are not able to provide a 
definitive conclusion with regards to whether Treg infusion would have a 
negative impact on the beneficial GvL effects. Considering the Treg mediated 
functional inhibition of cellular components that are critical for delivering 
beneficial GvL effects it is tempting to conclude that Treg treatment may lead to 
a compromised GvL response. However, based on the preliminary data 
showing reversibility of Treg supressed allo-reactive CTL function, the 
observation that the cytotoxic functions of CTL and NK cells were not 
completely negated by Treg treatment and the lack of association between 
higher Treg content in PBMC and leukaemia relapse, it is reasonable to suggest 
a ‘threshold’ concept. The idea being that Treg infused before or at the time of 
HSCT may predominantly target the overwhelming allo-immune responses and 
extensive inflammation that contribute to the development of aGvHD rather than 
GvL effect, where the consistent lower magnitude cytotoxic responses are 
required. In addition, infused Treg may only function early after HSCT and are 
therefore less likely to influence the long-term GvL effect following full 
engraftment and immune reconstitution. The research presented in this thesis, 
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although preliminary, supports the view that the use of Treg infusion as a 
clinical procedure to modulate GvHD may not result in a substantial loss in 
beneficial GvL effects post HSCT. Further investigation is required to confirm 
the preliminary results showing the reversibility of Treg mediated suppression of 
CD8+ T cell cytolytic functions. The in vitro studies are capable of providing 
invaluable insight into the cellular mechanisms of GvL; however, it is only 
partially representative of what occurs in vivo. Early clinical trials have reported 
no adverse effects of Treg infusion on the GvL effects. However, the final 
conclusion lies in the long-term follow-up of multi-centre prospective clinical 
trials, including a large patient cohort and careful control of all relevant clinical 
parameters. In the meantime the powerful effect of Treg on modulating allo-
reactivity may be utilised to aid other clinical needs where the GvL effect is not 
a concern, for example to ameliorate GvHD in HSCT for patients with non-
malignant disorders or to reduce rejection in solid organ transplantation. 
In summary, this project has been conducted to examine the role of Treg 
modulation in the context of both GvHD and the GvL effect in HSCT. This thesis 
has provided new evidence and new insight to address the highly complex 
mechanisms by which Treg modulate GvHD, which has advanced the 
knowledge and understanding related to the role of Treg in HSCT. The research 
outcome may also shed light on future clinical trials using Treg as an 
immunotherapy for GvHD and beyond. 
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